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Abstract: Background. Two prospective  randomised trials,  comparing 
neoadjuvant chemotherapy (NACT) with upfront debulking surgery (UDS) in 
advanced tubo-ovarian cancer (EORTC 55971 and MRC CHORUS)  , were 
analysed with the aim to examine the long term outcomes of the patients 
and identify any preferable therapeutic  approaches for subgroup 
populations. 
Methods. Pre-planned individual updated patient data meta-analysis of 
both trials (NCT00003636 and ISRCTN74802813). In the EORTC trial eligible 
women had biopsy proven stage IIIC or IV invasive epithelial tubo-ovarian 
carcinoma. In the CHORUS, trial the inclusion criteria were similar, but 
women with apparent stage IIIA and IIIB were also eligible. The main aim 
of the meta-analysis was  to show non-inferiority in overall survival 
with NACT compared UDS using the "reverse Kaplan-Meier" method. Test for 
heterogeneity was based on the Cochran's Q heterogeneity statistic. 
 
Findings. 1220 women were randomised. The overall median follow-up was 
7.6 years (EORTC 9.2 and CHORUS 5.9 years). Median patient age was 63 
years (range 25-88 years) and median size of the largest metastatic 
tumour at diagnosis was 8 cm (range 0-50 cm). FIGO stage  distribution 
was II-IIIB(4.5%), IIIC(68.1%), IV(18.9%) with 8.5% of data missing. 
There was no statistically significant difference for the entire 
population regarding the median overall survival (OS) between patients 
who underwent UDS and NACT (26.9 and 27.6 months; HR: 0.98, 95% CI: 0.87-
1.10; p = 0.688). Median OS for EORTC and CHORUS patients was 
significantly different at 30.2 and 23.6 months, respectively (HR: 1.20, 
95% CI:1.06-1.36;p=0.004) but not significantly heterogeneous (Cochran's 
Q p= 0.17). Variable outcomes were noted in some cohorts.   
 Interpretation. Long-term follow-up data confirm that NACT and UDS result 
in similar OS in advanced tubo-ovarian cancer, with preferential outcomes 
in some patients. This meta-analysis, with long-term follow-up, confirms 
that NACT is a valuable treatment option for patients with Stage IIIC-IV 
tubo-ovarian cancer, especially in patients with a high tumour burden at 
presentation and/or poor performance status.   
 
 
 
 
 
Leuven, July the 13th 
 
Dear Senior Editor, Dear Dr Lai,   
 
On behalf of the co-authors, I thank you for your decision to revise our paper and will answer the 3 
questions below:  
 
1. Editorial comment 8: thank you for providing the study selection flowchart. To conform to 
reporting standards, a figure like this is required in the main manuscript. Please could you 
add the figure to the main manuscript? As the two studies were prospectively selected for 
inclusion, the boxes on 'records excluded' and 'other studies...' can be removed from the 
figure.  
 
I have adapted the figure as requested to the main manuscript. The figure numbers and 
references have been adapted.  
 
2. Editorial comment 11: thank you for providing figure files. Unfortunately, the .doc files you 
have provided for your figures are not editable. The graphs are images and cannot be edited. 
Please could you provide editable files for all of your graphs and figures—eg, .eps, .ps or .pdf 
files saved directly from the original artwork or plotting device so we can reformat the 
original drawing. Please note that the text and drawings will need to be editable. If you have 
any questions about this, please do not hesitate to contact me directly.  
 
I have adapted the figures accordingly. 
 
3. Thank you for providing the list of authors for PubMed listing. Please could you suggest a 
group name for these authors under which the names will be listed, eg, 'EORTC and CHORUS 
study investigators'?  
 
I suggest “EORTC and MRC CHORUS study investigators”. 
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SUMMARY 41 
Background. Two prospective  randomised trials,  comparing neoadjuvant chemotherapy (NACT) with upfront 42 
debulking surgery (UDS) in advanced tubo-ovarian cancer (EORTC 55971 and MRC CHORUS)  , were 43 
analysed with the aim to examine the long term outcomes of the patients and identify any preferable therapeutic  44 
approaches for subgroup populations. 45 
Methods. Pre-planned individual updated patient data meta-analysis of both trials (NCT00003636 and 46 
ISRCTN74802813). , In the EORTC trial eligible women had biopsy proven stage IIIC or IV invasive epithelial 47 
tubo-ovarian carcinoma. In the CHORUS, trial the inclusion criteria were similar, but women with apparent 48 
stage IIIA and IIIB were also eligible. The main aim of the meta-analysis was  to show non-inferiority in overall 49 
survival with NACT compared UDS using the “reverse Kaplan-Meier” method. Test for heterogeneity was based 50 
on the Cochran’s Q heterogeneity statistic. 51 
Findings. 1220 women were randomised. The overall median follow-up was 7.6 years (EORTC 9.2 and 52 
CHORUS 5.9 years). Median patient age was 63 years (range 25-88 years) and median size of the largest 53 
metastatic tumour at diagnosis was 8 cm (range 0-50 cm). FIGO stage  distribution was II-IIIB(4.5%), 54 
IIIC(68.1%), IV(18.9%) with 8.5% of data missing. There was no statistically significant difference for the entire 55 
population regarding the median overall survival (OS) between patients who underwent UDS and NACT (26.9 56 
and 27.6 months; HR: 0.98, 95% CI: 0.87-1.10; p = 0.688). Median OS for EORTC and CHORUS patients was 57 
significantly different at 30.2 and 23.6 months, respectively (HR: 1.20, 95% CI:1.06-1.36;p=0.004) but not 58 
significantly heterogeneous (Cochran’s Q p= 0.17). Variable outcomes were noted in some cohorts.   59 
Interpretation. Long-term follow-up data confirm that NACT and UDS result in similar OS in advanced tubo-60 
ovarian cancer, with preferential outcomes in some patients. This meta-analysis, with long-term follow-up, 61 
confirms that NACT is a valuable treatment option for patients with Stage IIIC-IV tubo-ovarian cancer, 62 
especially in patients with a high tumour burden at presentation and/or poor performance status.   63 
 64 
This study was supported by grants (2U10 CA11488-28 through 2U10 CA011488-36) from the National Cancer 65 
Institute and by a donation from the “Vlaamse Liga tegen kanker (the Flemish League against Cancer)” to the 66 
EORTC Charitable Trust. Funding was provided by Cancer Research UK. Funding for a pilot phase of the trial 67 
was provided by the RCOG and supported by core MRC CTU funding. The trial sponsor was the MRC and the 68 
trial was conducted an analysed at the MRC CTU. 69 
 70 
INTRODUCTION 71 
Over 70% of women with carcinoma of the ovary, fallopian tube or peritoneum (hereafter referred to as tubo-72 
ovarian cancer) present with advanced disease, and usually have a very poor prognosis (1) Since Griffiths 73 
reported In 1975 (2) the association between low residual tumour load and improved survival rates  following 74 
debulking surgery,  primary surgery has been embedded in clinical practice as an essential, or even mandatory  75 
therapeutic strategy.(3) However, to date, no prospective randomised controlled trials have proven that primary 76 
debulking surgery improves the prognosis of patients with advanced tubo-ovarian cancer.  77 
An alternative approach to primary debulking surgery, is neoadjuvant chemotherapy (NACT), administered 78 
before attempting cytoreductive surgery. In  2010 the first randomised trial comparing NACT followed by 79 
interval debulking surgery (IDS) with upfront debulking surgery (UDS) was published (4). This randomised 80 
EORTC (European Organisation for Research and Treatment of Cancer) study showed a similar overall survival 81 
(OS) and progression-free survival (PFS) in women with FIGO 1988 (International Federation of Gynecology 82 
and Obstetrics) stage IIIC or IV tubo-ovarian cancer with both treatment strategies and a lower operative and 83 
postoperative morbidity with NACT. These results were later confirmed in the randomised Medical Research 84 
Council (MRC) CHORUS trial (5) and resulted in the acceptance of NACT followed by IDS as an alternative to 85 
UDS in stage IIIC and IV tubo-ovarian cancer (6).  However, the selection of women with advanced ovarian 86 
cancer for NACT or UDS remained controversial (7).  87 
In 2003, while the accrual of the EORTC study was ongoing but prior to the start of the CHORUS trial, we 88 
(EORTC/(MRC) planned the current analysis with the aim of analysing the long-term follow-up of both trials 89 
and to identify subgroups of women who might benefit more or less from NACT compared with UDS. Herein 90 
we report the results of this analysis. 91 
Methods 92 
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Study design and data collection 93 
This is a pre-planned individual updated patient data meta-analysis of the EORTC 55971 and MRC CHORUS 94 
trials. performed according to the PRISMA 2009 guidelines (Figure 1) (84) .  The eligibility criteria and study 95 
design of the EORTC and CHORUS trials have previously been reported (4,5). In short, in the EORTC trial 96 
eligible women had biopsy proven stage IIIC or IV invasive epithelial ovarian, primary peritoneal, or fallopian 97 
tube carcinoma.  If a biopsy was not available, fine needle aspiration showing an adenocarcinoma was 98 
acceptable under the following conditions: presence of a pelvic adnexal  mass, and presence of extrapelvic 99 
metastases of ≥ 2 cm (measured during diagnostic laparoscopy or laparotomy, and if not done, based on CT 100 
findings) and a CA125 (KU/L)/CEA (ng/mL) ratio > 25. If any features of the triad were not present then a 101 
biopsy was mandated. If the CA125/CEA ratio was less than 25, investigations to exclude a gastrointestinal 102 
carcinoma were necessary before entry. In the CHORUS, trial the inclusion criteria were similar, but women 103 
with apparent stage IIIA and IIIB were also eligible. In both trials randomisation was to UDS followed by at 104 
least 6 courses of platinum-based chemotherapy, versus  3 courses of NACT (platinum-based) followed by IDS, 105 
and then at least 3  additional courses of platinum based chemotherapy. In women randomised to UDS whose 106 
surgery was completed without optimal cytoreduction, IDS was permitted and these patients were included for 107 
analyses in the UDS arm. Randomisation included stratification with a minimization technique to stratify for 108 
institution, method of biopsy (image-guided, laparoscopy, laparotomy, fine needle aspiration), stage IIIC or IV, 109 
and largest tumour size (excluding ovaries) before surgery (less than 5, 5 – 10, 10.1 - 20 cm, or more than 20 110 
cm). Randomisation used a minimisation method with a random element, which stratified the patients according 111 
to randomising centre, largest radiological tumour size, clinical FIGO 1988 stage, and pre-specified 112 
chemotherapy regimen. 113 
 Data analysis 114 
The analysis was designed in 2003 by the chief investigators of the two trials (IV and SK) and members of the 115 
EORTC/MRC trial managing committees. Trial  databases were set up to ensure appropriate comparable 116 
information was collected in both trials to allow the planned individual patient data analysis. The women were 117 
followed until data base lock. CHORUS data were transferred to the EORTC Headquarters and analyzed in 118 
cooperation with the authors by the EORTC statistician (CC). The EORTC standard method for deriving median 119 
follow-up time using the “reverse Kaplan-Meier” method calculating time-to-event on all patients was used, 120 
while in the original CHORUS paper the median duration of follow-up of the surviving patients was used. 121 
At the planning stage it  was estimated that the pooled dataset would contain between 800 and 900 events 122 
(deaths). Assuming a median OS of 3 years, this allowed assessment of  non-inferiority (9,108,9) with a one-123 
sided type I error of 0.05 and a power of 80% where inferiority is considered as an increase of more than 18-19% 124 
in hazard. Similarly, it would allow a 90% power in excluding a hazard increase of 22-23%.  Applying a two-125 
sided test of superiority at 5%, the dataset would allow the detection of an 18% increase in hazard with 80% 126 
power.   127 
The principal analysis was performed on the intent-to-treat policy and the primary outcome was OS. The 128 
prespecified secondary endpoint was PFS.   Prespecified subgroup analyses based on the stratification factors 129 
that were common to both trials (randomising centre, largest tumour size (excluding ovaries) before surgery (less 130 
than 5, 5 – 10, 10.1 - 20 cm, or more than 20 cm), and clinical FIGO 1988 stage) were performed.  The 131 
definitions applied for OS and PFS have been previously published (4). Median OS and PFS were estimated by 132 
the Kaplan-Meier method and compared via the log rank test. Hazard ratio estimates and their confidence 133 
intervals were obtained from a Cox proportional hazards model. In those subgroups where the proportional 134 
hazards assumptions was violated, restricted mean survival times were calculated to provide a more useful 135 
general measure to report the average survival times between the two treatment arms (110) Multivariable time-136 
to-event analyses were performed using a Cox proportional hazards model, with univariate screening followed 137 
by a multivariable stepwise selection procedure (121). All baseline characteristics and results were checked for 138 
homogeneity between the two studies and stratified per trial where possible. Test for heterogeneity in PFS or OS 139 
was based on the Cochran’s Q heterogeneity statistic The size of the largest metastasis before randomisation was 140 
measured in the EORTC study during diagnostic laparoscopy or laparotomy, and if not done, based on CT 141 
findings. In  the CHORUS trial, these measurements were based on CT radiologic imaging only. All analyses 142 
were done using SAS, version 9.4. 143 
For details on size of residual tumour, residual tumor per country, type of surgery, number of cycles and type of 144 
chemotherapy, and time to (re)initiation of chemotherapy we refer to the original papers. (4,5). 145 
Role of funding source 146 
Formatted: Highlight
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The funders of the studies had no role in study design, data collection, data analysis, data interpretation, or 147 
writing of the report. CC, MN and MP had access to MRC CHORUS raw data. CC had access to the EORTC 148 
55971 raw data. The corresponding author (IV) had full access to all the data and had final responsibility to 149 
submit for publication. All authors have seen and approved the final version and, after consultation with the 150 
collaborators, agreed to submit for publication 151 
Results 152 
The patient data of both trials were updated and merged into one data-base (data-base lock EORTC June 6
th
, 153 
2015 and CHORUS June 3
rd
, 2014)that contained 1220 randomised patients. Total combined recruitment lasted 154 
almost 12 years (EORTC: 670 patients from Oct 12
th
, 1998 to Nov 29
th
 2006; MRC CHORUS: 550 patients from 155 
March 5
th, 2004 to August 26th, 2010). Median follow-up was 7.6 years (IQR: 6.0-9.6 years) (EORTC 9.2 years 156 
(IQR: 7.3-10.4 years) and CHORUS 5.9 years (IQR: 4.3-7.4 years)).  The characteristics of the patients by study 157 
and study arm are summarised in Tables 1 and 2, respectively. The pre-treatment characteristics were well 158 
balanced between both treatment groups.   159 
Overall survival (OS)  and progression-free survival (PFS) for the entire population were similar for NACT and 160 
UDS (median respectively for OS 27.6 (IQR: 14.1-51.3) and 26.9 (IQR: 12.7-50.1) months, HR: 0.97, 95% CI: 161 
0.86-1.09; and for PFS respectively 11.6 (IQR: 7.9-17.7) and 11.1 (IQR: 6.4-17.5) (Figure 12). The lower 1-162 
sided confidence of 95% confidence interval for OS and PFS hazard ratios were 0.87 and 0.89, excluding the 163 
18% non-inferiority margin. 164 
 165 
OS was significantly better in the EORTC trial compared with the CHORUS trial (median, respectively 30.2 166 
(IQR: 15.7-53.7) and 23.6 (IQR: 10.5-46.9) months; HR: 1.20, 95% CI: 1.06-1.36; p = 0.004) (Figure 32), but 167 
PFS was similar (median respectively, 11.5 (IQR: 8.0-17.0) and 10.9 (IQR: 6.1-18.1) months; HR 0.96, 95% CI: 168 
0.86-1.08; p= 0.0.531) (Supplemental file page 1).  169 
OS and PFS according to trial and treatment arms are presented in the Supplemental file (page 2 and 3).  170 
Cochran’s Q was not significant for either OS or PFS (p=0.17 and 0.32 respectively). 171 
Median OS was significantly different for Stage IV compared with stage III and stage II (median respectively, 172 
23.3 (IQR: 12.4-40.8), 30.0 (IQR: 15.6-55.7) and 45.4 (IQR: 31.6-NR) months; HR 2.75 and 1.92 for Stage III 173 
and IV versus stage II, p < 0.001; see Supplemental file page 4).  OS was similar for NACT and UDS in stage 174 
IIIC patients (median respectively, 30.8 (IQR: 16.5-51.3) and 28.4 (IQR: 14.1-55.7) months; HR: 1.04, 95% CI: 175 
0.90-1.21; p = 0.569; Supplemental file page 5).  PFS was similar for NACT and UDS in stage IIIC (median 176 
respectively, 12.2 (IQR: 8.4-18.3) and 11.7 (IQR: 7.5-19.9) months; HR: 1.06, 95% CI: 0.92-1.22; p = 0.429; 177 
Supplemental file page 6). However, in patients with stage IV tubo-ovarian cancer NACT resulted in 178 
significantly better OS than UDS (Figure 43) (median respectively, 24.3 (IQR: 14.1-47.6) and 21.2 (IQR: 10.0-179 
36.4) months; HR: 0.76, 95% CI: 0.58-1.00, p = 0.048).  PFS was also significantly better in stage IV disease 180 
with NACT than with UDS (median respectively, 10.6 (IQR: 7.9-15.0) and 9.7 (IQR: 5.2-13.2) months; HR: 181 
0.77, 95% CI: 0.59-1.00, p = 0.048) (Supplemental file page 7).  182 
OS was best in patients with a largest metastatic extrapelvic  tumour size < 5 cm at the time of randomisation 183 
(Supplemental file page 8).  In patients with stage IIIC disease and a largest metastatic tumour size < 5 cm, the 184 
PFS was better with UDS than with NACT (Figure 54A, respectively median 12.2 (IQR: 8.5-23.3) and 11.7 185 
(IQR: 8.3-16.4); HR: 1.36, 95% CI: 1.06-1.75; p=0.017;  hazard plots according to largest metastatic tumour size 186 
Supplemental file page 9), but the OS was not significantly different (median respectively, 33.0 (IQR: 13.5-78.7) 187 
and 30.2 (IQR: 16.5-51.3);  HR: 1.26, 95% CI: 0.96-1.65; p=0.092, Figure 54B).  Due to deviation from the 188 
proportional hazards assumption in this subgroup, restricted mean survival times are presented in table 3. Age 189 
and performance status were not predictive for treatment effect on survival (Supplemental file, page 10) 190 
Discussion 191 
This pre-planned analysis of updated data from the EORTC and CHORUS trials on NACT versus UDS in 192 
advanced tubo-ovarian cancer (stage IIIC and IV), confirms that with long-term follow-up NACT results in non-193 
inferior OS and PFS compared with UDS. The planned non-inferiority margin, an increase of more than 18-19% 194 
in hazard ratio, was well outside the lower confidence bounds (11% and 13% for PFS and OS respectively). 195 
Hence, this meta-analysis with long-term follow-up confirmed that both UDS and NACT are 2 possible 196 
treatment options for patients with FIGO Stage IIIC or IV tubo-ovarian cancer. However, the analysis also 197 
revealed  that PFS and OS was significantly better with NACT compared to UDS in patients diagnosed with 198 
stage IV disease. On the other hand, women with stage IIIC disease with a largest extrapelvic metastatic tumour 199 
 5 
 
mass of less than 5 cm had a significantly better PFS with UDS.  For those with stage III disease and larger sized 200 
metastatic disease, either approach resulted in the same OS. In the women with stage IIIC and largest metastatic 201 
tumours at diagnosis < 5 cm, both PFS and OS curves have crossing treatment arms indicating deviation from 202 
the proportional hazards assumptions. Therefore the restricted mean survival times (table 3) give a better 203 
indication of the treatment effect than the median times (Ref 110). These findings indicate that when deciding on 204 
a treatment strategy, not only should the risk of perioperative morbidity (6) and the possibility of debulking the 205 
patient’ disease to zero residual tumour (7) be taken into account, but also FIGO 1988 stage and the extent of the 206 
metastatic disease at presentation.  207 
Although in both studies, a cytological diagnosis of malignancy was permitted, with the evolution of our 208 
knowledge regarding tubo-ovarian cancer disease subtypes, presently only histology can reliably distinguish 209 
between high-grade and low-grade serous carcinomas (132). This is important since low grade serous 210 
carcinomas are much less sensitive to chemotherapeutic regimens and primary surgery is an important and much 211 
preferred intervention in this group (143). Thus to  facilitate optimal decision making, tissue should be obtained 212 
for histological diagnosis  in all cases and this should be  combined  with extensive radiological imaging.  213 
Obtaining tissue for histological examination is usually possible using image guided biopsy (usually of the 214 
omental cake), although a laparoscopic approach is necessary in some cases and provides additional information 215 
on disease distribution which can be included in the decision making process. (154-176)   216 
Both trials have been investigating the timing of surgery in advanced tubo-ovarian cancer and have been 217 
criticised for their low R0 rates and low survival rates. However, it should be noted that at the time these patients 218 
were randomised, NACT was not accepted as an alternative for UDS and the majority of the patients had 219 
extensive Stage IIIC or IV disease, visible on CT.   Furthermore, in addition to the EORTC 55971 and CHORUS 220 
trials,  the SCORPION (154)  and the JCOG0602 (187) randomised trials concluded that perioperative morbidity 221 
was more favourable with interval debulking after neoadjuvant chemotherapy than after primary  debulking 222 
surgery. Currently, the TRUST trial randomising NACT versus PDS in advanced tubo-ovarian cancer has been 223 
developed and is recruiting patients in selected centres with 50% or more R0 rates. The results of this new trial 224 
are awaited with interest. A limitation of this meta-analysis might be that in the EORTC trial only patients with 225 
stage IIIC and IV were included while in the CHORUS trial also a (limited) number of patients with stage IIIA 226 
and B were included. In addition, the number of patients with Stage IIIC-IV disease without residual tumor after 227 
UDS tended to be lower in the CHORUS than in the EORTC trial. 228 
Application of the findings of this analysis to the care of every woman with stage IIIC or IV tubo-ovarian cancer 229 
should be tempered by the patients’ clinical picture. For example, women in these studies had metastatic disease 230 
with a high tumour burden at presentation, and many had a poor performance status. (1897)  This clinical 231 
scenario is not uncommon and improving outcomes for this population is as important (if not more so) than those 232 
who have much better prognostic factors. Accepting the caveats implicit within all clinical trials, the results 233 
regarding the clinical management of stage IV disease are derived from one of the largest cohorts of women with 234 
stage IV disease in phase III studies. Although some stage IV patients have a better prognosis and present with 235 
less spread and more easily resectable disease (143) than the majority of Stage IV patients,  our data infer that 236 
NACT be the standard of care for most patients with stage IV tubo-ovarian cancer, and primary surgery should 237 
only be undertaken exceptionally in women selected on an individual basis.  238 
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SUMMARY 41 
Background. Two prospective  randomised trials,  comparing neoadjuvant chemotherapy (NACT) with upfront 42 
debulking surgery (UDS) in advanced tubo-ovarian cancer (EORTC 55971 and MRC CHORUS), were analysed 43 
with the aim to examine the long term outcomes of the patients and identify any preferable therapeutic  44 
approaches for subgroup populations. 45 
Methods. Pre-planned individual updated patient data meta-analysis of both trials (NCT00003636 and 46 
ISRCTN74802813). , In the EORTC trial eligible women had biopsy proven stage IIIC or IV invasive epithelial 47 
tubo-ovarian carcinoma. In the CHORUS, trial the inclusion criteria were similar, but women with apparent 48 
stage IIIA and IIIB were also eligible. The main aim of the meta-analysis was  to show non-inferiority in overall 49 
survival with NACT compared UDS using the “reverse Kaplan-Meier” method. Test for heterogeneity was based 50 
on the Cochran’s Q heterogeneity statistic. 51 
Findings. 1220 women were randomised. The overall median follow-up was 7.6 years (EORTC 9.2 and 52 
CHORUS 5.9 years). Median patient age was 63 years (range 25-88 years) and median size of the largest 53 
metastatic tumour at diagnosis was 8 cm (range 0-50 cm). FIGO stage  distribution was II-IIIB(4.5%), 54 
IIIC(68.1%), IV(18.9%) with 8.5% of data missing. There was no statistically significant difference for the entire 55 
population regarding the median overall survival (OS) between patients who underwent UDS and NACT (26.9 56 
and 27.6 months; HR: 0.98, 95% CI: 0.87-1.10; p = 0.688). Median OS for EORTC and CHORUS patients was 57 
significantly different at 30.2 and 23.6 months, respectively (HR: 1.20, 95% CI:1.06-1.36;p=0.004) but not 58 
significantly heterogeneous (Cochran’s Q p= 0.17). Variable outcomes were noted in some cohorts.   59 
Interpretation. Long-term follow-up data confirm that NACT and UDS result in similar OS in advanced tubo-60 
ovarian cancer, with preferential outcomes in some patients. This meta-analysis, with long-term follow-up, 61 
confirms that NACT is a valuable treatment option for patients with Stage IIIC-IV tubo-ovarian cancer, 62 
especially in patients with a high tumour burden at presentation and/or poor performance status.   63 
 64 
This study was supported by grants (2U10 CA11488-28 through 2U10 CA011488-36) from the National Cancer 65 
Institute and by a donation from the “Vlaamse Liga tegen kanker (the Flemish League against Cancer)” to the 66 
EORTC Charitable Trust. Funding was provided by Cancer Research UK. Funding for a pilot phase of the trial 67 
was provided by the RCOG and supported by core MRC CTU funding. The trial sponsor was the MRC and the 68 
trial was conducted an analysed at the MRC CTU. 69 
 70 
INTRODUCTION 71 
Over 70% of women with carcinoma of the ovary, fallopian tube or peritoneum (hereafter referred to as tubo-72 
ovarian cancer) present with advanced disease, and usually have a very poor prognosis (1) Since Griffiths 73 
reported In 1975 (2) the association between low residual tumour load and improved survival rates  following 74 
debulking surgery,  primary surgery has been embedded in clinical practice as an essential, or even mandatory  75 
therapeutic strategy.(3) However, to date, no prospective randomised controlled trials have proven that primary 76 
debulking surgery improves the prognosis of patients with advanced tubo-ovarian cancer.  77 
An alternative approach to primary debulking surgery, is neoadjuvant chemotherapy (NACT), administered 78 
before attempting cytoreductive surgery. In  2010 the first randomised trial comparing NACT followed by 79 
interval debulking surgery (IDS) with upfront debulking surgery (UDS) was published (4). This randomised 80 
EORTC (European Organisation for Research and Treatment of Cancer) study showed a similar overall survival 81 
(OS) and progression-free survival (PFS) in women with FIGO 1988 (International Federation of Gynecology 82 
and Obstetrics) stage IIIC or IV tubo-ovarian cancer with both treatment strategies and a lower operative and 83 
postoperative morbidity with NACT. These results were later confirmed in the randomised Medical Research 84 
Council (MRC) CHORUS trial (5) and resulted in the acceptance of NACT followed by IDS as an alternative to 85 
UDS in stage IIIC and IV tubo-ovarian cancer (6).  However, the selection of women with advanced ovarian 86 
cancer for NACT or UDS remained controversial (7).  87 
In 2003, while the accrual of the EORTC study was ongoing but prior to the start of the CHORUS trial, we 88 
(EORTC/(MRC) planned the current analysis with the aim of analysing the long-term follow-up of both trials 89 
and to identify subgroups of women who might benefit more or less from NACT compared with UDS. Herein 90 
we report the results of this analysis. 91 
Methods 92 
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Study design and data collection 93 
This is a pre-planned individual updated patient data meta-analysis of the EORTC 55971 and MRC CHORUS 94 
trials. performed according to the PRISMA 2009 guidelines (Figure 1) (8) .  The eligibility criteria and study 95 
design of the EORTC and CHORUS trials have previously been reported (4,5). In short, in the EORTC trial 96 
eligible women had biopsy proven stage IIIC or IV invasive epithelial ovarian, primary peritoneal, or fallopian 97 
tube carcinoma.  If a biopsy was not available, fine needle aspiration showing an adenocarcinoma was 98 
acceptable under the following conditions: presence of a pelvic adnexal  mass, and presence of extrapelvic 99 
metastases of ≥ 2 cm (measured during diagnostic laparoscopy or laparotomy, and if not done, based on CT 100 
findings) and a CA125 (KU/L)/CEA (ng/mL) ratio > 25. If any features of the triad were not present then a 101 
biopsy was mandated. If the CA125/CEA ratio was less than 25, investigations to exclude a gastrointestinal 102 
carcinoma were necessary before entry. In the CHORUS, trial the inclusion criteria were similar, but women 103 
with apparent stage IIIA and IIIB were also eligible. In both trials randomisation was to UDS followed by at 104 
least 6 courses of platinum-based chemotherapy, versus  3 courses of NACT (platinum-based) followed by IDS, 105 
and then at least 3  additional courses of platinum based chemotherapy. In women randomised to UDS whose 106 
surgery was completed without optimal cytoreduction, IDS was permitted and these patients were included for 107 
analyses in the UDS arm. Randomisation included stratification with a minimization technique to stratify for 108 
institution, method of biopsy (image-guided, laparoscopy, laparotomy, fine needle aspiration), stage IIIC or IV, 109 
and largest tumour size (excluding ovaries) before surgery (less than 5, 5 – 10, 10.1 - 20 cm, or more than 20 110 
cm). Randomisation used a minimisation method with a random element, which stratified the patients according 111 
to randomising centre, largest radiological tumour size, clinical FIGO 1988 stage, and pre-specified 112 
chemotherapy regimen. 113 
 Data analysis 114 
The analysis was designed in 2003 by the chief investigators of the two trials (IV and SK) and members of the 115 
EORTC/MRC trial managing committees. Trial  databases were set up to ensure appropriate comparable 116 
information was collected in both trials to allow the planned individual patient data analysis. The women were 117 
followed until data base lock. CHORUS data were transferred to the EORTC Headquarters and analyzed in 118 
cooperation with the authors by the EORTC statistician (CC). The EORTC standard method for deriving median 119 
follow-up time using the “reverse Kaplan-Meier” method calculating time-to-event on all patients was used, 120 
while in the original CHORUS paper the median duration of follow-up of the surviving patients was used. 121 
At the planning stage it  was estimated that the pooled dataset would contain between 800 and 900 events 122 
(deaths). Assuming a median OS of 3 years, this allowed assessment of  non-inferiority (9,10) with a one-sided 123 
type I error of 0.05 and a power of 80% where inferiority is considered as an increase of more than 18-19% in 124 
hazard. Similarly, it would allow a 90% power in excluding a hazard increase of 22-23%.  Applying a two-sided 125 
test of superiority at 5%, the dataset would allow the detection of an 18% increase in hazard with 80% power.   126 
The principal analysis was performed on the intent-to-treat policy and the primary outcome was OS. The 127 
prespecified secondary endpoint was PFS.   Prespecified subgroup analyses based on the stratification factors 128 
that were common to both trials (randomising centre, largest tumour size (excluding ovaries) before surgery (less 129 
than 5, 5 – 10, 10.1 - 20 cm, or more than 20 cm), and clinical FIGO 1988 stage) were performed.  The 130 
definitions applied for OS and PFS have been previously published (4). Median OS and PFS were estimated by 131 
the Kaplan-Meier method and compared via the log rank test. Hazard ratio estimates and their confidence 132 
intervals were obtained from a Cox proportional hazards model. In those subgroups where the proportional 133 
hazards assumptions was violated, restricted mean survival times were calculated to provide a more useful 134 
general measure to report the average survival times between the two treatment arms (11) Multivariable time-to-135 
event analyses were performed using a Cox proportional hazards model, with univariate screening followed by a 136 
multivariable stepwise selection procedure (12). All baseline characteristics and results were checked for 137 
homogeneity between the two studies and stratified per trial where possible. Test for heterogeneity in PFS or OS 138 
was based on the Cochran’s Q heterogeneity statistic The size of the largest metastasis before randomisation was 139 
measured in the EORTC study during diagnostic laparoscopy or laparotomy, and if not done, based on CT 140 
findings. In  the CHORUS trial, these measurements were based on CT radiologic imaging only. All analyses 141 
were done using SAS, version 9.4. 142 
For details on size of residual tumour, residual tumor per country, type of surgery, number of cycles and type of 143 
chemotherapy, and time to (re)initiation of chemotherapy we refer to the original papers. (4,5). 144 
Role of funding source 145 
The funders of the studies had no role in study design, data collection, data analysis, data interpretation, or 146 
writing of the report. CC, MN and MP had access to MRC CHORUS raw data. CC had access to the EORTC 147 
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55971 raw data. The corresponding author (IV) had full access to all the data and had final responsibility to 148 
submit for publication. All authors have seen and approved the final version and, after consultation with the 149 
collaborators, agreed to submit for publication 150 
Results 151 
The patient data of both trials were updated and merged into one data-base (data-base lock EORTC June 6
th
, 152 
2015 and CHORUS June 3
rd
, 2014)that contained 1220 randomised patients. Total combined recruitment lasted 153 
almost 12 years (EORTC: 670 patients from Oct 12
th
, 1998 to Nov 29
th
 2006; MRC CHORUS: 550 patients from 154 
March 5
th, 2004 to August 26th, 2010). Median follow-up was 7.6 years (IQR: 6.0-9.6 years) (EORTC 9.2 years 155 
(IQR: 7.3-10.4 years) and CHORUS 5.9 years (IQR: 4.3-7.4 years)).  The characteristics of the patients by study 156 
and study arm are summarised in Tables 1 and 2, respectively. The pre-treatment characteristics were well 157 
balanced between both treatment groups.   158 
Overall survival (OS)  and progression-free survival (PFS) for the entire population were similar for NACT and 159 
UDS (median respectively for OS 27.6 (IQR: 14.1-51.3) and 26.9 (IQR: 12.7-50.1) months, HR: 0.97, 95% CI: 160 
0.86-1.09; and for PFS respectively 11.6 (IQR: 7.9-17.7) and 11.1 (IQR: 6.4-17.5) (Figure 2). The lower 1-sided 161 
confidence of 95% confidence interval for OS and PFS hazard ratios were 0.87 and 0.89, excluding the 18% 162 
non-inferiority margin. 163 
 164 
OS was significantly better in the EORTC trial compared with the CHORUS trial (median, respectively 30.2 165 
(IQR: 15.7-53.7) and 23.6 (IQR: 10.5-46.9) months; HR: 1.20, 95% CI: 1.06-1.36; p = 0.004) (Figure 3), but 166 
PFS was similar (median respectively, 11.5 (IQR: 8.0-17.0) and 10.9 (IQR: 6.1-18.1) months; HR 0.96, 95% CI: 167 
0.86-1.08; p= 0.0.531) (Supplemental file page 1).  168 
OS and PFS according to trial and treatment arms are presented in the Supplemental file (page 2 and 3).  169 
Cochran’s Q was not significant for either OS or PFS (p=0.17 and 0.32 respectively). 170 
Median OS was significantly different for Stage IV compared with stage III and stage II (median respectively, 171 
23.3 (IQR: 12.4-40.8), 30.0 (IQR: 15.6-55.7) and 45.4 (IQR: 31.6-NR) months; HR 2.75 and 1.92 for Stage III 172 
and IV versus stage II, p < 0.001; see Supplemental file page 4).  OS was similar for NACT and UDS in stage 173 
IIIC patients (median respectively, 30.8 (IQR: 16.5-51.3) and 28.4 (IQR: 14.1-55.7) months; HR: 1.04, 95% CI: 174 
0.90-1.21; p = 0.569; Supplemental file page 5).  PFS was similar for NACT and UDS in stage IIIC (median 175 
respectively, 12.2 (IQR: 8.4-18.3) and 11.7 (IQR: 7.5-19.9) months; HR: 1.06, 95% CI: 0.92-1.22; p = 0.429; 176 
Supplemental file page 6). However, in patients with stage IV tubo-ovarian cancer NACT resulted in 177 
significantly better OS than UDS (Figure 4) (median respectively, 24.3 (IQR: 14.1-47.6) and 21.2 (IQR: 10.0-178 
36.4) months; HR: 0.76, 95% CI: 0.58-1.00, p = 0.048).  PFS was also significantly better in stage IV disease 179 
with NACT than with UDS (median respectively, 10.6 (IQR: 7.9-15.0) and 9.7 (IQR: 5.2-13.2) months; HR: 180 
0.77, 95% CI: 0.59-1.00, p = 0.048) (Supplemental file page 7).  181 
OS was best in patients with a largest metastatic extrapelvic  tumour size < 5 cm at the time of randomisation 182 
(Supplemental file page 8).  In patients with stage IIIC disease and a largest metastatic tumour size < 5 cm, the 183 
PFS was better with UDS than with NACT (Figure 5A, respectively median 12.2 (IQR: 8.5-23.3) and 11.7 (IQR: 184 
8.3-16.4); HR: 1.36, 95% CI: 1.06-1.75; p=0.017;  hazard plots according to largest metastatic tumour size 185 
Supplemental file page 9), but the OS was not significantly different (median respectively, 33.0 (IQR: 13.5-78.7) 186 
and 30.2 (IQR: 16.5-51.3);  HR: 1.26, 95% CI: 0.96-1.65; p=0.092, Figure 5B).  Due to deviation from the 187 
proportional hazards assumption in this subgroup, restricted mean survival times are presented in table 3. Age 188 
and performance status were not predictive for treatment effect on survival (Supplemental file, page 10) 189 
Discussion 190 
This pre-planned analysis of updated data from the EORTC and CHORUS trials on NACT versus UDS in 191 
advanced tubo-ovarian cancer (stage IIIC and IV), confirms that with long-term follow-up NACT results in non-192 
inferior OS and PFS compared with UDS. The planned non-inferiority margin, an increase of more than 18-19% 193 
in hazard ratio, was well outside the lower confidence bounds (11% and 13% for PFS and OS respectively). 194 
Hence, this meta-analysis with long-term follow-up confirmed that both UDS and NACT are 2 possible 195 
treatment options for patients with FIGO Stage IIIC or IV tubo-ovarian cancer. However, the analysis also 196 
revealed  that PFS and OS was significantly better with NACT compared to UDS in patients diagnosed with 197 
stage IV disease. On the other hand, women with stage IIIC disease with a largest extrapelvic metastatic tumour 198 
mass of less than 5 cm had a significantly better PFS with UDS.  For those with stage III disease and larger sized 199 
metastatic disease, either approach resulted in the same OS. In the women with stage IIIC and largest metastatic 200 
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tumours at diagnosis < 5 cm, both PFS and OS curves have crossing treatment arms indicating deviation from 201 
the proportional hazards assumptions. Therefore the restricted mean survival times (table 3) give a better 202 
indication of the treatment effect than the median times (11). These findings indicate that when deciding on a 203 
treatment strategy, not only should the risk of perioperative morbidity (6) and the possibility of debulking the 204 
patient’ disease to zero residual tumour (7) be taken into account, but also FIGO 1988 stage and the extent of the 205 
metastatic disease at presentation.  206 
Although in both studies, a cytological diagnosis of malignancy was permitted, with the evolution of our 207 
knowledge regarding tubo-ovarian cancer disease subtypes, presently only histology can reliably distinguish 208 
between high-grade and low-grade serous carcinomas (13). This is important since low grade serous carcinomas 209 
are much less sensitive to chemotherapeutic regimens and primary surgery is an important and much preferred 210 
intervention in this group (14). Thus to  facilitate optimal decision making, tissue should be obtained for 211 
histological diagnosis  in all cases and this should be  combined  with extensive radiological imaging.  Obtaining 212 
tissue for histological examination is usually possible using image guided biopsy (usually of the omental cake), 213 
although a laparoscopic approach is necessary in some cases and provides additional information on disease 214 
distribution which can be included in the decision making process. (15-17)   215 
Both trials have been investigating the timing of surgery in advanced tubo-ovarian cancer and have been 216 
criticised for their low R0 rates and low survival rates. However, it should be noted that at the time these patients 217 
were randomised, NACT was not accepted as an alternative for UDS and the majority of the patients had 218 
extensive Stage IIIC or IV disease, visible on CT.   Furthermore, in addition to the EORTC 55971 and CHORUS 219 
trials,  the SCORPION (15)  and the JCOG0602 (18) randomised trials concluded that perioperative morbidity 220 
was more favourable with interval debulking after neoadjuvant chemotherapy than after primary  debulking 221 
surgery. Currently, the TRUST trial randomising NACT versus PDS in advanced tubo-ovarian cancer has been 222 
developed and is recruiting patients in selected centres with 50% or more R0 rates. The results of this new trial 223 
are awaited with interest. A limitation of this meta-analysis might be that in the EORTC trial only patients with 224 
stage IIIC and IV were included while in the CHORUS trial also a (limited) number of patients with stage IIIA 225 
and B were included. In addition, the number of patients with Stage IIIC-IV disease without residual tumor after 226 
UDS tended to be lower in the CHORUS than in the EORTC trial. 227 
Application of the findings of this analysis to the care of every woman with stage IIIC or IV tubo-ovarian cancer 228 
should be tempered by the patients’ clinical picture. For example, women in these studies had metastatic disease 229 
with a high tumour burden at presentation, and many had a poor performance status. (19)  This clinical scenario 230 
is not uncommon and improving outcomes for this population is as important (if not more so) than those who 231 
have much better prognostic factors. Accepting the caveats implicit within all clinical trials, the results regarding 232 
the clinical management of stage IV disease are derived from one of the largest cohorts of women with stage IV 233 
disease in phase III studies. Although some stage IV patients have a better prognosis and present with less spread 234 
and more easily resectable disease (14) than the majority of Stage IV patients,  our data infer that NACT be the 235 
standard of care for most patients with stage IV tubo-ovarian cancer, and primary surgery should only be 236 
undertaken exceptionally in women selected on an individual basis.  237 
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Table 1. Baseline characteristics by study 
 
 EORTC 
 (n= 670)  
CHORUS 
(n=550)  
TOTAL 
(n=1220)  
Median Age (years) (range) 62 (25-86) 
IQR: 54.0 - 69.0 
65 (26-88) 
IQR: 58.0 - 72.0 
63 
IQR: 56.0 - 71.0 
Largest metastatic tumor size (mm) 
(range) 
80 (0-400) 
IQR: 42.0 - 140.0 
80 (7-500) 
IQR: 50.0 - 120.0 
80 
IQR: 48.0 - 130.0 
CA125 at entry (KU/L) (range) 1161 (15-41456) 
IQR: 
1016 (26-39323) 
IQR: 
1089 
IQR: 
 
 
 
 
 
Table 1
 Table 2. Baseline characteristics by allocated treatment  
 UDS 
(n=612)  
NACT 
(n=608)  
TOTAL 
(n=1220)  
Median Age (years) (range) 63 (25-87)  
IQR: 55.0 - 71.0 
64 (33-88)  
IQR: 57.0 - 70.0 
63  
IQR: 56.0 - 71.0 
Largest metastatic tumor size 
(mm) 
 (range) 
80 (0-430)  
IQR: 49.0 - 130.0 
80 (0-500)  
IQR: 47.0 - 125.0 
80  
IQR: 48.0 - 130.0 
CA125 at entry (KU/L) (range) 1039 (16-39323) 
IQR:  409.0 - 
2547.5 
1137 (15-41456)  
IQR: 446.0 - 
2606.0 
1089  
IQR: 431.0 - 
2599.0 
 
Table 2
1 
 
 1 
Table 3: restricted mean survival time (RMST) estimates in patients with FIGO Stage IIIC and largest 2 
metastatic tumour size < 5 cm at entry 3 
 
  RMST 95% CI 
Overall survival UDS 47.3 months 40.4 – 54.1 
 NACT 39.3 months 33.9 – 44.8 
Progression free survival UDS 27.5 months 21.2 – 33.8 
 NACT 17.0 months 13.8 – 20.2 
 4 
Table 3
  
PRISMA 2009 Flow Diagram 
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synthesis (meta-analysis) 
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The trial steering 
committees of both the 
EORTC-55971 and MRC 
CHORUS agreed on strategy 
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schedule to facilitate 
pooling. 
Figure 1
(years)
0 2 4 6 8 10
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk : Treatment
528 612 323 149 74 27
525 608 338 147 65 22
Upfront debulking surgery
Neoadjuvant chemotherapy
Overall survival
O
ve
ra
ll 
su
rv
iv
al
 (%
)
Overall Score test stratified for Study: p=0.586
Figure 2 Panel A
(years)
0 2 4 6 8 10
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk : Treatment
588 612 87 48 27 16
583 608 92 39 26 8
Upfront debulking surgery
Neoadjuvant chemotherapy
Progression free survival
Pr
og
re
ss
io
n 
fre
e 
su
rv
iv
al
 (%
)
Overall Score test stratified for Study: p=0.688
Figure 2 Panel B
(years)
0 2 4 6 8 10
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk : Study
602 670 395 185 102 42
451 550 266 111 37 7
EORTC 55971
MRC CHORUS
Overall survival
O
ve
ra
ll 
su
rv
iv
al
 (%
)
Overall Score test: p=0.004
Figure 3
(years)
0 2 4 6 8 10
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk : Treatment
112 118 53 13 7 2
104 112 57 25 8 4
Upfront debulking surgery
Neoadjuvant chemotherapy
Overall survival
FIGO IV
O
ve
ra
ll 
su
rv
iv
al
 (%
)
Overall Score test stratified for Study: p=0.048
Figure 4 Panel A
FIGO Stage
Events / Patients
UDS NACT
Statistics
  (O-E) Var.
HR & CI*
:(UDS NACT) HR (95% CI)
Overall Survival
*95% CI everywhere
Treatment effect: p>0.1
better betterQ=11.93 (df=2) p<0.01, I 2= 83.2% (49.1% ; 94.5%)
UDS NACTHeterogeneity
0.25 0.5 1.0 2.0 4.0
IV          112 / 118          104 / 112         14.3         52.3 1.31 (1.00 ; 1.72)
Total          499 / 579          462 / 537         14.5       236.2 1.06 (0.94 ; 1.21)
(86.2 %) (86 %)
IIIc          366 / 433          347 / 398         -7.6       176.9 0.96 (0.83 ; 1.11)
I-IIIb           21 / 28           11 / 27          7.8            7 3.02 (1.44 ; 6.32)
Figure 4 Panel B
(years)
0 2 4 6 8 10
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk : Trtm arm
130 136 32 21 15 10
128 130 19 7 4 1
UDS
NACT
Progression free survival
FIGO IIIc and <5cm
Pr
og
re
ss
io
n 
fre
e 
su
rv
iv
al
 (%
)
Overall Score test: p=0.017
Figure 5 Panel A
(years)
0 2 4 6 8 10
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk : Trtm arm
108 136 88 44 32 13
110 130 78 30 12 5
UDS
NACT
Overall survival
FIGO IIIc and <5cm
O
ve
ra
ll 
su
rv
iv
al
 (%
)
Overall Score test: p=0.092
Figure 5 Panel B
  
Supplementary appendix
Click here to download Necessary Additional Data: Supplemental file Meta-analysis.pdf
  
Research in context Vergote
Click here to download Necessary Additional Data: Research in context Vergote resubmission 2 clean.docx
  
List of investigators for PubMed
Click here to download Necessary Additional Data: List of investigators to be mentioned on Pubmed-two columns.docx
  
Appendix II MRC-EORTC stast plan in data release agreement
Click here to download Necessary Additional Data: MRC CHORUS_EORTC Data disclosure agreement Appendix II.pdf
CHORUS  Chemotherapy OR Upfront Surgery 
Version 2.0  5 June 2008 
 
 
 
 
                                   
 
CHORUS - A randomised trial to determine the impact of timing of surgery 
and chemotherapy in newly diagnosed patients with advanced epithelial 
ovarian, primary peritoneal or fallopian tube carcinoma 
 
 
 
Version 2.0 
 
 
   
5 June 2008 
EUDRACT number:  2007-004429-45 
ISRCTN:  74802813 
 
 
  
 
 
 
 
                              
 
 
                                                        RCOG     
 
 
 
 
 
 
                                         
 
 
 
 
Authorised by: 
 
Name:     Prof S Kehoe Role: Chief Investigator 
Signature: 
 
Date: 5th June 2008 
 
 
Name:     Dr Ann Marie Swart Role: Senior Clinical Epidemiologist  
MRC CTU 
Signature: 
 
Date: 5th June 2008 
 
 
CHORUS  Chemotherapy OR Upfront Surgery 
Version 2.0  5 June 2008 
General Information 
This document describes the CHORUS trial, and provides information about procedures 
for entering patients into it. The protocol should not be used as an aide-memoire or 
guide for the treatment of other patients. Every care was taken in its drafting, but 
corrections or amendments may be necessary. These will be circulated to known 
investigators in the trial, but centres entering patients for the first time are advised to 
contact the MRC Clinical Trials Unit (CTU) to confirm they have the most up to date 
version in their possession. Clinical problems relating to this study should be referred to 
the Chief Investigator or Medical Oncology Advisor. 
 
Chief 
Investigator 
 
 
 
 
 
Prof Sean Kehoe 
Nuffield Department of  
Obstetrics and Gynaecology 
John Radcliffe Hospital 
Headington 
Oxford OX3 9DU 
 
 
Tel:  0186 5222 007 
Fax: 0186 5221 001 
 
 
 
 
 
Medical Oncology 
Advisor 
 
 
Prof Gordon Jayson 
CRUK Dept of Medical Oncology 
Christie Hospital 
Wilmslow Road 
Withington 
Manchester M20 4BX 
 
 
Tel:  0161 446 3606 
Fax: 0161 446 8565 
 
 
 
Senior Clinical 
Epidemiologist 
 
Dr Ann Marie Swart  
MRC Clinical Trials Unit 
 
Tel: 0207 670 4764 
Email: ams@ctu.mrc.ac.uk 
 
 
Trial Manager 
 
Chorus Trial Manager 
MRC Clinical Trials Unit 
 
Tel:  0207 670 4804 
Email: 
CHORUS@ctu.mrc.ac.uk 
 
Senior 
Statistician 
 
Dr Wendi Qian 
MRC Clinical Trials Unit 
 
Tel: 0207 670 4705 
Email: wq@ctu.mrc.ac.uk 
 
Trial 
Coordination: 
 
 
Cancer Group 
MRC Clinical Trials Unit 
222 Euston Road 
London NW1 2DA  
 
CHORUS email: 
CHORUS@ctu.mrc.ac.uk 
 
Fax: 0207 670 4818 
Website: www.ctu.mrc.ac.uk 
 
RANDOMISATION 
Tel. +44 (0) 20 7670 4777 
(between 0900 and 1700 hours, Monday to Friday) 
 
SAFETY REPORTING 
Fax: +44 (0) 20 7670 4818 
CHORUS  Chemotherapy OR Upfront Surgery 
Version 2.0  5 June 2008 
CONTENTS 
    Page 
1. Trial Schema............................................................................................................ 2 
2. Summary.................................................................................................................. 3 
3. Background and Rationale ..................................................................................... 5 
3.1 Additional Considerations................................................................................. 7 
4. Aims ......................................................................................................................... 8 
5. Selection of sites and clinicians............................................................................. 8 
5.1 Selection of sites and clinicians ........................................................................ 8 
5.2 Site Approval.................................................................................................... 9 
6. Selection of patients ............................................................................................. 10 
6.1 Eligibility Criteria............................................................................................. 10 
6.2 Screening and pre-randomisation investigation .............................................. 10 
7. Randomisation ...................................................................................................... 10 
8. Pre-treatment Assessments ................................................................................. 12 
8.1 Disease confirmation (Neoadjuvant Chemotherapy Arm) ............................... 12 
8.2 Disease confirmation (Primary Surgery Arm).................................................. 12 
9. Treatment of Patients............................................................................................ 12 
9.1 Primary Surgery Arm ...................................................................................... 12 
9.2 Neoadjuvant Chemotherapy Arm ................................................................... 12 
10. Treatment Details ................................................................................................ 13 
10.1 Chemotherapy.............................................................................................. 13 
10.2 Surgery ........................................................................................................ 14 
10.3 Co-enrolment ............................................................................................... 14 
11. Schedule of Assessment and Follow-up ........................................................... 15 
11.1 Case Report Form Schedule ........................................................................ 15 
11.2 Clinical follow up........................................................................................... 15 
11.2.1 Long term follow-up ................................................................................... 16 
11.3 Disease Assessment .................................................................................... 16 
11.4 Trial Closure................................................................................................. 16 
12. Discontinuation of trial intervention and withdrawal of consent ..................... 19 
12.1 Discontinuation from trial intervention........................................................... 19 
12.2 Withdrawal of Consent ................................................................................. 19 
13. Serious Adverse Events (SAEs) ......................................................................... 20 
13.1 Definitions of Adverse Events/Reactions ...................................................... 20 
13.2 CHORUS Specific Exceptions to Seriousness Criteria ................................. 21 
13.3 Clinical Trial Site/Investigator Responsibilities .............................................. 21 
13.4  Investigator Assessment ............................................................................. 21 
13.4.1 SERIOUSNESS...................................................................................... 21 
13.4.2 CAUSALITY .......................................................................................... 21 
13.4.3 EXPECTEDNESS ................................................................................... 21 
13.5 Notification ................................................................................................... 22 
13.5.1 NOTIFICATION PROCEDURE:.................................................................. 22 
13.6  MRC CTU Responsibilities .......................................................................... 23 
14. Statistical Considerations................................................................................... 25 
14.1 Method of randomisaton............................................................................... 25 
14.2 Outcome Measures ...................................................................................... 25 
14.3 Sample size.................................................................................................. 25 
14.4 Statistical Analysis Plan................................................................................ 25 
15. Ancillary Studies ................................................................................................. 26 
15.1 Quality of Life ............................................................................................... 26 
15.1.1 INSTRUMENT ........................................................................................ 26 
15.1.2 COMPLETION OF QOL QUESTIONNAIRES ................................................ 26 
15.2 Health Economics ........................................................................................ 26 
16. Ethical Considerations and approval................................................................. 27 
16.1 Ethical Considerations.................................................................................. 27 
CHORUS  Chemotherapy OR Upfront Surgery 
Version 2.0  5 June 2008 
16.2 Ethical Approval ........................................................................................... 27 
16.3 Patient Confidentiality................................................................................... 28 
16.4 Regulatory Approval ..................................................................................... 28 
17. Sponsorship and Indemnity ............................................................................... 28 
18. Finance................................................................................................................. 28 
19. Trial Committees ................................................................................................. 29 
20. Publication........................................................................................................... 30 
21. Protocol Amendments ........................................................................................ 30 
22. References........................................................................................................... 31 
 
APPENDICES 
Appendix A  Calculations for GFR and Carboplatin Dose…………………………….33 
Appendix B  Recommended Dose Modification………………………………………..34 
Appendix C  Evaluation Criteria of Disease Status…………………………………….38 
Appendix D  WHO Performance Status…………………………………………………39 
Appendix E  FIGO Staging (Ovarian Cancer)…………………………………………..40 
Appendix F  List of Expected Toxicities………………………………………………….41 
LIST OF TABLES 
 
Table 1:  Summary of Non-randomised Studies of neoadjuvant platinum-based  
  Chemotherapy…………………………………………………………….………6 
Table 2  Trial Assessment Schedule………………………………………….…………..17 
Table 3:  Definitions of Adverse Events/Reactions  …………………………………….20 
Table 4:  Definitions of Causality …………………………………………….……………22 
Table 5:  SAE Notification Procedure……………………………………….…………….23 
 
LIST OF FIGURES 
Figure 1: CHORUS Trial Schema ………....…………………………………......................2 
Figure 2: Safety Reporting Flowchart…………………………………………………..…...24 
Figure 3: Diagram of relationships between trial committees………………...…………..29 
 
 
 
 
CHORUS  Chemotherapy OR Upfront Surgery 
Version 2.0  5 June 2008 
ABBREVIATIONS 
AE  Adverse Event 
AR  Adverse Reaction 
AUC  Area Under the Curve 
BSA  Body Surface Area 
CEA level Carcinoembryonic Antigen 
CHORUS Chemotherapy Or Upfront Surgery 
CI  Chief Investigator 
CRF  Case Report Form 
Cr  Serum Creatinine 
CTU  Clinical Trials Unit 
CrCl  Creatinine Clearance 
CT scan  Computed Tomographic Scan  
CTA  Clinical Trial Authorisation 
CV   Curriculum Vitae 
ECOG  Eastern Cooperative Oncology Group 
EORTC  European Organisation for Research and Treatment of Cancer 
FIGO  International Federation of Gynaecology and Obstetrics 
GFR  Glomerular Filtration Rate 
HR  Hazard Ratio 
ICON  International Collaborative Ovarian Neoplasm 
IDMC  Independent Data Monitoring Committee 
IDS  Interval Debulking Surgery 
IPD   Individual Patient Data 
LREC  Local Research Ethics Committee 
MRC  Medical Research Council 
MHRA  Medicine and Healthcare Regulatory Authority 
NCI CTCAE National Cancer Institute- Common Terminology Criteria for Adverse Events 
NCRI  National Cancer Research Institute 
ONS  Office of National Statistics 
OS  Overall Survival 
PFS  Progression Free Survival 
QoL  Quality of Life 
RCOG  Royal College of Obstetrics and Gynaecology 
R&D  Research and Development 
SAE  Serious Adverse Event 
SAR  Serious Adverse Reaction 
SCOTROC Scottish Randomised Trial in Ovarian Cancer 
SCr  Serum Creatinine 
SLL  Second Look Laparotomy 
SOP  Standard Operation Procedure 
SPC  Summary of Product Characteristics 
SUSAR  Suspected Unsuspected Serious Adverse Reaction 
TAH/BSO Total Abdominal Hysterectomy with Bilateral Salpingo-oopherectomy 
TMG  Trial Management Group 
TSC  Trial Steering Committee 
WHO  World Health Organisation 
Wt  Weight
 
 
CHORUS  Chemotherapy Or Upfront Surgery 
Version 2.0 Page 2 of 43 5 June 2008 
1. Trial Schema 
Figure 1: CHORUS Trial Schema 
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2. Summary 
 
Type of design 
CHORUS is a multi-centre randomised trial designed to evaluate the safety and efficacy 
of neoadjuvant chemotherapy i.e. chemotherapy given before and after primary surgery 
compared to standard surgery followed by chemotherapy.   
 
Patients to be included 
CHORUS is a trial predominantly for women with newly diagnosed, suspected 
advanced ovarian carcinoma.  However, women with primary peritoneal or fallopian 
tube cancer who fulfil other entry criteria, with clinical and/or imaging evidence of 
extrapelvic metastatic disease at presentation may be randomised. 
 
Treatment of patients in the Trial 
The standard treatment of ovarian cancer is primary cytoreductive surgery followed by 6 
cycles of platinum-based chemotherapy.  In CHORUS, patients will be randomly 
assigned to either the standard treatment (primary surgery) arm or to the neoadjuvant 
chemotherapy arm in which 3 cycles of carboplatin-based chemotherapy will be given 
followed by radical surgery and a further 3 cycles of carboplatin-based chemotherapy.   
 
Patients randomised to the primary surgery arm will have disease confirmed at surgery.  
Those who have residual disease following primary surgery and 3 cycles of 
chemotherapy may have additional interval debulking surgery after the 3rd cycle of 
chemotherapy if their surgeon has specified this prior to randomisation and believes 
that it is in the best interest of the patient. 
 
Patients randomised to the neoadjuvant chemotherapy arm, who have not had 
confirmation of cancer prior to randomisation, are required to have histological or 
cytological confirmation of ovarian, primary peritoneal or fallopian tube cancer prior to 
starting chemotherapy.  This will be performed by laparoscopic assessment (open 
laparoscopy permitted), image guided trucut biopsy/core biopsy or fine needle 
aspiration.  All women who are fit to have surgery after 3 cycles of chemotherapy are 
required to undergo cytoreductive surgery. Imaging evidence of no residual disease at 
mid-treatment assessment is not a reason for not performing radical surgery.  
 
Duration of treatment 
Treatment of patients in both arms includes surgery and 6 cycles (18 weeks) of 
chemotherapy is expected to be complete after 28 weeks.  In the standard treatment 
(primary surgery) arm, surgery is expected to be performed within 4 weeks after 
randomisation and chemotherapy to start within 6 weeks after surgery.  In the 
neoadjuvant arm, chemotherapy is expected to start within 4 weeks after 
randomisation, radical surgery to start as close to 3 weeks after cycle 3 as possible and 
chemotherapy to restart within 6 weeks following surgery.  It should be noted that the 
duration of treatment may be extended in either arm if treatment delays occur due to 
toxicity from chemotherapy or delayed recovery from surgery. 
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Outcome Measures 
 
The primary outcome measure is overall survival (OS).  The secondary outcome 
measures include progression-free survival (PFS), safety and patient reported 
outcomes of quality of life (QoL). 
 
Evaluation of Outcome Measures 
 
Patients will be clinically assessed prior to surgery and each cycle of chemotherapy. 
Regular examinations and blood tests will be performed during treatment to monitor 
safety.  Tumour assessments will be performed after 3 and 6 cycles of chemotherapy 
and when clinically indicated.   After treatment is completed follow-up reports will be 
requested at 9 months and 12 months after randomisation and every 3 months in the 
2nd year, every 6 months in the 3rd year after randomisation and then annually. Follow-
up forms will record details of disease status, toxicities and any further treatment given.  
 
Patients should be treated for relapse according to standard local practice. 
 
Sample Size and Data Maturity 
 
150 patients were randomised in the feasibility study.  An additional 400 patients are 
required to be randomised over a further 48 months.  The primary analysis will occur 
when 550 patients have been randomised and the last patient randomised has been 
followed for 2 years.   
 
When combined with EORTC 55971 trial, data on a total of 1250 randomised patients 
will be analysed (550 CHORUS, 704 EORTC 55971) and will reliably exclude a 5-6% 
difference in 3-year overall survival. This trial is designed as a non-inferiority trial. 
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3. Background and Rationale 
Ovarian cancer is the leading cause of death from gynaecological cancer and the fourth 
most frequent cause of death from cancer in women. In most cases, a combination of 
surgery and chemotherapy forms the basic management strategy. While there have 
been improvements in overall survival, mortality rate remains high and there is a 
significant  need to increase the number of treatment options for women with ovarian 
cancer.  The surgical approach in ovarian cancer, of primary surgery followed by 
chemotherapy, is unique for solid malignant tumours in that primary debulking surgery 
is advocated for advanced disease, although macroscopic residual disease remains in 
a significant proportion of patients. Evidence for the standard approach is based on 
many non-randomised studies, comparing survival of patients with optimum 
cytoreduction to those suboptimally cytoreduced. The true impact of primary 
cytoreductive surgery has never been exposed to the accepted standard of a 
randomised clinical trial. Indeed, a systematic review of non-randomised studies of 
cytoreductive surgery indicates that platinum-based chemotherapy rather than 
cytoreductive surgery may be the treatment which primarily influences survival.1 
 
Currently only one modestly sized randomised trial provides evidence supporting 
cytoreductive surgery and this in the context of a second surgical procedure, interval 
debulking surgery (IDS), specifically in patients with chemosensitive disease.3  
Conversely, the results of another similar sized randomised trial, which investigated the 
effect of IDS on patients with suboptimally debulked advanced ovarian cancer, 
suggests that progression-free and overall survival is not altered by IDS.4  A smaller trial 
in Birmingham supports this.5 
 
Whilst clarification on the role of IDS after primary surgery is required, the most 
important question to answer is the impact of primary debulking surgery. The main 
debate surrounding primary debulking surgery in ovarian cancer is the relationship 
between the ability to achieve successful optimum debulking, inherent tumour biology 
and chemo-sensitivity. Studies of neoadjuvant chemotherapy may throw some light on 
this relationship. There are four reports specifically relating to neoadjuvant 
chemotherapy in ovarian cancer (see Table 1). 
 
Schwartz et al.6 compared 59 women who underwent neoadjuvant chemotherapy, (with 
debulking surgery after chemotherapy in 41 cases), with 206 women who had primary 
debulking surgery followed by platinum-based chemotherapy. There was no clear 
evidence of a survival difference, although the trend favoured conventionally treated 
patients. However, the neoadjuvant patients had a significantly poorer ECOG score, 
and some were considered unfit for surgery, whilst in the conventional arm some 
patients had no macroscopic disease, or were optimally cytoreduced. Thus a poorer 
survival would have been anticipated in the neoadjuvant patient population. In this trial, 
diagnosis was made on clinical examination, positive cytology/histology (using trucut 
biopsy/fine needle aspiration) in conjunction with CT scans.  
 
Surwit et al.7 administered neoadjuvant platinum-based chemotherapy to 29 women 
with advanced disease diagnosed on clinical/imaging methods with adenocarcinoma 
confirmed on cytology or trucut biopsy of abdominal tumour. Dose intensive cisplatin or 
carboplatin was given followed by definitive cytoreductive surgery. The overall median 
survival was 22.5 months.  
Vergote et al.8 reported a retrospective study on a cohort of patients undergoing 
neoadjuvant chemotherapy, with the use of laparoscopy to facilitate diagnosis followed 
by IDS. They achieved a crude 3-year survival of 24.8%. The authors concluded that in 
patients with advanced ovarian carcinoma, and a large tumour load deemed not 
resectable, neoadjuvant chemotherapy affords an alternative strategy of care. 
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Jacob et al.9 undertook a prospective non-randomised 3-arm study of advanced ovarian 
carcinoma using neoadjuvant chemotherapy. In arm 1, 22 patients underwent a 
diagnostic laparotomy (biopsy only, residual disease >2cm) followed by 2-4 cycles of 
platinum based therapy, IDS, 6 cycles of platinum therapy and second look laparotomy 
(SLL). In arm 2, 22 patients with more than 2cm residual disease after primary 
debulking received 6 cycles of platinum therapy followed by SLL with debulking surgery. 
In arm 3, 18 patients with more than 2cm residual disease after primary surgery went 
on to receive immediate re-laparotomy and debulking surgery followed by 6 cycles of 
therapy and SLL. The median survival in all groups appeared to be similar at 16, 19.3 
and 18 months respectively. 
 
Table 1: Non-randomised Studies of neoadjuvant platinum-based chemotherapy 
Study 
Reference 
No. of 
patients 
Stage Surgical Procedures Median 
Survival 
 
Schwartz6 
 
59 
 
206 
IIIc/IV 
 
IIIc/IV 
Debulking (41) after 
chemotherapy 
Primary surgery  
12.8 months 
 
26.2 months 
Surwit7 29 IIIc/IV Debulking after chemotherapy 22.5 months 
Vergote8 41 III/IV Interval debulking surgery (IDS) 24.8% at 3yr 
 
 
Jacob9 
22 
 
22 
 
 
18 
IIIc/IV 
 
IIIc/IV 
 
 
IIIc/IV 
Interval debulking surgery and 
second look laparotomy 
Primary surgery and debulking 
surgery at second look 
laparotomy 
Primary surgery, re-laparotomy  
and debulking surgery at second 
look laparotomy 
16 months 
 
19.3 months 
 
 
18 months 
These exploratory studies are small and non-randomised. However, they do raise 
important questions in managing women with advanced ovarian cancer. Firstly, 
neoadjuvant chemotherapy does not appear to adversely affect survival compared with 
conventionally treated patients and secondly, the ability to diagnose disease without 
resorting to laparotomy is feasible with present diagnostic tools. The optimum approach 
to debulking in patients with ovarian cancer by either treatment modality requires a 
prospective randomised trial.   
The European Organisation for Research and Treatment of Cancer (EORTC) has 
performed a similar trial to CHORUS (EORTC 55971) which closed to recruitment in 
December 2006.  First results are not expected until 2008 and since the EORTC trial on 
its own has only 80% power to exclude a difference of 8%, which is a large difference to 
accept as ‘non-inferiority’ in this setting, the results are unlikely to be conclusive.  Other 
trials, considered as positive and influencing clinical practice, like ICON410, showed an 
absolute difference in 2 year overall survival of 7% between platinum based 
chemotherapy alone and platinum plus paclitaxel.  It is therefore important to conduct 
CHORUS both to provide additional data on the effect of neoadjuvant chemotherapy 
and to be able to combine data from EORTC 55971 in a prospective meta-analysis to 
be able to exclude a 5% difference in overall survival.    
Even if neoadjuvant chemotherapy does not itself improve outcome of women with 
ovarian cancer, robust evidence from these randomised trials of ‘non-inferiority’ will 
improve the treatment options with improved flexibility of timing of surgery and 
chemotherapy and will open up the possibility of new research questions, for example 
whether surgery can be delayed until all chemotherapy has finished or whether 
CHORUS  Chemotherapy Or Upfront Surgery 
Version 2.0 Page 7 of 43 5 June 2008 
chemotherapy could replace surgery as primary treatment in women with advanced 
disease. 
This protocol for the full CHORUS trial follows on from the successfully completed 
CHORUS feasibility study which opened in March 2004.  The feasibility study reached 
its target accrual with good clinical and QoL data return rates and no safety issues were 
identified. 
 
3.1 Additional Considerations 
 
• The results of an individual patient data (IPD) meta-analysis demonstrated that 
platinum-based chemotherapy is better than non-platinum therapy in terms of 
overall survival of patients with ovarian cancer, and that cisplatin and carboplatin 
are equally effective therapies.11 However, in view of the superiority of 
carboplatin with respect to toxicity and quality of life during treatment, carboplatin 
has been selected as the platinum-based chemotherapy of choice in this trial.12 
• CHORUS is aimed primarily at women with ovarian cancer, however under 
certain situations women with primary peritoneal and fallopian tube cancer can 
be included. 
• Extra-ovarian primary peritoneal carcinoma can account for up to 10% of 
women with a presumed clinical diagnosis of advanced ovarian cancer. The 
clinical presentation is primarily abdominal distension with ascites, evidence of 
omental metastasis and raised CA 125. This condition is frequently 
indistinguishable from advanced ovarian cancer pre-operatively. In addition, 
there is also little difference between the two groups in terms of epidemiological 
characteristics, treatment strategy, response to chemotherapy, and prognosis. 
Because of this, patients with primary peritoneal carcinoma who present with a 
pelvic mass as well as extra-pelvic disease may be considered for entry to 
CHORUS.   
• Primary cancer of the fallopian tube accounts for only 0.5% of all gynaecologic 
cancers. As with primary peritoneal cancer, this condition is frequently 
indistinguishable from advanced ovarian cancer pre-operatively, and the staging 
and therapeutic management has been adapted to that of ovarian cancer. For 
this reason, patients with fallopian tube carcinoma, who present with a pelvic 
mass and extra-pelvic disease may be considered for entry to CHORUS. 
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4. Aims 
The aim of this randomised trial is to investigate the impact of timing of surgery and 
chemotherapy in newly diagnosed patients with advanced ovarian, primary peritoneal, 
or fallopian tube cancer in terms of overall survival, progression-free survival, quality of 
life, and safety. 
 
5. Selection of sites and clinicians 
 
5.1 Selection of sites and clinicians 
 
In order for a site to participate in the CHORUS study, the Principal Investigator for the 
clinical trial site must sign a CHORUS Investigator statement and the nominated person 
for the Hospital Trust must sign a Clinical Trial Site Agreement (CTSA) based on the 
“Model agreement for non-commercial research in the NHS”. 
 
By signing the investigator statement and the CTSA, the PI and his/her hospital trust 
agree to the following: 
 
• The clinical trial site regularly undertakes the treatment of ovarian cancer. 
• The investigator has appropriate experience of conducting trials according to 
International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) 
and the trial is conducted in compliance with the GCP and applicable regulatory 
requirements. 
• The clinical trial site has an adequate number of qualified staff and adequate 
facilities, for the foreseen duration of the trial, to conduct the trial properly and 
safely. 
• The clinical trial site has experienced surgeons accredited in gynae-oncology 
and who specialise in the management of patients with gynaecological 
malignancies. 
• The clinical trial site has appropriate pathologists who specialise in the reporting 
of gynae-oncology specimens. 
• The clinical trial site has trained oncologists to deliver chemotherapy, who 
specialise in the treatment of ovarian cancer, and who are integrated into the 
gynae-oncology multi-disciplinary team and are experienced in the care of 
patients receiving carboplatin and paclitaxel. 
• All staff assisting with the trial are to be adequately informed about the protocol 
and their trial related duties. 
• The study must be conducted in accordance with the current protocol and 
changes will only be made when necessary to protect the safety, rights and 
welfare of patients. 
• Formal protocols are to be in place at the clinical trial site to deal with acute 
medical or acute surgical complications of treatment. 
• The clinical trial site permits monitoring by the MRC Clinical Trials Unit (MRC 
CTU), and inspection by the appropriate regulatory authorities. This includes 
direct access to all trial related sites, documents, reports and data. 
• The clinical trial site must maintain a trial master file, which will contain essential 
documents for the conduct of the trial. 
• All trial data must be submitted in a timely manner as described in the protocol. 
• Individual clinical trial sites may be suspended on the recommendation of the 
Trial Management Group (TMG) if data returns are poor or if trial conduct is 
violated in other ways. 
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• All Serious Adverse Events (SAE) must be reported immediately to the MRC 
CTU, except for those that the protocol identifies as not requiring immediate 
reporting. 
• Initial SAE reports must be promptly followed by detailed written reports as 
appropriate. 
• No trial data can be disclosed without the approval of the Trial Steering 
Committee (TSC). 
• All trial related documents must be retained for 5 years after the completion of 
the trial. 
 
5.2 Site Approval 
 
Clinical trial site will be authorised to randomise patients in this trial only when they 
have returned the following documents to the MRC CTU: 
• Confirmation of Local Research Ethics Committee (site-specific assessment) 
favourable opinion 
• Confirmation of Local R&D approval  
• Copy of the most recent version of the patient information sheet and consent 
form on local headed paper 
• CV for Principal Investigator  
• Clinical Trials Site Agreement 
• Signed investigator statement  
• Completed delegation log (signature list and delegation of responsibilities) 
• Full contact details for all site personnel 
• Completed local trial master file self assessment form 
 
For each clinical trial site, the responsibilities and contact details (phone, fax and email 
address) of each person working on the CHORUS trial must be documented on the 
Delegation of Responsibility Log. Clinical trial sites must notify MRC CTU of any 
subsequent changes to trial personnel and/or their responsibilities. 
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6. Selection of patients 
 
6.1 Eligibility Criteria  
• Imaging evidence (with or without clinical evidence) of a pelvic mass with extra-
pelvic metastatic disease (compatible with FIGO stage III/IV) at presentation. 
Patients must be randomised within 6 weeks of the imaging evidence of a pelvic 
mass. 
• Serum CA 125/CEA ratio > 25 [if the serum CA 125/CEA ≤ 25 and the serum CEA 
is above the upper limit of normal, the patient should undergo investigations to 
exclude gastrointestinal cancer] 
• Patient planned to receive carboplatin-based chemotherapy 
• Patient fit to undergo protocol treatment and follow-up 
• No concomitant or previous malignancy likely to interfere with protocol treatments or 
comparisons.  Patients may have received previous adjuvant chemotherapy for 
other malignancies e.g. breast or colorectal carcinoma if diagnosed over 5 years 
ago with no evidence of subsequent recurrence. 
• Written informed consent of the patient 
 
6.2 Screening and pre-randomisation investigation 
 
Assessment of the stage of disease is required prior to randomisation. Clinical 
staging should include thorough physical examination and imaging of abdominal 
and pelvic regions, and should be compatible with the FIGO staging criteria (see 
Appendix E).  A chest X ray should also be performed. Histological and cytological 
disease confirmation prior to randomisation is permitted. 
 
7. Randomisation 
 
Before entering any patients into the trial, written informed consent must be obtained 
from the patient. One copy of the consent form should be given to the patient, one copy 
should be kept with the hospital notes and one copy should be kept at the local site 
master file 
 
The baseline Quality of Life questionnaire must also be completed before the patient is 
informed which treatment has been allocated.  
 
To enter a patient, complete the Randomisation Form, CHORUS/R, and telephone the 
MRC Clinical Trials Unit on 020 7670 4777 (Monday to Friday, 9 am - 5 pm). The 
following information must be available after first confirming the patient satisfies the 
eligibility criteria: 
 
• Protocol title and number 
• Name of entering clinician 
• Name of entering hospital 
• Name of gynaecological surgeon 
• Surgery hospital  
• Name of oncologist 
• Oncology hospital 
• Patient’s initials 
• Date of birth  
• Hospital number (at both surgery and oncology hospitals) 
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• Date of imaging evidence of disease prior to randomisation 
• Stage of disease (based on clinical and imaging evidence of disease) 
− if compatible with stage IV disease, reason why 
• Largest tumour size measured radiologically  
• CA 125 level, and date of test 
• CEA level, and date of test 
• CA 125/CEA ratio 
− if the CA 125/CEA ratio ≤ 25 and the serum CEA is above the upper limit of 
normal, the patient should undergo investigations to exclude gastrointestinal 
cancer before randomising 
• WHO performance status (Appendix D) 
• Chosen carboplatin-based chemotherapy (single agent carboplatin; carboplatin and 
paclitaxel; carboplatin and other) 
• Intention to perform interval debulking surgery (yes or no) 
• Confirmation of the date on which histological or cytological confirmation of disease 
will be obtained if randomised to neoadjuvant arm. 
The patient will be allocated a trial number and treatment arm which should be 
recorded. Written confirmation of the patient’s entry into the trial, the trial number and 
the treatment allocated will be sent to the hospital by post. Following randomisation, 
the Randomisation Form (CHORUS/R) should be sent immediately to the MRC Clinical 
Trial Unit.  
This trial is a comparison of treatment policies; once a patient has been 
randomised they will remain in the trial and full documentation of cancer 
treatments and follow up will be required. 
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8. Pre-treatment Assessments  
  
8.1 Disease confirmation (Neoadjuvant Chemotherapy Arm) 
 
Before neoadjuvant chemotherapy, evidence of carcinoma must be established 
histologically or cytologically (providing the patient has a pelvic mass and CA 
125/CEA ratio ≥ 25).  
If randomised to the neoadjuvant chemotherapy arm, patients should undergo one 
of the following procedures to confirm their malignancy type: 
• Laparoscopic assessment (open laparoscopy permitted) 
• Image guided trucut biopsy/core biopsy 
• Fine needle aspiration 
Pathological tumour assessments should be performed by a recognised specialist 
gynaecological pathologist. It is recommended that, in appropriate cases, 
immunohistochemical markers are used to achieve an accurate diagnosis.  
 
8.2 Disease confirmation (Primary Surgery Arm) 
 
Patients randomised to the primary surgery arm should have disease status 
confirmed by FIGO staging and histology at primary surgery.  
 
9. Treatment of Patients 
 
9.1 Primary Surgery Arm 
 
Comprises radical surgery followed by 6 cycles of carboplatin-based 
chemotherapy* at 3-weekly intervals. The interval between randomisation and the 
initiation of surgery should be a maximum of 4 weeks. Chemotherapy should 
commence within 6 weeks of primary surgery.  
Interval debulking surgery may be carried out at the discretion of the clinician if 
appropriate and if stated as the intention prior to randomisation; this should be 
carried out as close as possible to 3 weeks after the 3rd cycle of chemotherapy. 
Chemotherapy should be resumed within 6 weeks of interval debulking surgery. 
9.2 Neoadjuvant Chemotherapy Arm 
 
Comprises histological or cytological confirmation of disease followed by 3 cycles 
of carboplatin-based chemotherapy* at 3-weekly intervals. Neoadjuvant 
chemotherapy should be started within 4 weeks of randomisation. Surgery 
following neoadjuvant chemotherapy to be performed as close as possible to 3 
weeks after the 3rd cycle of chemotherapy. A further 3 cycles of carboplatin-based 
chemotherapy* should be given within 6 weeks of surgery.  
*The treatment schedule in CHORUS is compatible with SCOTROC4 trial (See section 
10.3 for more details) 
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10. Treatment Details 
 
10.1 Chemotherapy 
Six, 3-weekly cycles of carboplatin, as a single agent or in combination with a taxane 
or other chemotherapy are to be given according to standard local practice. 
Experience in the use of these drugs is essential. Dose reduction may be required 
and recommended dose modifications are provided in Appendix B.  
 
The choice of chemotherapy regimen may be made on an individual patient basis, 
but must be specified prior to randomisation. Patients randomised to primary 
surgery arm will have surgery prior to any chemotherapy. Those allocated to 
neoadjuvant chemotherapy arm will have surgery after the 3rd cycle of 
chemotherapy.  
 
Carboplatin  
Minimum recommended dose 
Carboplatin   5 x (51Cr-EDTA clearance + 25) mg 
or 
6 x (calculated or 24hr urinary clearance +25) mg 
repeated every 3 weeks for 6 cycles 
Renal function 
GFR should be measured before the first cycle, by 51Cr-EDTA  
clearance if possible. Subsequent doses of carboplatin should usually 
be based on this value of GFR. However, if the patient’s serum 
creatinine changes significantly (>10% change from baseline value), 
the GFR must be re-measured/re-calculated in order to determine the 
correct dose of carboplatin to maintain the appropriate AUC. The 
reason for any change in GFR should also be considered. Urinary tract 
infection, and the development of ureteric obstruction, should be 
excluded by the appropriate investigations. 
[See Appendix A for more information on measurement/calculation of 
GFR.] 
 
Carboplatin and Paclitaxel  
Minimum recommended dose 
Carboplatin   5  x (51Cr-EDTA clearance + 25) mg 
or 
6 x (calculated or 24 hr urinary clearance +25) mg 
Paclitaxel  175mg/m2 
 
repeated every 3 weeks for 6 cycles 
Appropriate anti-emetic and hypersensitivity prophylaxis should be administered 
as per local guidelines. 
 
[See Appendix A for more information on measurement/calculation of GFR.] 
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10.2 Surgery 
 
Radical surgical procedures in both arms should be performed by a surgeon with 
specialist expertise in gynaecological oncological surgery. Surgeons wishing to 
participate in CHORUS should satisfy one of the following eligibility criteria: 
• Consultant gynaecologists with specialist expertise in gynaecological oncology 
who perform the majority of gynaecological cancer workload in their unit. 
• Consultant gynaecological oncologists who have obtained recognition of their 
subspeciality training or experience by the RCOG. 
The name of the surgeon performing the procedure will be required at 
randomisation.  
 
The recommended procedures for radical surgery will be as follows: 
• Midline incision 
• Sampling of free fluid or peritoneal washings for cytology 
• Thorough examination of the peritoneal cavity, liver, gall bladder, diaphragm, 
large and small bowel, stomach, peritoneal surfaces, pelvis, omentum, and 
retroperitoneal spaces 
• Hysterectomy, bilateral oophorectomy and omentectomy 
• Tumour debulking with the intention of leaving no macroscopic disease 
• Documentation of residual tumour size and location 
 
Whilst the intent of radical surgery should always be clearance of all macroscopic 
disease, in cases where this is obviously not feasible the disease should be correctly 
staged, tumour samples collected and any other surgical procedure deemed 
necessary on clinical grounds performed. Biopsy of pelvic and para-aortic nodes 
should be performed in patients who appear to have FIGO stage IIIb disease or less. 
 
Facilities and expertise for bowel resection or diversion and para-aortic/pelvic 
lymphadenectomy should be immediately available. The decision as to whether 
these procedures are justifiable will depend on the surgeons overall assessment of 
each patient, but the necessary expertise/facilities must be available. It is 
recognised that achieving cytoreduction may require procedures such as resection of 
large or small bowel, stoma formation, splenectomy, partial cystectomy and para-
aortic/pelvic lymphadenectomy. These procedures should only be undertaken if they 
will facilitate cytoreduction to less than 1cm residual tumour deposits. 
 
Patients in the primary surgery arm for whom the intention was to perform IDS (as 
stated at randomisation) should not have this procedure if: 
• They are shown to have progressive disease 
• They had optimal debulking primary surgery (including TAH/BSO, omentectomy)  
leaving <1cm residual disease 
• There is no evidence clinically/radiologically of disease requiring excision. 
 
10.3 Co-enrolment 
 
Double randomisation in the SCOTROC4 (A Prospective, Multicentre, Randomised Trial 
of Carboplatin Flat Dosing Vs Intrapatient Dose Escalation in First Line Chemotherapy of 
Ovarian, Fallopian Tube and Primary Peritoneal Cancers) is allowed, as is MRC 
OV07/EORTC 55041 (Erlotinib in Ovarian Cancer).  
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11. Schedule of Assessment and Follow-up 
 
All assessments and trial procedures must be performed in compliance to the most up to 
date version of the protocol, ICH-GCP, any relevant research governance and other 
regulatory requirements as appropriate.  
 
Summary information on timing of interventions and assessments for safety and efficacy 
are given in Table 2. 
 
11.1 Case Report Form Schedule 
 
• Randomisation Form (CHORUS/R) to be completed prior to randomisation. 
• Disease Confirmation Form (CHORUS/DC) to be completed for patients 
  allocated to neoadjuvant chemotherapy, following histological or cytological   
  confirmation of disease (prior to first cycle of chemotherapy). A copy of the           
  pathology report should be sent to the MRC Clinical Trials Unit for reference.  
• Chemotherapy Form (CHORUS/C) to be completed after each cycle of 
chemotherapy. 
• Disease Assessment Form (CHORUS/DA) to be completed after 3 cycles of 
chemotherapy has been received, and at termination of protocol treatment, or if 
protocol treatment discontinued prematurely. (see section 11.3 for further details) 
• Surgery Form (CHORUS/S) to be completed by the surgeon after primary 
surgery, or surgery following neoadjuvant chemotherapy. If surgery was not 
performed, this form should still be completed at approximate time of planned 
surgery. 
• Interval Debulking Surgery Form (CHORUS/IDS) to be completed for patients 
allocated to primary surgery by the surgeon after interval debulking surgery (if 
intention stated at randomisation). If interval debulking surgery was not 
performed, this form should still be completed at approximate time of planned 
surgery. 
• Follow-up Form (CHORUS/FU) at 9 months after randomisation and then every 
3 months for the first 2 years, every 6 months for the following 3 years, and then 
annually.  
• Follow-up Form for Ineligible Patients (CHORUS/FUIP) to be completed every 
6 months for the first 2 years and then annually for patients confirmed with either 
no disease or a malignancy type that render them ineligible after randomisation. 
QoL Questionnaires are not required for this group of patients. 
• Progression Form (CHORUS/PD) to be completed at time of first progression. If 
first progression is based on an elevated CA 125 level only, a second form 
should be completed at time of first clinical/radiological progression. 
• Quality of Life Questionnaire to be completed prior to randomisation, after the 
3rd and 6th cycle of chemotherapy, and at 6 and 12 months after randomisation. 
 
11.2 Clinical follow up  
After treatment is completed follow-up reports will be requested at 9 months after 
randomisation, then every 3 months for the first 2 years, every 6 months for 3 
years thereafter and then annually. These follow-up reports will record details of 
disease status, toxicities and any further treatment given. Patients should be treated for 
relapse according to local practice. Once randomised, all patients remain in the trial, 
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and clinical forms are required even when a patient does not receive protocol 
treatment. 
 
11.2.1 Long term follow-up  
Every effort should be made to follow-up patients who have been randomised. Patients 
should, if possible, remain under the care of an oncologist or gynaecologist for the 
duration of the trial. If the care of a patient is returned to the General Practitioner, it is still 
the responsibility of the investigator to ensure that the follow-up data required by the 
protocol is collected and reported. The consent of patients should be obtained for their 
names to be flagged for survival information through national registries. 
 
 
11.3 Disease Assessment 
Disease status should be assessed by clinical examination and imaging of abdomen and 
pelvis prior to randomisation for all patients.  For those in the standard treatment arm it is 
also assessed midway through treatment (after 3 cycles of chemotherapy), and at end of 
treatment (after 6 cycles, or if protocol treatment stopped prematurely for whatever 
reason). For patients in the neoadjuvant arm, mid-treatment disease assessment should 
be carried out after the 3rd cycle of chemotherapy, prior to any surgery. CT scanning is 
the preferred cross-sectional imaging modality; however, MRI is considered an 
acceptable technique.  
 
Measurement of disease progression should be based on the criteria outlined in 
Appendix C. 
 
 
11.4 Trial Closure 
The trial will be considered closed after data on overall survival (primary outcome) are 
sufficiently mature (as defined in the protocol) for the primary publication. Further 
observational follow-up of all patients enrolled in the trial may continue indefinitely. This 
will initially be via hospital and clinics, but in the longer term may exploit national 
registers.  
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1. If serum CA125/CEA ≤ 25 and the serum CEA is above the upper limit of normal 
2. For women randomised to the neoadjuvant arm, disease confirmation performed prior to 
randomization is also permitted. 
3. For women randomised to the primary surgery arm, surgery should be performed within 4 weeks of 
randomisation 
4. For women randomised to the neoadjuvant arm, surgery should be performed as close to 3 weeks 
after the 3rd cycle of chemotherapy  
5. For women randomised to the primary surgery arm, interval debulking surgery should be performed as 
close to 3 weeks after the 3rd cycle of chemotherapy 
6. Chemotherapy should be resumed within 6 weeks of either interval debulking surgery (primary surgery 
arm) or primary surgery (neoadjuvant arm) 
7. Adverse event collected at primary surgery or interval debulking surgery 
8. After completion of protocol treatment, 1st progression can be based on either serum CA125 or tumour 
assessment (CT or MRI of the pelvis and abdomen). Detailed guidance is outlined in Appendix C
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12. Discontinuation of trial intervention and withdrawal of consent 
 
In consenting to the trial, patients are consenting to trial treatment, trial follow-up and 
data collection.  
 
12.1 Discontinuation from trial intervention 
A patient may discontinue trial treatment for the following reasons: 
 
• Progression whilst on therapy 
• Unacceptable toxicity 
• Patient refusal of trial treatment 
• Any alterations in the patient’s condition or any intercurrent illness which justifies  
  the discontinuation of treatment in the investigator’s opinion.  
 
If a patient wishes to discontinue trial treatment, centres should nevertheless explain 
clearly to patient the importance of remaining on trial follow-up. This is because the data 
analysis is set up based on intention to treat, all the follow-up information (including 
quality of life and progression data) collected will be included in the data analysis. 
 
12.2 Withdrawal of Consent 
In rare circumstances, patients may withdraw their consent to participate in the trial.  
If the patient explicitly states their wish not to contribute further data to the trial, MRC 
CTU should be informed in writing and the withdrawal of consent should be documented 
by the investigator in the patient’s case report form.  
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13. Serious Adverse Events (SAEs) 
 
This trial is aimed at assessing the impact of timing of surgery and chemotherapy in 
patients with advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer. 
The effects and toxicities of individual chemotherapy regimens are not being formally 
considered, however ICH GCP requires that both investigators and sponsors follow 
specific procedures when reporting adverse events/reactions to IMP in clinical trials.   
 
In addition all serious adverse events that are considered by the responsible clinician to 
be related to the surgical procedures outlined in this protocol should also be notified to 
the MRC CTU, these events will be reviewed by the IDMC.  Any SAE that is related (to 
chemotherapy and surgery) and unexpected will be reported to the Main research ethics 
committee (REC). 
 
13.1 Definitions of Adverse Events/Reactions   
The definitions from ICH GCP apply in this trial protocol. These definitions are given in 
Table 3 
Table 3:  Definitions of Adverse Events/Reactions   
Term Definition 
Adverse Event (AE)  Any untoward medical occurrence in a patient or clinical trial 
subject to whom a medicinal product has been administered 
including occurrences which are not necessarily caused by or 
related to that product. 
Adverse Reaction (AR)
  
Any untoward and unintended response to an investigational 
medicinal product related to any dose administered. 
Serious AE (SAE) or 
Serious AR (SAR) 
 
Any untoward medical occurrence or effect that at any dose:  
" results in death 
" is life-threatening1 
" requires hospitalisation or prolongation of existing 
hospitalisation2 
" results in persistent or significant disability or incapacity 
" consists of a congenital anomaly or birth defect  
Suspected Unexpected 
Serious Adverse Reaction 
(SUSAR)  
 
A SUSAR is a SAR that is classified as ‘unexpected’ i.e. a serious 
adverse reaction, the nature and severity of which is not 
consistent with the information about the medicinal product in 
question set out in the summary of product characteristics (or 
Investigator brochure) for that product. 
Medical judgement should be exercised in deciding whether an AE/AR is serious in other 
situations.  Important AE/ARs that are not immediately life-threatening or do not result in 
death or hospitalisation but may jeopardise the subject or may require intervention to 
                                               
1
 The term ‘life-threatening’ in the definition of ‘serious’ refers to an event in which the patient was 
at risk of death at the time of the event; it does not refer to an event which hypothetically might 
have caused death if it were more severe. 
2
 Hospitalisation is defined as an inpatient admission, regardless of length of stay, even if the 
hospitalisation is a precautionary measure for continued observation.  Hospitalisations for a pre-
existing condition (including elective procedures that have not worsened) do not constitute an 
SAE. 
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prevent one of the other outcomes listed in the definition above, should also be 
considered serious. Other non-serious AE/AR should be reported on the side effects of 
treatment section of chemotherapy form (CHORUS/C) or the surgical complications 
section of the surgery (CHORUS/S) or interval debulking surgery form (CHORUS/IDS).  
 
13.2 CHORUS Specific Exceptions to Seriousness Criteria 
The following events, in the context of this trial, should not be considered as SAEs.  No 
SAE form is required and they are exempt from expedited reporting.   
• Disease progression or death as a result of disease progression  
• Elective hospitalisation and any non protocol-surgery for treatment of ovarian 
cancer, primary peritoneal cancer, fallopian tube cancer or its complications.  
• Elective hospitalisation to simplify treatment or procedures. 
• Elective hospitalisation for pre-existing conditions that have not been exacerbated 
by trial treatment. 
 
13.3 Clinical Trial Site/Investigator Responsibilities 
 
All non-serious AEs/ARs, whether expected or not, should be recorded in the toxicity 
(symptoms) section of the appropriate CRF. The relevant subset of the NCI Common 
Terminology Criteria for Adverse Event v3.0 (http://ctep.cancer.gov/reporting/index.html) 
should be used for reporting and grading the severity (i.e. intensity) of operative injuries 
encountered during radical surgery, and all toxicities experienced during chemotherapy 
given in this trial, and at follow-up.  
 
SAEs/SARs should be notified to the MRC CTU as described below.   
A flowchart (Figure 2) is given at the end of this section to help explain the notification 
procedures. Any questions concerning this process should be directed to the MRC CTU.    
 
13.4  Investigator Assessment  
13.4.1 SERIOUSNESS  
When an AE/AR occurs the investigator responsible for the care of the patient must first 
assess whether the event is serious using the definitions given in Table 3. If the event is 
serious and not exempt from expedited reporting, then an SAE form must be completed 
and faxed to MRC CTU.  
13.4.2 CAUSALITY 
The Investigator must assess the causality of all adverse events in relation to the 
chemotherapy and surgery using the definitions in Table.3 There are 5 causality 
categories: unrelated, unlikely, possible, probable and definitely related.  If the causality 
assessment is unrelated or unlikely to be related then for reporting purposes the event 
will not be regarded as an adverse reaction to trial therapy.  If the causality is assessed 
as either possible, probable or definitely related then for reporting purposes the event is 
classified as an adverse reaction. (see Table 4).  
13.4.3 EXPECTEDNESS  
The investigator must assess the expectedness of all serious adverse reactions in 
relation to chemotherapy only from the list of expected toxicities provided in Appendix F.  
The expected toxicities are based on the information of the current SPCs for carboplatin 
and paclitaxel.  Investigators must file the current version of the Expected Adverse 
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Events listing in the safety reporting section of their Investigator File, and use this list to 
determine the expectedness of all serious adverse reactions.  If other chemotherapy 
drugs are used in CHORUS then the investigator must assess expectedness against the 
current SPC for the specific drugs used.   
 
Medically qualified staff at the MRC CTU and/or the Chief Investigator (or a medically 
qualified delegate) will assess the expectedness of all serious adverse reactions reported 
in relation to surgery (based on the surgical complications criteria on the surgery form).  
 
Table 4:  Definitions of Causality  
Relationship Description Event Type 
Unrelated There is no evidence of any causal relationship Adverse 
event 
Unlikely There is little evidence to suggest there is a causal 
relationship (e.g. the event did not occur within a 
reasonable time after administration of the trial 
medication/surgery).  There is another reasonable 
explanation for the event (e.g. the patient’s clinical 
condition, other concomitant treatment). 
Adverse 
event 
Possible There is some evidence to suggest a causal relationship 
(e.g. because the event occurs within a reasonable time 
after administration of the trial medication/surgery).  
However, the influence of other factors may have 
contributed to the event (e.g. the patient’s clinical 
condition, other concomitant treatments). 
Adverse 
reaction 
Probable There is evidence to suggest a causal relationship and 
the influence of other factors is unlikely. 
Adverse 
reaction 
Definitely There is clear evidence to suggest a causal relationship 
and other possible contributing factors can be ruled out. 
Adverse 
reaction 
 
13.5 Notification  
 
13.5.1 NOTIFICATION PROCEDURE: 
1. The SAE form must be completed by the investigator (consultant named on the 
signature list and delegation of responsibilities log who is responsible for the 
patient’s care), with due care being paid to the grading, causality and expectedness 
of the event as outlined above.  In the absence of the responsible investigator the 
form should be completed and signed by a member of the site trial team.  The 
responsible investigator should subsequently check the SAE form, make changes 
as appropriate, sign and then re-fax to MRC CTU as soon as possible. The initial 
report shall be followed by detailed, written reports as appropriate.  
2.  Initial SAE reports must be faxed to the contacts shown in Table 5 within one 
working day of the investigators’ knowledge of the event.  
3. Follow-up: Patients must be followed-up until clinical recovery is complete and 
laboratory results have returned to normal or baseline, or until the event has 
stabilised.  Follow-up should continue after completion of protocol treatment if 
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necessary.  Follow-up information should be noted on a further SAE form by ticking 
the box marked ‘follow-up’ and faxing to the MRC CTU as soon as information 
becomes available.  Extra, annotated information and/or copies of test results may 
be provided separately.  The patient must be identified by trial number, date of birth 
and initials only.  The patient’s name should not be used on any correspondence. 
4. Staff at the clinical trial site must notify their local research ethics committee 
(LREC) of the event (as per the clinical trial sites standard local procedure).  
Table 5:  SAE Notification Procedure 
Country/Group Procedure 
UK (MRC/NCRI) Notify MRC CTU by FAX:  020 7670 4818 
All other groups Notify MRC CTU by FAX: +44 (0) 20 7670 4818 
 
13.6  MRC CTU Responsibilities 
Medically qualified staff at the MRC CTU and/or the Chief Investigator (or a medically 
qualified delegate) will review all SAE reports received.  The causality assessment given 
by the local Investigator at the hospital cannot be overruled and in the case of 
disagreement, both opinions will be provided in any subsequent reports. 
The MRC CTU is undertaking the duties of trial sponsor with respect to reporting of 
SUSARs and other SARs to the regulatory authority (MHRA) and the main REC. 
The MRC CTU will inform investigators of any safety issues that arise during the course 
of the trial.   
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No 
  No 
Unlikely 
Not 
related 
Yes 
Expected 
Figure 2: Safety Reporting Flowchart
Adverse Event/Adverse Reaction 
Was the event serious? 
 
• Resulted in death 
• Life-threatening 
• Required inpatient hospitalisation or prolongation of existing 
hospitalisation 
• Resulted in persistent or significant disability/incapacity 
• Consists of a congenital anomaly/birth defect 
 
Was the SAE specified in the protocol as being exempt from 
expedited reporting? 
Causal relationship to protocol medication/surgery? 
Was the SAE one of the recognised undesirable effects of the 
trial medication? 
SUSAR 
Record on an SAE 
form.  Notify MRC CTU 
within one working day 
of becoming aware of 
the event 
 
SAR 
Record on an SAE 
form.  Notify MRC CTU 
within one working day 
of becoming aware of 
the event 
 
   Unexpected 
Exempt SAE 
Record on the 
appropriate CRF 
AE/AR 
Record on the 
appropriate CRF 
SAE 
Record on an SAE 
form.  Notify MRC CTU 
within one working day 
of becoming aware of 
the event 
 Definitely, Probably, Possibly 
CRF:  Case Report From   SAE:  Serious Adverse Event    
AE:     Adverse Event   SAR:  Serious Adverse Reaction  
AR:    Adverse Reaction   SUSAR:  Suspected Unexpected Serious Adverse Reaction 
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14. Statistical Considerations 
 
14.1 Method of randomisaton 
Patients will be randomly assigned to one of the two treatment groups in a 1:1 ratio.  
Minimization with a random element to ensure that the groups are well balanced with 
respect to 5 factors: randomizing centres, largest tumour size measured radiologically, 
clinical stage, chosen chemotherapy regimen and intention to perform debulking surgery.  
 
14.2 Outcome Measures 
The primary outcome measure of this trial is: 
• Overall survival 
Secondary outcome measures are 
• Progression-free survival 
• Quality of life 
• Safety 
Survival will be assessed from date of randomisation to date of death; surviving patients 
will be censored at date last known to be alive. 
Progression-free survival will be assessed from date of randomisation to diagnosis of 
progression or death (from any cause). Details on definitions of progression can be found 
on Appendix C.  
Quality of life is being assessed using the EORTC QLQ-C30 questionnaire and the QLQ-
OV28 module. Comparisons will be made between arms at defined timepoints: after 3rd 
and 6th cycle of chemotherapy, and at 6 and 12 months after randomisation. 
 
14.3 Sample size 
CHORUS is designed to demonstrate that the neoadjuvant chemotherapy arm is not inferior 
to the primary surgery arm in terms of overall survival by combining the data with 704 
patients from EORTC 55971 trial. We aim to accrue 400 patients in 4 years combined with 
150 patients from the feasibility CHORUS study, giving a total of 550 patients. The sample 
size estimation is based on 2-year follow-up (minimum) after the completion of accrual. The 
3-year overall survival rate is approximately 50-55% (based on data from ICON3 and taking 
into account more optimally debulked patients in EORTC 55971) in the primary surgery arm.  
 
With 1250 patients randomised (550 CHORUS, 704 EORTC 55971) the trial will have 
80% power to exclude a maximum difference of 5% (901 events required), or 90% power 
to exclude a maximum difference of 6% (868 events required) in 3-year overall survival 
with a significance level of 10% (one-sided). 
 
14.4 Statistical Analysis Plan 
 
 A statistical analysis plan for the study to include detailed information on the analysis of 
primary and secondary outcome measures and plans for the prospective meta-analysis will 
be available on request from the MRC CTU. 
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15. Ancillary Studies  
 
15.1 Quality of Life 
 
Quality of life measurements are increasingly being used in randomised clinical trials to 
provide systematic, unbiased comparative data on patients’ wellbeing, social and 
psychological functioning, their experience of disease symptoms and treatment-related 
side effects. As a considerable proportion of patients in the trial will relapse and die within 
2 years, the impact that treatment has on their quality of life during this period is an 
important consideration. If neoadjuvant chemotherapy decreases mortality from ovarian, 
primary peritoneal, or fallopian tube cancer, the benefit will need to be considered in the 
context of the psychological and physical implications.  
 
15.1.1 INSTRUMENT 
 
There are number of instruments available for assessing quality of life. We have 
chosen the EORTC QLQ-C30 questionnaire, a brief yet sensitive measure of quality 
of life for patient completion. The QLQ-C30 is a 30 item self-reporting questionnaire 
incorporating five functional scales (physical, role, cognitive, emotional and social), a 
global QL scale, three symptom scales (fatigue, pain and nausea & vomiting) and a 
number of single item measures. The questionnaire is widely used in trials worldwide 
and its practicality, validity and reliability have been well demonstrated.12,13  In 
addition to the QLQ-C30 we shall also use the ovarian cancer module (QLQ-OV28) 
which is currently being developed by the EORTC quality of life trial group and is in 
the process of validation. 
 
15.1.2 COMPLETION OF QOL QUESTIONNAIRES 
 
Given the poor prognosis for advanced ovarian cancer and hence the importance of 
treatment-related toxicity, all patients should be asked to complete a QLQ-C30 
questionnaire and QLQ-OV28 module before randomisation, after the 3rd and 6th 
cycle of chemotherapy, and at 6 months and 12 months after randomisation. It 
should be emphasised that the completion of these forms helps doctors find out 
more about the effects of cancer treatment on patients’ wellbeing. It is important to 
explain to the patient that the questions refer to how they have been feeling during 
the past week, and that all questions should be answered by circling the answer 
which is closest to the way they have been feeling. 
The patient should be asked to complete the questionnaire, without conferring, whilst 
waiting to be seen in the clinic, in a quiet area if possible. The clinician or nurse in 
charge of the patient should collect the questionnaire before the patient leaves and 
should ask the patient to check that all questions have been answered. Patient 
privacy should be respected.  
 
15.2 Health Economics 
 
Within this trial, patients will be exposed to equivalent surgical and chemotherapeutic 
regimens, albeit at different times. Thus, it is not anticipated that costs should vary 
greatly. Some patients in the primary surgery arm may be considered for IDS by some 
clinicians, on the basis of clinical grounds, but this does not form part of this clinical trial. 
Health economics will therefore not be measured in this trial. 
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16. Ethical Considerations and approval 
 
16.1 Ethical Considerations 
This is a randomised controlled trial, therefore neither the patient nor the surgeon will be 
able to choose the patient’s treatment.   Treatment will be allocated randomly accruing to 
a computer-generated list.  This is to ensure that the groups of patients allocated to the 
two arms are similar.   
 
Prior to randomization, in some cases patients may have to have additional 
investigations to exclude gastro-intestinal cancer in order to comply with the eligibility 
criteria. Compared to the standard arm, patients randomised to the research arm will 
have to undergo an additional procedure to confirm that they do have ovarian, primary 
peritoneal or fallopian tube cancer.  This has been balanced against the potential risk of 
administering inappropriate chemotherapy.   
 
The trial will abide by the principles of the Declaration of Helsinki. 
 
16.2 Ethical Approval 
 
The protocol has the appropriate national research ethics committee (REC) approval for 
the countries in which it will be conducted. 
 
Prior to allowing randomisation of any patient, each clinical centre must obtain local REC 
approval including approval of the local patient information sheet. Each patient’s written 
consent to participate in the trial should be obtained after a full explanation has been 
given of the treatment options, including the conventional and generally accepted 
methods of treatment. 
One copy of the signed form should be given to the patient, one copy should be filed with 
the patient’s case notes and one copy should be filed in the Principal investigator site 
master file. With regard to quality of life, patients should receive a full explanation of the 
purposes of this part of the trial, the nature of the questionnaire and the frequency of 
completion. 
 
The right of the patient to refuse to participate in the trial without giving reasons must be 
respected. After the patient has entered the trial, the clinician must remain free to give 
alternative treatment to that specified in the protocol, at any stage, if it is felt to be in the 
best interests of the patient. However, the reason for doing so should be recorded and 
the patient will need to remain within the trial for the purposes of follow-up and data 
analysis according to the treatment option she has been allocated. Similarly, the patient 
must remain free to withdraw at any time from the protocol treatment, or from completion 
of the quality of life questionnaires, without giving reasons or prejudicing her future 
treatment.  
A statement of MRC policy on ethical considerations in clinical trials of cancer therapy, 
including the question of informed consent, is available from the MRC Head Office web 
site (http://www.mrc.ac.uk). This may be used to give guidance to participating 
investigators and to accompany applications to LREC. 
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16.3 Patient Confidentiality 
 
The MRC CTU is registered under the UK Data Protection Act to hold data as required 
for trial purposes. Trial databases will be held by MRC CTU. Patients will be allocated a 
unique trial number that will link all of the clinical information held about them on the trial 
databases. It will also be used in all correspondence with participating clinical trial sites. 
At no point in presentations or publications of trial data will individual patients be 
identified. 
 
16.4 Regulatory Approval 
 
Investigators may not enrol patients to this trial without: 
 
" The necessary notification or approval of the protocol and any amendments by 
the competent authority. 
" The approval of the protocol and any amendments by the Ethics 
Committee/Institutional Review Board. 
 
17. Sponsorship and Indemnity  
 
The MRC is the Sponsor of the trial. 
 
The MRC accepts liability attached to its sponsorship and as such would give 
sympathetic consideration to claims for any non-negligent harm suffered by a subject as 
a result of participating in the trial. Like other publicly-funded bodies, any liability arising 
from the MRC’s activities is underwritten by the UK Government and there is, therefore, 
no need to take out further cover for subjects participating in the trial. 
Where studies are carried out in a hospital, the hospital continues to have a duty of care 
to a patient being treated within that hospital, whether or not the patient is participating in 
an MRC-supported trial. Therefore, the MRC does not accept any liability for negligence 
on the part of employees of hospitals. This applies whether the hospital is a NHS Trust or 
not, and the MRC Cannot be held liable for any breach in the hospital’s duty of care. 
 
18. Finance 
 
The trial is coordinated at and by the MRC Clinical Trials Unit in London.  Funding for the 
full trial has been obtained from Cancer Research UK. 
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19. Trial Committees 
Figure 3 shows the relationships between the various trial committees 
 
The Chief Investigators (CI) and the MRC CTU are responsible for the day to day running 
of the trial.  The MRC CTU will prepare reports for the TMG, TSC and IDMC, including 
interim analysis, and will make safety and progress reports to the main REC and 
Medicines and Healthcare Products Regulatory Agency (MHRA). 
 
The Trial Management Group (TMG) will receive regular updates on the trial and will 
aim to meet at least once per year.  The TMG will advise the CIs and MRC CTU in the 
promotion and running of the trial. TMG members will review serious adverse events 
which have occurred in the trial.  If there are specific safety concerns these may be 
raised with the TSC and IDMC.  TMG members will include active trial investigators.  
Trial Steering Committee (TSC).  The MRC Gynaecology Trial Steering Committee has 
members who are independent of investigators and the MRC CTU while also including 
CTU staff working on the trial.  It will provide overall supervision of the trial. It will meet at 
least annually, and will receive reports from the MRC CTU, TMG and IDMC. 
Independent Data Monitoring Committee (IDMC) is independent of investigators and 
the MRC CTU. The group will meet at least once every year while patients are receiving 
trial treatment and thereafter as required.  The IDMC will review reports from the MRC 
CTU and give advice on continuing recruitment.  No formal stopping rules for efficacy are 
planned.  A recommendation to discontinue recruitment (in all patients or in selected 
subgroups) will be made only if the emerging safety data indicate that the safety of the 
patients is not ensured. The IDMC will make recommendations to the TSC as to the 
Independent Data Monitoring  
Committee 
Trial Steering  
Committee 
Trial Management Group 
CHORUS/EORTC 55971 
Liaison Group 
Participating Centres 
MRC  
(Sponsor) 
Question/Feedback Question/Feedback 
Report Report 
Feedback 
IDMC report to TSC  
via MRC CTU 
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continuation of the trial.  A copy of the IDMC charter is available from the MRC CTU on 
request.  
Charters will be developed for all committees. 
CHORUS/EORTC 55971 Liaison Group consisting of the Chief Investigators of 
CHORUS and EORTC 55971 and representatives of MRC CTU and EORTC Data 
Centre have met to ensure that similar data are being collected in both trials to enable a 
prospective meta-analysis and will continue to meet as required.   
 
20. Publication  
The results from different centres will be analysed together and published as soon as 
possible. Individual clinicians must not publish data concerning their patients that are 
directly relevant to questions posed by the study until the Trial Management Group has 
published its report. The Trial Management Group will form the basis of the Writing 
Committee and advise on the nature of publications.  
All publications shall include a list of participants, and will acknowledge the role of all  
individuals in the trial and the role of the writing committee (which should include the 
Principal Investigator, Medical Oncology Advisor, Clinical Trial Manager(s), and 
Statistician(s) involved in the trial). 
 
21. Protocol Amendments  
Please check that you are using the most recent version of the CHORUS protocol. 
 
The Chorus protocol had a non-substantial amendment on the 5th June 2008.  The 
following changed were made: 
• There were changes to the trial staff on the inside front cover. 
• Section 6.1 was rewritten to clarify eligibility regarding clinical and imaging 
assessment, and that patient must be randomised within 6 weeks of imaging, to 
reflect standard practice within the trial. 
• Section 7 on page 10 was changed regarding the collection of patient names.  
Patient names are no longer collected as standard practice. 
• The wording in section 8.1, on page 12, was clarified to confirm that the 
histological/cytological disease confirmation may have been carried out before 
randomisation (for patients randomised to the neoadjuvant chemotherapy arm).  
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APPENDIX A: CALCULATIONS FOR GFR AND CARBOPLATIN DOSE 
 
Estimation and Measurement of Glomerular Filtration Rate for Calculation of 
Carboplatin Dose 
 
Estimation and Measurement of Glomerular Filtration Rate (GFR) 
 
For the purposes of this protocol, the GFR can be considered equivalent to the creatinine 
clearance (CrCl). The following methods are suggested however it is advised that the 
centre calculates the GFR according to local guidelines:  
 
" Estimation of GFR using the Wright formula 
 
There are a number of different Wright formulae, depending on whether or not the 
creatinine kinase is available and used in the calculation, and also depending on 
how the serum creatinine is measured. The formula immediately below does not 
require a creatinine kinase measurement. This formula is also only valid if the 
laboratory measuring the serum creatinine uses the Jaffe method to do this. 
Centres will need to check with their local pathology laboratory how the serum 
creatinine is measured.  
 
GFR  =  {[6580 – (38.8 x age)] x BSA x 0.832} 
     SCr 
 
If the creatinine is measured using enzymic methods then following Wright formula 
should be used: 
 
GFR = {[6230-(32.8 x age)] x BSA x 0.77} 
     SCr 
 
" Estimation of GFR using the Jelliffe formula 
  GFR =  0.9 x [98-{0.8(age-20)}] x [BSA/1.73] 
      SCr x 0.0113 
 
" Estimation of GFR using the Cockcroft-Gault formula 
   GFR = 1.05 x (140-age) x Wt 
                 SCr 
 
Where  CrCl   = Creatinine Clearance (ml/min) 
  GFR  = Glomerular Filtration Rate (ml/min) 
  BSA  = DuBois Body Surface Area (m2) 
  SCr  = Serum Creatinine (µmol/l) 
  Wt  = Weight (kg) 
  Age  = Age in years (20 to 80) 
 
To convert serum creatinine in mg/dml to µmol/l use the following formula: 
    Cr (µmol/l)  =  Cr (mg/dl) x 88.4 
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Measurement of GFR  
A measured GFR is recommended if the serum creatinine is less than or equal to 53 µmol/l 
(0.6 mg/dl) or the calculated GFR is < 60ml/min. The lower of the two values of creatinine 
clearance should be used to calculate dose. The GFR can be measured by  
• 24 hour urine collection or 
• Isotopic GFR (using the value uncorrected for body surface area, BSA) 
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APPENDIX B: RECOMMENDED DOSE MODIFICATIONS 
Whenever doses are modified or delayed a 3-weekly schedule should be resumed for 
subsequent cycles if possible. The following recommendations apply only to patients who 
have not been double randomised into SCOTROC4. For patients randomised to SCOTROC4 
please follow the dose modification guidelines in the appropriate protocol.   
 
Single Agent Carboplatin 
 
Haematological 
 
Blood counts must be measured immediately prior to each cycle. For patients enrolled in 
CHORUS only, treatment should be given on schedule if neutrophil count is ≥ 1.5 x 109/l and 
platelet count is ≥ 100 x 109/l.   
 
In patients not achieving a neutrophil count of ≥ 1.5 x 109/l or a platelet count of ≥ 100 x 109/l, 
it is recommended that a one week delay in treatment should be instituted. If the 
haematological parameters have recovered after one week (i.e. neutrophils ≥ 1.5 x 109/l; 
platelets ≥ 100 x 109/l), treatment should continue at the same dose. If patients are required 
to delay for two weeks due to prolonged haematological toxicity then it is recommended that 
the dose of carboplatin should be reduced by 1 AUC unit (to AUC4 for patients dosed on 
isotopic GFR or AUC5 for those doses on calculated clearance).   
 
All subsequent doses should remain at the reduced level. The use of G-CSF or a change from 
carboplatin to cisplatin is permitted according to local practice. If blood counts do not recover 
after two dose delays (i.e. two weeks), the patient should be taken off protocol treatment at 
the discretion of the clinician. 
The patient should be advised that neutropenic fever may occur during the cycle and to seek 
medical advice if a high temperature or fever is experienced. 
 
  
Renal 
 
The GFR should be measured before the first cycle by 51Cr-EDTA clearance if possible. 
Subsequent doses of carboplatin would normally be based on this value of GFR. However, 
the GFR should be re-measured or re-calculated and the appropriate new dose of carboplatin 
prescribed in the following circumstances. 
 
 
" Renal toxicity (CTC grade 2, serum creatinine >1.5 x ULN) 
" Changes in serum creatinine of ≥ 10% 
" Each dose modification of carboplatin 
" Cycle 2, if there has been significant doubt about the true GFR at cycle 1 (e.g due to 
significant ascites) 
 
1- If the patient has been double-randomised into SCOTROC4 then a nadir blood count should be 
performed between days 14-18 as mandated. Dose modifications should be performed on the 
basis of this count following the guidelines given in the SCOTROC4 protocol (Pg 8) 
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Paclitaxel And Carboplatin 
 
Haematological 
 
Blood counts must be measured immediately prior to each cycle. Treatment should be given 
on schedule if neutrophil count is ≥ 1.5 x 109/l and platelet count is ≥ 100 x 109/l. In patients 
not achieving a neutrophil count of ≥ 1.5 x 109/l or a platelet count of ≥ 100 x 109/l, it is 
recommended that a one week delay in treatment should be instituted. If the haematological 
parameters have recovered after one week (i.e. neutrophils ≥ 1.5 x 109/l; platelets ≥ 100 x 
109/l), treatment should continue at the same dose. If patients are required to delay for two 
weeks due to prolonged haematological toxicity then the recommended dose modifications 
are given below. 
 
 
 Neutrophils > 1.5 x 109/l Neutrophils ≤ 1.5 x 109/l 
Platelets > 100 x 109/l Carboplatin: 100% dose 
Paclitaxel:  100% dose 
Carboplatin: 100% dose 
Paclitaxel: 75% dose 
Platelets ≤ 100 x 109/l Carboplatin reduce by 1 AUC 
unit (AUC to 4 if using isotopic 
GFR and 5 if using calculated 
clearance) 
Paclitaxel: 100% dose 
Carboplatin reduce by 1 
AUC unit (AUC to 4 if using 
isotopic GFR and 5 if using 
calculated clearance) 
Paclitaxel: 75% dose 
 
All subsequent doses should remain at the reduced level. The use of G-CSF or a change 
from carboplatin to cisplatin is permitted according to local practice. If blood counts do not 
recover after two dose delays (i.e. two weeks), the patient should be taken off protocol 
treatment at the discretion of the clinician.  
The patient should be advised that neutropenic fever may occur during the cycle and to 
seek medical advice if a high temperature or fever is experienced. 
 
Neuropathy 
If patients describe Grade 2 sensory or motor neuropathy, paclitaxel should be reduced in 
all subsequent cycles to 135mg/m2. If progressive neuropathy is observed after this dose 
reduction then treatment with paclitaxel should be discontinued. If patients describe ≥ 
grade 3 neuropathy, paclitaxel should be discontinued. 
Hypersensitivity 
A hypersensitivity reaction to paclitaxel is not a dose-limiting toxicity.  The acute 
management should be as per local practice. 
 
Hypersensitivity is not a contraindication to paclitaxel and patients may be retreated at full 
dose at the discretion of the investigator. If re-treatment is felt to be beneficial despite a 
hypersensitivity reaction, the following re-challenge schedule may be adopted: 
Dexamethasone 20mg iv given the night before chemotherapy, 20mg given with 
breakfast on the day of chemotherapy and 20mg iv 30 minutes prior to paclitaxel.  
Ranitidine 50mg iv or cimetidine 300mg stat 30 minutes prior to paclitaxel 
Chlorpheniramine 10mg iv stat 30 minutes prior to paclitaxel 
Paclitaxel given at 10% of the rate needed to give the solution over 3 hours i.e. 
approximately 16ml/hour.  If no further reaction is seen within 2 hours, then the 
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rate can be increased to 32ml/hour for one hour, then 64ml/hour for one hour, then 
120ml/hour for one hour and finally back to the standard 166ml/hour. Each 
escalation of rate should only be undertaken if no hypersensitivity has been seen 
in the previous hour 
Emergency resuscitation equipment and personnel should be available during the period 
of re-challenge.  
If the re-challenge is occurring within 72 hours of the original intended dosing, and a 
negligible quantity i.e. 50ml or less of the original dose was administered, re-administer 
the full dose. If a substantial proportion (i.e. ≥ 10% total dose) has been given the balance 
of the full original dose should be re-administered. 
If the re-challenge is being considered more than 72 hours after the original intended 
dosing then a full blood count should be taken to check suitability. 
Renal 
Carboplatin and paclitaxel using the schedule previously described is not expected to 
cause renal toxicity.  There are therefore no specific dose modifications for renal toxicity, 
however the administered dose of carboplatin must be recalculated, based on a 
recalculated or re-measured GFR for  
 
• Renal toxicity (CTC grade 2, serum creatinine >1.5 x ULN) 
• Changes in serum creatinine of ≥ 10% 
• Each dose modification of carboplatin 
• Cycle 2, if there has been significant doubt about the true GFR at cycle 1 (e.g due 
to significant ascites) 
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APPENDIX C: EVALUATION CRITERIA OF DISEASE STATUS 
DEFINITION OF PROGRESSION (based on WHO Criteria16) 
Progression is defined as ANY of the following: 
− An estimated increase of 25% or more in tumour masses documented at baseline 
− The appearance of one or more new lesions 
− Death due to disease without prior objective documentation of progression 
− Global deterioration in health status attributable to the disease requiring a change in 
therapy without objective evidence of progression 
 
After completion of protocol-directed treatment, progression can also be based upon 
serum CA 125 as follows: 
− Patients with elevated CA 125 pretreatment and normalisation of CA 125 must show 
evidence of CA 125 greater than or equal to two times the upper normal limit on two 
occasions at least one week apart or 
− Patients with elevated CA 125 pretreatment, which never normalises must show 
evidence of CA 125 greater than or equal to two times the nadir value on two 
occasions at least one week apart or 
− Patients with CA 125 in the normal range pretreatment must show evidence of CA 125 
greater than or equal to two times the upper normal limit on two occasions at least one 
week apart 
 
Please note:-  
Due to the potential for false-elevations of CA 125 levels secondary to surgical or 
medical disturbance to the peritoneum, CA 125 levels within 4 weeks after surgery 
should not be taken into account.17  
Patients with elevations of CA 125 during treatment should continue to receive 
protocol-directed treatment; however, clinicians are encouraged to perform 
additional assessments (e.g. physical examination, radiographic imaging) in order 
to exclude clinical or radiological progression. In the event of clinical or 
radiological progression, protocol-directed treatment may be stopped. 
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APPENDIX D: WHO PERFORMANCE STATUS 
 
0 = Normal activity without restriction 
1 = Strenuous activity restricted, can do light work 
2 = Up and about > 50% of waking hours, capable of self-care 
3 = Confined to bed >50% of waking hours, limited self care 
4 = Confined to bed or chair, no self-care, completely disabled 
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APPENDIX E: FIGO STAGING (OVARIAN CANCER) 
 
Stage 
I Growth limited to the ovaries 
Ia Growth limited to one ovary; no ascites. No tumour on the external surfaces; 
capsule intact 
Ib Growth limited to both ovaries; no ascites. No tumour on the external surfaces; 
capsule intact 
Ic Tumour either Stage Ia or Ib, but with tumour on surface on one or both ovaries; or 
with capsule ruptured; or with ascites present containing malignant cells or with 
positive peritoneal washings 
  
  
II Growth involving one or both ovaries with pelvic extension 
IIa Extension and/or metastases to the uterus and/or tubes 
IIb Extension to other pelvic tissues 
IIc Tumour either Stage IIa or IIb, but with tumour on surface on one or both ovaries; or 
with capsule(s) ruptured; or with ascites present containing malignant cells or with 
positive peritoneal washings 
  
  
III Tumour involving one or both ovaries with peritoneal implants outside the pelvis 
and/or positive retroperitoneal or inguinal nodes. Superficial liver metastasis equals 
Stage III. Tumour is limited to the true pelvis but with histologically proven malignant 
extension to small bowel or omentum 
IIIa Tumour grossly limited to the true pelvis with negative nodes but with histologically 
confirmed microscopic seeding of the peritoneal surfaces 
IIIb Tumour involving one or both ovaries with histologically confirmed implants of 
abdominal peritoneal surfaces nodes none exceeding 2cm in diameter. Nodes are 
negative 
IIIc Abdominal implants greater than 2cm in diameter and/or positive retroperitoneal or 
inguinal nodes 
  
  
IV Growth involving one or both ovaries with distant metastases. If pleural effusion is 
present there must be positive cytology to allot a case to Stage IV 
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APPENDIX F:  LIST OF EXPECTED TOXICITIES 
 
Toxicities/side effects that have previously occurred and are listed in the SPC are listed 
here.  Please record all side effects on the chemotherapy form.  These will not have to 
be reported to the MHRA but will be collected as toxicity is an endpoint of the trial.  If 
the outcome of the side effect is serious (see CHORUS protocol for definitions), the 
Serious Event Reporting Form should also be completed.  Any toxicity not described 
below, i.e. a toxicity that is unexpected, will be reported as a SUSAR. 
 
Toxicity Carboplatin Paclitaxel 
Haemapoeitic:   
Anaemia ! ! 
Febrile neutropenia ! ! 
Grade 3 or 4 lab abnormalities (according to CTC v3.0) ! ! 
Leukopenia ! ! 
Neutropenia ! ! 
Thrombocytopenia ! ! 
Gastrointestinal or Hepatobiliary:   
Abdominal pain / cramps ! No 
Anorexia  No ! 
Ascites No ! 
Constipation ! ! 
Diarrhoea (including fatal diarrhoea) / Loose stools ! ! 
Gastrointestinal ischaemia (including fatal) (including 
mesenteric vein thrombosis, and/or causing enteritis/ 
colitis / proctitis) 
No 
! 
Gastrointestinal obstruction (large and small bowel) ± 
dilatation 
No ! 
Gastrointestinal perforation (large or small bowel or 
gallbladder) 
No ! 
Hepatic failure (including encephalopathy, fatal and long 
term) 
No ! 
Nausea ! ! 
Oesophagitis/ gastritis/ enteritis / colitis (inc Clostridium 
difficile colitis) / caecitis 
No ! 
Pancreatitis No ! 
Stomatitis / mucositis / mouth ulceration No ! 
Taste disturbance / Dysgeusia ! No 
Vomiting ! ! 
Neurotoxicity:   
Asthenia / fatigue No ! 
Ataxia No ! 
Autonomic neuropathy No ! 
Confusional state  No ! 
Convulsion No ! 
Dizziness No ! 
Encephalopathy No ! 
Headache No ! 
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Toxicity Carboplatin Paclitaxel 
Ototoxicity (hearing loss and/or tinnitus and/or vertigo) ! ! 
Peripheral neuropathy (sensory and/or motor) / ! !  
Transient visual disturbance / blindness ! ! 
Biochemistry   
Elevated alkaline phosphatise (including grade 3 or 4 ! ! 
Elevated ALT (including grade 3 or 4 [CTC v3.0]) ! ! 
Elevated AST (including grade 3 or 4 [CTC v3.0]) ! ! 
Elevated bilirubin (including grade 3 or 4 [CTC v3.0]) ! ! 
Hyperuraemia ! No 
Hyperuricaemia ! No 
Cardiovascular:   
Angina pectoris / Myocardial ischaemia / Myocardial 
Infarction (MI) (fatal) 
No ! 
Arrhythmia (ventricular and supraventricular, including 
atrial fibrillation) (fatal) 
No ! 
Bradycardia No ! 
Cardiomyopathy No ! 
Deep vein thrombosis No ! 
Embolic event (peripheral or pulmonary) No ! 
Hypertension (including hypertensive crisis or 
hypertensive encephalopathy) 
No ! (milder) 
Hypotension No ! 
Peripheral oedema No ! 
Thrombophlebitis No ! 
Cutaneous:   
Alopecia ! ! 
Epidermal necrolysis No ! 
Erythema multiforme No ! 
Exfoliative dermatitis No ! 
Nail changes including onycholysis No ! 
Rash  ! ! 
Skin discolouration No ! 
Stevens-Johnson syndrome No ! 
Respiratory effects:   
Cough No ! 
Dyspnoea ! ! 
Interstitial pneumonitis No ! 
Pleural effusion / malignant pleural effusion No ! 
Pulmonary fibrosis (rare) ! ! 
Respiratory distress (long term)  ! No 
Respiratory failure No ! 
Gynaecological and Urological effects:   
Renal impairment / failure ! ! 
General undesirable effects:   
Acute myeloid leukaemia No ! 
Drug hypersensitivity / anaphylactic reaction ! ! 
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Toxicity Carboplatin Paclitaxel 
Arthralgia ! ! 
General undesirable effects / miscellaneous:   
Chills / pyrexia No ! 
Dehydration No ! 
Flu-like syndrome !  
Injection site reaction ! ! 
Infection / sepsis (fatal) (including wound infection) / 
abscess 
! ! 
Myalgia No ! 
Myelodysplastic syndrome No ! 
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Randomization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stage 3c or 4 ovarian, fallopian tube or peritoneal cancer 
(Biopsy proven; no more surgery 
Upfront Maximal Cytoreductive 
Surgery 
No Primary Cytoreductive 
Surgery 
3 courses of platin-based chemotherapy 
≥ 75 mg/m2 cisplatin or 
5 AUC     Carboplatin 
3 courses of platin-based chemotherapy 
≥ 75 mg/m2 cisplatin or 
5 AUC     Carboplatin 
Interval Debulking Surgery is recommended 
when: 
1. Primary Debulking not optimal and 
2. No progression 
No progression 
3 courses of platin based chemotherapy as 
above 
3 courses of platin based chemotherapy as 
above 
Second-look surgery allowed Second-look surgery allowed 
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1. BACKGROUND AND INTRODUCTION 
Virtually all studies of advanced ovarian carcinoma demonstrated that the size of residual tumor 
prior to the initiation of chemotherapy was an important determinant of prognosis in advanced 
ovarian carcinoma (Stage III and IV) 1-8. Present practice in such situations in many institutions is to 
optimally “debulk” the tumor. Unfortunately, no prospective randomized controlled trials 
concerning the role of primary cytoreductive surgery in advanced ovarian carcinoma have been 
performed. In the past 20 years the definition of an “optimal debulking” has changed many times, 
going from a largest residual tumor mass of 2 cm to no residual tumor. Using the authors’ definition 
of “optimal” debulking, it has been shown that the median survival is 39 and 17 months, 
respectively, for patients who have undergone successful surgical cytoreduction compared with 
patients with “suboptimal” residual disease 9. Based on these data the general opinion is that in 
patients in whom the tumor cannot be optimally debulked, cytoreductive surgery to larger lesions 
does not improve survival. The problem still fiercely under debate is whether the observed survival 
benefits for cytoreduced patients are a function of surgical skill, tumor biology or both. Indirect 
evidence is available that inherent tumor biology relates to resectability 9-12. Many retrospective 
studies showed that the prognosis in debulked patients is related to other factors than residual 
disease such as the amount of tumor in the upper abdomen prior to surgery 9,10,13,14, the presence of 
ascites 10,14, age, poor degree of differentiation 15, and the presence of uncountable peritoneal 
metastases 9,16,17.  All these studies hamper the unavoidable bias comparing patients with different 
prognostic factors.  
The only randomized trial on cytoreductive surgery was performed by the EORTC-GCCG and 
showed that interval cytoreductive surgery after 3 courses of platin-based chemotherapy lengthened 
progression-free and overall survival in the group of patients that could not be cytoreduced 
primarily18. Even in patients with a suboptimal debulking surgery the tumor reduction showed a 
survival benefit. Based on these data one could conclude that also at primary surgery tumor 
reduction, even when in patients with suboptimal cytoreduction results in a survival benefit. On the 
contrary recently neoadjuvant chemotherapy has been proposed in patients with established bulky 
disease 19-23. In one retrospective study the survival of a group of patients (n = 174) with advanced 
ovarian carcinoma treated neo-adjuvant chemotherapy when unfavorable characteristics were 
present was similar to a former series (n = 112) treated at the same institution with “optimal” 
debulking (<1.5 cm) in 89% of the patients 23. The studies suggest that the same survival with a 
lower operative morbidity might be obtained with neoadjuvant chemotherapy compared with 
primary cytoreductive surgery. Nelson proposed computerized tomographic criteria to predict 
operability in patients with suspect ovarian masses 24.Another possibility is to perform an (open) 
laparoscopy to confirm the diagnosis and to evaluate the operability 25.  
In this prospective study patients with Stage IIIc or IV ovarian carcinoma will be randomized to 
neoadjuvant chemotherapy followed by interval debulking surgery or primary debulking surgery 
followed by chemotherapy with or without interval debulking surgery. 
2. OBJECTIVES OF THE TRIAL  
The main question to be answered by this protocol is whether neo-adjuvant chemotherapy followed 
by interval debulking surgery has the same survival compared with upfront debulking surgery 
followed by postoperative chemotherapy, and analyzing whether this approach results in a lower 
postoperative morbidity and improved of quality of life.  
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The primary endpoint is overall crude survival.  
The secondary endpoints are:  
1. Progression-free survival. 
2. Quality of life according to the EORTC questionnaire QLQ-C30  
3. To assess the different treatment complications in relation to treatment arm.  
3. PATIENT SELECTION CRITERIA 
1. Preferentially biopsy proven Stage IIIc or IV epithelial ovarian carcinoma, or peritoneal or 
fallopian tube carcinoma. If biopsy is not available, fine needle aspiration (FNA) showing an 
adenocarcinoma is acceptable under the following conditions: 
♦ the patient has a pelvic (ovarian) mass, AND 
♦ omental cake or other metastasis larger than 2 cm in the upper abdomen and/or regional 
lymphnode metastasis irrespective of size, or stage IV AND 
♦ serum CA125/ CEA ratio  > 25 (ref 42). If the serum CA125/CEA ratio is < 25, a barium 
enema (or colonoscopy) and gastroscopy (or radiological examination of the stomach) 
should be negative for the presence of a primary tumor (< 6 weeks before randomization), 
and normal mammography (< 6 weeks). 
2. WHO performance status of 0, 1, or 2. 
3. No other serious disabling diseases contraindicating for primary cytoreductive surgery or primary 
platin based chemotherapy. 
4. No other prior primary malignancies, except for carcinoma in situ of the cervix and basal 
carcinoma of the skin.  
5. No clinical evidence of brain or leptomeningeal metastases. 
6. Adequate hematological, renal and hepatic function to permit platin- paclitaxel based 
chemotherapy: WBC > 3.0 x 109/L, platelets > 100 x 109/L, serum creatinine < 1.25 x upper normal 
range, serum bilirubin < 1.25 x upper normal range.  
7. Absence of any psychological, familial, sociological or geographical condition potentially 
preventing compliance with the study protocol and follow-up schedule; those conditions should be 
assessed with the patient before registration in the trial. 
8. Before patient registration/randomization, informed consent must be obtained and documented 
according to national and local regulatory requirements and the local rules followed in the 
institution. 
4. TRIAL DESIGN. 
For schema see page 3.  
Diagnosis: 1. Intraperitoneal biopsy taken with the help of laparoscopy, laparotomy, imaging-
guidance or Fine Needle Aspiration should prove the presence of epithelial ovarian, 
peritoneal or fallopian tube carcinoma.  Patients who undergo laparotomy or 
laparoscopy should not have had any other procedure than the diagnostic biopsies. 
AND 
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2. Presence of a tumor larger than 2 cm (excluding ovaries) on laparoscopy or CAT 
scan.  
Treatment: Randomization to: 
Arm A: Upfront maximal cytoreductive surgery followed by 3 courses of platin based 
chemotherapy (for details see Section 5). Immediately after surgery, patient must be 
randomized in trial 55012 (if intended to randomize patients in both trials). Interval 
debulking surgery is recommended but can be performed at physician’s discretion  in 
patients with non-optimal primary debulking surgery and again at least 3 courses of  
platin based chemotherapy (same regimen as before the interval debulking surgery). 
Arm B: Three courses of chemotherapy as in arm A followed by interval debulking surgery in 
all patients with response or stable disease. Immediately after randomization to this 
arm, patient must be randomized in trial 55012 (if intended to randomize patients in 
both trials). Followed again by at least 3 courses of platin based chemotherapy (same 
regimen as before the interval debulking surgery).  For details see section 5. 
 
Stratification:  1. Institution. 
2. Method of biopsy (laparoscopy, imaging-guidance or laparotomy, FNA). 
3. FIGO Stage IIIc or IV (Appendix 3) 
4. Largest tumor size (excluding ovaries) before surgery of 2 - 5 cm, 5 - 10 
cm, 10 - 20 cm, > 20 cm. The tumor size is preferentially measured during 
surgery and if not done based on CT findings.  
5. Intention to randomize the patient also in the 55012 trial 
Principal surgeon.  Only senior surgeons will be allowed to have the responsibility for the 
primary, interval or second-look surgery. Each institution will have to 
appoint their senior surgeons prior to starting the study.   Each senior surgeon 
will follow carefully the guideline for surgery as mentioned in appendix 4.  
This will be checked by an on-site visits.  
Second-look surgery: Each institution will have to declare before starting the study, whether 
they will perform second-look surgery or not in their patients. This 
policy must be adhered to for all patients included in both arms.  
Percentage of optimal primary debulking.  As stated in the statistics it is expected that 
about 50% randomized to primary debulking 
surgery will have a optimal debulking. Each 
year the percentage of optimal debulking 
procedures will be computed by the EORTC 
Data Center and discussed with the 
Independent Monitoring Committee which 
might consequently advise to redefine the 
required number of patients. 
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5. THERAPEUTIC  REGIMENS.  
Arm A: a. Upfront maximal cytoreductive surgery within 3 weeks after biopsy (see 
diagnosis) Immediately after surgery, patient must be randomized in trial 55012 (if 
intended to randomize patients in both trials) 
b. Followed within 3 weeks by 3 courses of chemotherapy. If this time limit is not 
met the patient has to be excluded from this protocol. Chemotherapy should be an 
cisplatin (starting dose of at least 75 mg/m2/3 weeks, or other schedules containing a 
minimum of 25 mg/m2 per week) or carboplatin-containing regimen (dose of AUC 5 
based on EDTA or Iohexol determination or, if not feasible (than omitted) 
Cockroft or Chatelut formula) The recommended regimens are summarized in 
Appendix 2.  
c. Interval debulking surgery is recommended but can be performed at physician’s 
discretion in patients with non-optimal primary debulking surgery (i.e. at least in all 
patients with > 1 cm largest residual tumor following primary surgery). Interval 
debulking surgery should be performed within 6 weeks after course 3 in all patients 
with response or stable disease. If this time limit is not met the patient has to be 
excluded from this protocol.  
d. Followed by at least 3 courses of chemotherapy within 3 weeks after surgery as in 
b. 
e. Second-look surgery is allowed if clinically indicated. 
Arm B: a. 3 courses of chemotherapy as in arm A, initiated within 3 weeks after biopsy. 
Immediately after randomization to this arm, patient must be randomized in trial 
55012 (if intended to randomize patients in both trials) 
b. Interval debulking surgery should be performed within 6 weeks after course 3 in 
all patients with response or stable disease. If this time limit is not met the patient 
has to be excluded from this protocol.  
c. Followed by at least 3 courses of chemotherapy within 3 weeks following surgery 
as in a.  
d. Second-look surgery is allowed if clinically indicated. 
Each institution must choose for a policy (and declare this on the New Commitment form) 
before the inclusion of the first patient: 
1. To follow one of the recommended regimens (see Appendix 2) for all patients. If 
another (not recommended) regimen is chosen this should be approved by the study 
coordinator. If an institution wishes to change the used regimen in their patients 
during the accrual of the protocol this has also to be approved by the study 
coordinator.  
2. each investigator may also decide to simultaneously include patients in both trials, 55971 
and 55012. In such a case, either all eligible patients will be randomized in both trials, or 
only specific subgroup(s). This should be communicated to the study coordinator and to the 
respective Data Center and will be regularly checked by the respective Data Center. 
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6. CLINICAL EVALUATION, LABORATORY TESTS, FOLLOW-UP AND 
CRITERIA OF EVALUATION.  
Clinical evaluation, laboratory test and follow-up are summarized in Table 1 and 2: 
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TABLE 1. ARM A. Primary Debulking Surgery.  
 Inclusion Primary 
Debulking 
Course 1 
d1 
Course 2 
d1 
Course 3 
d1 
Interval 
Debulking£ 
Course 4 
d1 
Course 5 
d1 
Course 6 
d1 
Second- 
look& 
Follow-up§ 
Check inclusion 
criteria 
x           
WHO Performance 
status (APP 7) 
x x
*
 x x x x
*
 x x x x
*
 x 
Serumµ xç x* x x x x* x x x x*  
QOL-C30**  x*   x (d20)    x (d20)  x (after 6 
and 12 mths) 
Tumor tissue for 
basic research& 
 x
&
    x
&
    x
&
  
Surgical form  x    x    x  
Postoperative 
complications 
 x (first 4 
weeks) 
   x (first 4 
weeks) 
   x (first 4 
weeks) 
 
Tumor measurement 
(preferentially CT 
abdomen) 
x  x
*
  x (day 
14-21) 
 x
*!
 
 x (day 
14-21) 
  
* Maximal 1 week before; £. Recommended when primary surgery not optimal and in addition stable disease or response on chemotherapy;  
& Optional; µ Serum: Leukocytes, neutrophiles, thrombocytes, hemoglobin, creatinine, bilirubin, Mg++ Optional: CA125  
ç CA125 and CEA recommended; In case of elevated CEA are endoscopic or radiologic examination of stomach and colon recommended. 
$ To be sent to Oncotech, USA, with the schemes and payment by Oncotech.  
§ Follow-up every 3 months the first 2 years; every 6 months year 3 - 5; yearly afterwards. 
** QOL: For patients simultaneously randomized in 55012, follow schedule of 55012 
! Only if interval debulking surgery performed  
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TABLE 2. ARM B. Neoadjuvant Chemotherapy.  
 Inclusion Course 1 
d1 
Course 2 
d1 
Course 3 
d1 
Interval 
Debulking£ 
Course 4 
d1 
Course 5 
d1 
Course 6 
d1 
Second- 
look& 
Follow-up§ 
Check inclusion 
criteria 
x          
Performance status x x x x x* x x x x* x 
Serumµ xç x x x x* x x x x*  
QOL-C30**  x  x (d20)    x (d20)  x (after 6 
and 12 mths) 
Tumor tissue for 
basic research& 
    x
&
    x
&
  
Surgical scheme     x    x  
Postoperative 
complications 
    x (first 4 
weeks) 
   x (first 4 
weeks) 
 
Tumor measurement 
(preferentially CT 
abdomen) 
 x
*
  x (day 
14-21) 
   x (day 
14-21) 
  
* Maximal 1 week before.  
£. Only when stable disease or response on chemotherapy. 
& Optional 
µ Serum: Leukocytes, neutrophiles, thrombocytes, hemoglobin, creatinine, bilirubin,  Mg++; optional: CA125.  
ç CA125 and CEA recommended; In case of elevated CEA are endoscopic or radiologic examination of stomach and colon recommended. 
$ To be sent to Oncotech, USA, with the schemes and payment by Oncotech.  
§ Follow-up every 3 months the first 2 years; every 6 months year 3 - 5; yearly afterwards. 
** QOL: For patients simultaneously randomized in 55012, follow schedule of 55012 
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Clinical or radiological response.  Radiological examinations or eventually physical examinations 
can be used to determine the tumor size may be used but should be identical during the first-line 
chemotherapy. The assessment of response involves all parameters. The poorest response 
designation shall prevail and if progressive disease occurs at one site  then the overall result will be 
progressive disease.  
a. Complete response (CR). Disappearance of all known disease, determined by 2 observations not 
less than 4 weeks apart.  
b. Partial response (PR)  In the case of bi-dimensionally measurable disease, decrease by at 
least 50% of the sum of the products of the largest perpendicular 
diameters of the lesions which have been measured to determine the 
effect of therapy by 2 evaluations not less than 4 weeks apart. For uni-
dimensional measurable lesions, decrease by at least 50% in the sum 
of the largest diameters of all lesions as determined by 2 evaluations 
not less than 4 weeks apart. It is not necessary for all lesions to 
qualify for partial response, but no lesions should have progressed or 
no new lesion should appear.  
c. Stable Disease (SD) A ≥ 50% decrease in the sum of the products of the largest 
perpendicular diameters (bi-dimensionally measurable disease) or 
largest diameters (uni-dimensionally measurable disease) of all 
lesions cannot be established nor can a progression as defined below 
be established.  
d. Progressive disease (PD) A ≥ 25% increase in the size of one or more bi- or uni-dimensionally 
measurable disease or appearance of a new lesion. The occurrence of 
cytologically malignant ascites or pleural fluid is also considered as 
PD.  
 
CA125 response evaluation. 26-29 
a. 50% response is defined as a 50% decrease in serum CA125 levels . There must be 2 initial 
elevated samples followed by a third sample showing a 50% fall. The samples showing a 50% fall 
must be confirmed by a fourth sample (i.e. requires 4 CA125 samples). The final sample has to be 
analyzed at least 28 days after the previous sample.  
b. 75% response. A 75% response has occurred if there has been a serial decrease in serum CA125 
levels of more than 75% over 3 samples (i.e. requires 3 CA125 levels). The final sample has to be 
analyzed at least 28 days after the previous sample.  
c. CA125 Stable disease. The criteria for 50% response, 75% response or CA125 progression are 
not (yet) fulfilled.  
d. CA125 disease progression. Disease progression based on CA125 relies on at least 3 samples. 
One of the following criteria must be fulfilled.  
1. Patients with CA125 ≤ 30 KU/L. Progression is defined by 2 consecutive samples > 60 
KU/L.  
2. Patients with CA125 > 30 KU/L. Progression according to CA125 has occurred if there 
has been either: 
♦ A 25% increase of a third sample compared with the 2 former samples which is 
confirmed by a 4th sample, or 
♦ A 50% serial increase in CA125 over 3 samples, or 
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♦ A persistent elevation of CA125 over 100 KU/L for more than 56 days without a 
50% decrease.  At least 3 samples are needed.  
Surgical evaluation. Evaluation at interval debulking, second-look or later surgery refers to prior 
surgical findings. The assessment of response involves all parameters. The poorest response 
designation shall prevail and if progressive disease occurs at one site  then the overall result will be 
progressive disease.  
a. Pathological Complete response (pCR). Disappearance of all known disease noted on prior 
surgery; all biopsies are microscopically negative.  
b. Surgical Partial response (sPR). In the case of bi-dimensionally measurable disease, decrease by 
at least 50% of the sum of the products of the largest perpendicular diameters of the lesions which 
have been measured on prior surgery. For uni-dimensional measurable lesions, decrease by at least 
50% in the sum of the largest diameters of all lesions as determined bat prior surgery. It is not 
necessary for all lesions to qualify for partial response, but no lesions should have progressed or no 
new lesion should appear. In case of macroscopically negative but microscopic positive disease the 
patient is classified as sPR.  
c. Surgical Stable Disease (sSD). A ≥ 50% decrease in the sum of the products of the largest 
perpendicular diameters (bi-dimensionally measurable disease) or largest diameters (uni-
dimensionally measurable disease) of all lesions cannot be established nor can a progression as 
defined below be established.  
d. Progressive disease (sPD). A ≥ 25% increase in the size of one or more bi- or uni-dimensionally 
measurable disease or appearance of a new lesion. The occurrence of cytologically malignant 
ascites is also considered as sPD.  
 
Time to progression will be defined as the time to clinically, CA125 or surgically defined PD as 
defined above, whichever occurs first.  
Overall survival is defined as the time from randomization to the time of death of any cause. 
Overall survival will be censored at the last follow-up assessment at which the paients was know to 
be alive.   
Performance status is evaluated according to the WHO criteria (See appendix 7). 
Toxicity of chemotherapy will be evaluated according to the NCIC Common toxicity criteria  (See 
Appendix 8). The worst level of each toxicity encountered by each patient will be reported.  
Toxicity of surgery will also be reported according to the NCIC Common toxicity criteria and will 
be separately recorded for each surgery.  
7. PATIENT REGISTRATION PROCEDURE 
Patients registration/randomization will only be accepted from authorized investigators.  
A patient can be registered / randomized after verification of eligibility directly on the EORTC Data 
Center computer, 24 hours a day, 7 days a week, through the Eurocode or the INTERNET network. 
Alternatively registration/randomization can be done by telephone to the EORTC Data Center from 
9.00 am to 6.00 p.m. Monday through Friday. 
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This must be done before the start of the treatment. 
Telephone:   (32 2) 774 16 00 
EuroCODE (modem): (32 2) 772 04 26 
EuroCODE (X25):  (206) 221 51 24 
Internet:  telnet ecvax.eortc.be 
http://www.eortc.be/eurocode 
An exhaustive list of questions to be answered during the registration/randomization procedure is 
included in the registration check-list, which is part of the case report forms. This check-list should 
be completed by the responsible investigator before the patient is registered/randomized. 
♦ protocol number ? 
♦ institution number ? 
♦ callers name ? 
♦ name of the responsible investigator ? 
♦ patient's initials (maximum 4 letters) ? 
♦ patient's chart number (if available) ? 
♦ patient's birth date (day/month/year) ? 
♦ performance status at registration 
♦ eligibility criteria : 
♦ all eligibility criteria will be checked;  
♦ actual values of the eligibility parameters will be requested when applicable 
♦ intention to randomize the patient also in the 55012 trial 
♦ DATE foreseen for TREATMENT START? 
♦ At the end of the registration/randomization procedure, a number will be allocated to the 
patient (patient sequential identification number). This number has to be recorded on the 
registration check-list, along with the date of registration/randomization. The completed 
check-list must be signed by the responsible investigator and returned to the data center with 
the initial data of the patient. The sequential identification number attributed to the patient at 
the end of the registration procedure identifies the patient and must be reported on all case 
report forms. 
8. FORMS AND PROCEDURES FOR COLLECTING DATA.  
8.1 CASE REPORT FORMS AND SCHEDULE FOR COMPLETION 
Data will be reported on the EORTC Phase III forms and sent to: 
Livia Giurgea 
EORTC Data Center 
Avenue Emmanuel Mounier, 83, bte 11 
B - 1200 BRUSSELS 
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Case report forms must be completed according to the following schedule: 
A. Before the treatment starts. 
The patient must be registered at the Data Center by EuroCODE, INTERNET or by phone (Chapter 
7). 
The following set of forms has to be returned to the Data Center: 
♦ Randomization checklist Form 0 
♦ On-study form Form 1 
♦ QOL-C30 (see chapter 11, 
quality of life assessment) 
 
The optimal way to work is to complete the registration check-list and, if possible, the above set of 
forms first, and to register the patient through EuroCODE as soon as data are complete; the date of 
registration and patient sequential identification number are then completed on the check-list, and 
the whole set can be sent to the Data Center. As soon as the patient has been registered, the first 
treatment may be administered. 
B. Immediately after each surgery. 
The following form has to be sent to ONCOTECH together with the sample: 
 
♦ PATIENT SPECIMEN ONCOTECH 
REQUISITION FORM (see 
instructions in appendix 1 and on the 
form) 
 
As more than one form could be sent at each surgery, please use one “PATIENT SPECIMEN 
ONCOTECH REQUISITION FORM” by anatomic site. 
P.S. “Primary debulking biopsy form” , “Interval debulking biopsy form”, “Second look biopsy 
form” have to be completed by ONCOTECH. 
C. Maximum 4 weeks after each surgery. 
The following set of forms has to be returned to the Data Center: 
In case of primary debulking :  
♦ Primary debulking form Form 2 
♦ Primary debulking complications form Form 3 
In case of Interval debulking:  
♦ Interval debulking form Form 6 
♦ Interval debulking complications form Form 7 
In case of Second look surgery:  
♦ Second look form Form 9 
♦ Second look complications form Form 10 
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D. After each chemotherapy cycle. 
The following form has to be returned to the Data Center : 
 
♦ Chemotherapy form Form 5 
E. On the last day of the third chemotherapy cycle and on the last day of the sixth 
chemotherapy cycle. 
The following form has to be returned to the Data Center: 
♦ QOL-C30 (see chapter 11, quality of life assessment) 
F. As soon as the investigator has decided to stop the treatment 
The following forms have to be returned to the Data Center: 
 
♦ End of treatment form Form 12 
♦ Follow-up form Form 13 
 
G. After treatment discontinuation 
Every 3 months the first 2 years, every 6 months year 3-5, yearly afterwards, the following 
form has to be returned to the Data Center: 
 
♦ Follow-up form Form 13 
 
After 6 and 12 months, the following form has to be returned to the Data Center: 
 
♦ QOL-C30 (see chapter 11, quality of life assessment) 
 
H. Upon patient first relapse. 
The following form has to be returned to the Data Center: 
 
♦ First progression form Form 13 
 
I. Upon patient death 
The following forms have to be returned to the Data Center: 
 
♦ Death form Form 15 
♦ Follow-up form Form 13 
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J. Upon occurrence of a Serious Adverse Event during the treatment period and until 30 days 
after the end of the last cycle of treatment 
♦ a serious adverse event form (form 89) must be completed and faxed to the EORTC Safety 
Desk according to the procedure described in chapter 9. 
8.2 DATA FLOW 
The case report forms must be completed and signed by the investigator as soon as the requested 
information is available, according to the above described schedule. It is the responsibility of the 
investigator to check that all original case report forms have been sent to the Data Center (except 
the “PATIENT SPECIMEN ONCOTECH REQUISITION FORM which has to be sent to 
ONCOTECH”) and that they are completely and correctly filled out. 
The original copy must be immediately returned to the EORTC Data Center, and a copy must be 
kept by the investigator. 
The EORTC Data Center will perform extensive consistency checks on the CRFs and issue Query 
Forms in case of inconsistent data. Those Query Forms must be immediately answered and signed 
by the investigator. The original must be returned to the EORTC Data Center, and a copy must be 
appended to the investigators copy of the CRFs. 
If an investigators needs to bring modifications to a CRF after the original copy has been returned 
to the EORTC Data Center, he should notify the Data Center in writing (and sign the notification), 
and append a copy of the notification to his own copy of the CRFs. 
The investigator's copy of the CRFs may not be modified unless modifications are reported on a 
Query From (or a written and signed notification), and the Query Form (or notification) reference is 
indicated on the CRF. 
9. REPORTING ADVERSE EVENTS 
Adverse events need only to be reported during the treatment period and until 30 days after the 
end of the last cycle of treatment 
(first-line chemotherapy or in relation to primary or interval debulking surgery). 
9.1 DEFINITIONS 
Adverse Drug Reactions (ADR) (where the product is marketed) are responses to a drug which are 
noxious and unintended and which occur at doses normally used in man for prophylaxis, diagnosis, 
or therapy of diseases or for modification of physiological function. 
An Adverse Event (AE) is any untoward medical occurrence or experience in a patient or clinical 
investigation subject which occurs following the administration of the trial medication regardless of 
the dose or causal relationship. This can include any unfavorable and unintended signs (such as rash 
or enlarged liver), or symptoms (such as nausea or chest pain), an abnormal laboratory finding 
(including blood tests, x-rays or scans) or a disease temporarily associated with the use of the study 
medication. 
(‘Responses to a medicinal product’ in the above definitions means that a causal relationship 
between the medicinal product and the adverse event is at least a reasonable possibility, i.e. the 
relationship cannot be ruled out) 
Serious Adverse Events (SAE) or Serious Adverse Drug Reactions (SADR) are defined as any 
undesirable experience occurring to a patient, whether or not considered related to the 
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investigational drugs or surgical procedure. Adverse events and adverse drug reactions which are 
considered as serious are those which result in: 
♦ death 
♦ a life-threatening event (i.e. the patient was at immediate risk of death at the time the 
reaction was observed) 
♦ hospitalization or prolongation of hospitalization 
♦ persistent or significant disability/incapacity 
♦ a congenital anomaly/birth defect 
9.2 REPORTING PROCEDURES 
9.2.1 NON-SERIOUS ADVERSE EVENTS AND NON-SERIOUS ADVERSE DRUG REACTIONS 
All Adverse Events (AE) and Adverse Drug Reactions (ADR) occurring during the treatment period 
and until 30 days after the end of the last cycle of treatment will be recorded on the toxicity forms. 
The investigator will decide if those events are related to the surgery or one of the products used as 
first-line chemotherapy (i.e. unrelated, unlikely, possible, probable, definitely and not assessable) 
and the decision will be recorded on the toxicity forms. Adverse Events (AE) definitely not drug 
related (i.e. reported as unrelated) will not be considered as adverse drug reactions or toxicity, but 
reported separately. 
The assessment of causality is made by the investigator using the following: 
 
RELATIONSHIP DESCRIPTION 
UNRELATED There is no evidence of any causal relationship 
UNLIKELY There is little evidence to suggest there is a causal relationship (e.g. 
the event did not occur within a reasonable time after the surgery or 
of the administration of first-line chemotherapy). There is another 
reasonable explanation for the event (e.g. the patients clinical 
condition, other concomittant treatments). 
POSSIBLE There is some evidence to suggest a causal relationship (e.g. 
because the event occurs within a reasonable time after the surgery 
or of the administration of first-line chemotherapy). However, the 
influence of other factors may have contributed to the event (e.g. 
the patients clinical condition, other concomittant treatments). 
PROBABLE There is evidence to suggest a causal relationship and the influence 
of other factors is unlikely.  
DEFINITELY There is clear evidence to suggest a causal relationship and other 
possible contributing factors can be ruled out. 
NOT 
ASSESSABLE 
There is insufficient or incomplete evidence to make a clinical 
judgment of the causal relationship. 
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9.2.2 SERIOUS ADVERSE EVENTS AND SERIOUS ADVERSE DRUG REACTIONS  
All Serious Adverse Events (SAE) and Serious Adverse Drug Reactions (SADR) must be reported 
to the EORTC safety desk by fax within 24 hours of the initial observation of the event. All details 
should be documented on the specified Serious Adverse Event/Serious Adverse Drug Reaction 
Form. In circumstances where it is not possible to submit a complete report an initial report may be 
made giving only the mandatory information as described in the “Guidelines for Completing and 
Reporting Serious Adverse Events/Serious Adverse Drug Reactions.” Initial reports must be 
followed-up by a complete report within a further 10 calender days and sent to the EORTC Safety 
Desk. The Safety Desk will forward all reports within 24 hours of receipt to the trial coordinator 
and to the Data Manager. In order that regulatory reporting requirements may be met  
documentation of  all reported serious adverse events or serious adverse drug reactions must be 
completed within 10 calendar days of the initial event.  
PLEASE SEND THE REPORT TO EORTC SAFETY DESK 
TEL +32 2 774 16 76 
Fax +32 2 772 80 27 
It should be recognized that Serious Adverse Events (SAE) and Serious Adverse Drug Reactions 
(SADR) which have not been previously documented, or which occur in a more severe form than 
anticipated (i.e. they are unexpected), are subject to rapid reporting to Regulatory Authorities by 
the promoter, however, this is not applicable to SAE or SADR which are considered unrelated to 
the study product whether expected or not. This also applies to reports from spontaneous sources 
and from any type of clinical or epidemiological investigation, independent of design or purpose. 
The source of the report (investigation, spontaneous, other) should always be specified. 
Any serious adverse events which are observed at ANY TIME after the completion of participation 
in the clinical trial and considered to be possibly related must also be reported to the Safety Desk 
using the same procedure. 
Any questions concerning the reporting of a SAE or a SADR can be asked by phone or E-mail 
(Safetydesk@EORTC.be). All forms must be dated and signed by the responsible investigator or one 
of his/her authorized staff member. 
10. STATISTICAL CONSIDERATIONS 
10.1 SAMPLE SIZE 
The primary endpoint of this study is the overall survival. Group A is considered as the standard 
arm. Based on earlier EORTC-GCCG experience about 50% of the patients with Stage IIIc or IV 
disease is optimally debulked and show a median survival of 39 months 9. (See also “Percentage of 
optimal debulking under Section 4 .trial design). Based on the EORTC-GCCG interval debulking 
surgery trial the median survival is in the other patients expected to be 26 months 18. The median 
survival of the whole group of patients randomized to Arm A is therefore expected to be 31 months. 
With an accrual time of 4 years and a minimum follow-up of 3 years, 704 patients are required in 
order to show equivalence with respect to survival between Arm A and B, with a one-sided type I 
error of 0.05 and a power of 80%. A hazard ratio larger than 0.8 is regarded equivalent; this 
corresponds to a median survival of more than 25 months in arm B, if the median survival in arm A 
is 31 months. According to the expressed interest of the EORTC-GCCG centers and former 
EORTC-GCCG experience 18, this number of patients can be accrued in 4 years. At the end of the 
trial, if no statistical differences are observed between the 2 arms, the preferred treatment will be 
chosen on the basis of its morbidity or of the quality of life of the patients.  
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10.2 Analysis 
♦ The analysis will be performed according to the intent to treat policy: all randomized 
patients will be included in the principal analysis, whatever their eligibility and evaluability 
status.  
♦ Overall survival (OS) will be measured from the date of randomization to the date of death, 
whatever the cause. OS will be estimated in both therapeutic arms by the Kaplan-Meier 
method. Comparisons will use the log rank test. A confirmatory analysis, stratified by 
center, will be performed, to take into account eventual differences between surgeons. 
♦ Progression free survival (PFS) will be measured from the date of randomization to the first 
documented date of progression, or death, whichever occurs first. PFS will be estimated in 
both arms by the Kaplan-Meier method. Comparisons will use the log rank test.  
♦ Treatment complications will be reported in contingency tables; comparisons between 
therapeutic arms will use the log rank test for trend.  
Quality of life will be analyzed according to the methods described in chapter 11. 
11. QUALITY OF LIFE ASSESSMENT 
Given the poor survival rate of patients with ovarian cancer and the toxicity of treatments, quality of 
life has become an important endpoint in clinical trials. Psychological distress such as symptoms of 
anxiety and depression, physical impairments, diminished sexual response and relationship 
concerns are commonly experienced by patients with ovarian cancer 30,31. One third of ovarian 
cancer patients being treated with chemotherapy report high levels of psychological distress 30. 
Nausea and vomiting, hair loss, peripheral neuropathy, and fatigue are the most prevalent side 
effects experienced by those patients 31. In patients with advanced ovarian cancer pain has been 
reported in approximately 40 % which results in functional impairments in 50 - 66 % of this group 
32
.  
Debulking surgery and chemotherapy may be associated with substantial side effects and functional 
impairments. Guidozzi 31 found decreased quality of life among patients with persistent ovarian 
cancer after surgery and chemotherapy compared with treatment responders. Blythe et al. 33 showed 
that optimal debulking surgery improved quality of life as measured in terms of continuation of 
normal activities, employment, confinement to bed, eating regularly, and ability to enjoy life. This 
study focuses on patients with advanced ovarian carcinoma comparing two different therapeutic 
strategies. One of the secondary endpoints of this study will be to assess Quality of Life (QOL) 
benefits in relation to the different therapeutic strategies (arm A versus arm B) and to determine 
whether the various QOL domains (physical, psychological, social, symptoms) are enhanced by one 
treatment arm.  
11.1 QOL MEASUREMENTS 
The EORTC core questionnaire QLQ-C30 will be used module to assess the QOL 34. The EORTC 
QLQ-C30 addresses physical, psychological and social aspects of QOL. The EORTC QLQ-C30 
consists of five functional scales (physical, role, cognitive, emotional, and social); three symptom 
scales (fatigue, pain, and nausea and vomiting); a global health and a QL scale; six single items 
concerning appetite loss, constipation, diarrhea, dyspnoe, sleep disturbance, and economic 
consequences of the disease and treatment. The questionnaire is designed for use in international 
clinical trials and has been developed in a multicultural setting which facilitates cross study 
comparisons. Translation for the questionnaire is available in 26 languages.  
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11.2 DATA COLLECTION PROCEDURE 
The EORTC QLQ-C30 will be administered at five points in time (T) in both treatment arms: 
T1: before randomization; prior to surgery (arm A), prior to chemotherapy (arm B) 
T2: on the last day of the third cycle of chemotherapy 
T3: on the last day of the sixth cycle of chemotherapy 
T4: 6-months follow-up 
T5: 12-months follow-up 
The number and frequency of assessment points in both treatment arms are equal. The baseline 
QOL assessment (T1) allows the comparability of the treatment groups before therapy is initiated. 
The second and third assessment (T2, T3) will be performed after the third cycle, respectively the 
sixth cycle of chemotherapy. This timing allows the evaluation of short term treatment effects on 
QOL, parallel across the trial arms. Two follow-up assessments (6-months T4; 12-months T5) 
provide long term effect of treatment on QOL in relation to the therapeutic strategies.  
For patients who are randomized in both the 55971 and 55012 trials, QOL forms will be collected 
according to the 55012 schedule only.  
T1: within 7 days before randomization 
T2: day 1 of the cycle 3 of chemotherapy 
T3: day 1 of the cycle 5 of chemotherapy 
T4: day 1 of the cycle 7 of chemotherapy 
T5: at the end of last cycle 
T6: 1st year follow up at 3 and 6 months and than stop  
Please refer to the 55012 protocol for more details. 
11.3 PROCEDURE OF DATA COLLECTION 
The questionnaire will be handed out preferably a research assistant (e.g. research nurse) trained in 
the administration of the QOL instruments. The research assistant will explain the purpose of QOL 
assessment as well as the handling of the questionnaire and will assist the patient if needed. 
Preferably, the patient should complete the questionnaires without conferring with a relative or a 
member of the staff.  
12. COST EVALUATION 
Cost evaluation will not be performed in this study. 
13. DATA MONITORING COMMITTEE 
An Independent Data Monitoring Committee will be appointed to monitor the recruitment rate, the 
toxicity and the percentage of optimal debulking surgery. If this percentage is substantially different 
from 50%, the committee may advise to recompute the sample size on the basis of new hypotheses. 
The toxicity will be reported to the investigators at each half-yearly meeting of the EORTC-
Gynecologic Cancer Cooperative Group, according to the standard praxis of the group.   
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14. QUALITY ASSURANCE 
Control of data consistency 
Data forms will be entered in the database of the EORTC Data Center by a double data entry 
procedure. Computerized and manual consistency checks will be performed on newly entered 
forms; queries will be issued in case of inconsistencies. Consistent forms will be validated by the 
Data Manager to be entered on the master database. Inconsistent forms will be kept "on-hold" until 
resolution of the inconsistencies. 
15. ETHICAL CONSIDERATIONS 
15.1 PATIENT PROTECTION 
The responsible investigators will ensure that this study is conducted in agreement with either the 
Declaration of Helsinki (Tokyo, Venice, Hong Kong and Somerset West amendments), or the laws 
and regulations of the country, whichever provides the greatest protection of the patient. 
The protocol has been written, and the study will be conducted according to the guidelines for Good 
Clinical Practice issued by the European Union (See Appendix 5). The protocol will by approved by 
the EORTC Protocol Review Committee and by the Local, Regional or National Ethical Review 
Boards. 
15.2 SUBJECT IDENTIFICATION 
The name of the patient will not be asked for nor recorded at the Data Center. A sequential 
identification number will be automatically attributed to each patient registered in the trial. This 
number will identify the patient and must be included on all case report forms. In order to avoid 
identification errors, patients initials (maximum of 4 letters), date of birth and local chart number (if 
available) will also be reported on the case report forms. 
15.3 INFORMED CONSENT 
All patients will be informed of the aims of the study according to the Patient information sheet in 
Appendix 6, and will consent voluntary in writing (see appendix 6). Documented informed consent 
must be obtained for all patients included in the study before they are registered or randomized at 
the EORTC Data Center. This must be done in accordance with the national and local regulatory 
requirements. 
16. INVESTIGATOR COMMITMENT STATEMENT AND 
ADMINISTRATIVE RESPONSIBILITIES 
Investigators will be authorized to register or randomize patients in this trial only when they have 
returned to the Data Center: 
♦ a commitment form, indicating that they will fully comply with the protocol, to include an 
estimate of their yearly accrual and if any conflict of interest may arrive due to their 
participation in the trial. 
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♦ a “ new commitment form” indicating: 
♦ chemotherapy policy for every institution or their intention to include patients in 
trials 55971 and 55012 and a policy regarding second look operation 
♦ obligation to first randomize in 55971 prior to randomize in 55012 (for patients 
entered in 55971 and 55012) 
♦ obligation to complete both CRF (for patients entered in 55971 and 55012) with the 
exception of the Quality of Life forms.  Only Quality of Life forms of the 55012 schedule 
need to be completed (for patients entered in 55971 and 55012) 
♦ obligation to obtain 2 informed consents (for patients entered in 55971 and 55012) 
♦ obligation to report a SAE for both trials (for patients entered in 55971 and 55012) 
♦ notify the local Ethical Committee of the amendments made to the protocol  
♦ Reminder: the time planned interval debulking surgery is after 3 courses of chemotherapy. 
♦ a copy of the letter of acceptance of the protocol by their local ethical committee 
♦ a signed conflict of interest disclosure form: this document will be required only if a 
possible conflict is declared by the commitment form.  
♦ The name of the responsible surgeons who will perform the surgery for all included patients.  
♦ The description of the chemotherapy selected for this study (applicable in the 2 treatment 
arms). 
♦ the description of the 2nd look policy (applicable in the 2 treatment arms). 
♦ and, if the following documents are not yet available at the Data Center: 
♦ their updated Curriculum Vitae 
♦ the list of the normal ranges, in their own institution, of all laboratory data required by the 
protocol 
As soon as all the documents have been received at the Data Center, the new investigator will be 
added to the “authorization list”, and will be allowed to register/randomize patients in the trial. 
Patients registration/randomization from centers not (yet) included on the authorization list will not 
be accepted. 
The Study Coordinators (in cooperation with the Data Center) will be responsible for writing the 
protocol, reviewing all case report forms and documenting their review on evaluation forms, 
discussing the contents of the reports with the Data Manager and the Statistician, and for publishing 
the study results. He will also generally be responsible for answering all clinical questions 
concerning eligibility, treatment, and the evaluation of the patients. 
16.1 STUDY COORDINATORS: 
Ignace Vergote, MD, PhD, 
Department Gynecologic Oncology, 
University Hospitals Leuven, Gasthuisberg, 
B-3000 Leuven, Belgium.  
Tel.: +32/16/344635 
Fax: +32/16/344629 
e-mail: Ignace.Vergote@UZ.Kuleuven.ac.be 
and, 
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Sergio Pecorelli, MD, PhD,  
Department. Gynecologic Oncology,  
Spedali Civili – University of Brescia, 
P. le Spedali Civilli 1, 
25123 Brescia (Italy),  
Tel.:.39 30 3995483 
Fax.  39 30 3384460 
 
The EORTC Data Center will be responsible for reviewing the protocol, collecting case report 
forms, controlling the quality of the reported data, and generating reports and analyses in 
cooperation with the Study Coordinator. All methodological questions should be addressed to the 
EORTC Data Center. 
16.2 EORTC DATA CENTER 
83, avenue Emmanuel Mounier, Bte 11 
B - 1200 BRUSSELS, BELGIUM 
Fax: 32-2-772.35.45 
http://www.eortc.be 
Registration of patients:  
Tel.: 32-2-774.16.00 
Coordinating physician: 
Ivana Teodorovic, MD, MSc 
EORTC Data Center 
Av. E. Mounier 83, box.11 
B 1200 - BRUSSELS 
Phone: +32 2 774 16 92 
Fax: +32 2 771 38 10 
E-mail: ite@eortc.be 
 
Statistician: 
Corneel Coens 
Av. E. Mounier 83, box.11 
B 1200 - BRUSSELS 
Phone: + 32 2 774 16 32 
Fax: + 32 2 771 38 10 
E-mail: cco@eortc.be  
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Data Manager: 
Livia Giurgea 
EORTC Data Center 
Av. E. Mounier 83, Box 11 
1200 Brussels, Belgium 
phone +32 2 774 16 09 
fax +32 2 772 35 45 
E-mail:ite@eortc.be 
All questions concerning membership in the cooperative group should be addressed to the chairman 
of the EORTC-GCCG: 
Ignace Vergote 
Dept Gynecologic Oncology 
University Hospitals Leuven, Gasthuisberg 
B-3000 Leuven Belgium 
Tel.: +32/16/344635 
Fax: +32/16/344629 
e-mail: Ignace.Vergote@UZ.Kuleuven.ac.be 
17. TRIAL SPONSORSHIP/FINANCING 
The Sponsor of the study is the EORTC. 
The Director General of the EORTC Central Office/Data Center is: 
 Professor Françoise Meunier 
 EORTC Central Office 
 Avenue Mounier 83, Bte 11 
 B 1200  -  Brussels   (Belgium) 
 Tel: + 32 2 - 774 16 41 
 Fax: + 32 2 - 771 20 04 
18. TRIAL INSURANCE 
The EORTC insurance program covers all patients entered in EORTC studies except patients from 
USA and Canada. 
Insurance within the European Union: 
When specific requirements are stated in the national laws of the E.U. countries, the insurance 
program will take these requirements into account.   
For countries where there are no specific requirements, the EORTC provides an insurance coverage 
which is valid for two years after a patient has completed the treatment strategy being studied by the 
research protocol. This insurance program covers the EORTC as the promoter, the investigators and 
all local hospital staff. 
Insurance outside the European Union: 
The EORTC insurance program only covers claims against the EORTC as the promotor in its role 
of coordinator of the research and not the investigators and local hospital staff.  
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19. PUBLICATION POLICY 
The final publication of the trial results will be written by the Study Coordinators on the basis of the 
statistical analysis performed at the EORTC Data Center. The Data Center report will be completed 
no later than 18 months after the last patient has discontinued therapy. A draft manuscript will be 
submitted by the study coordinators to the Data Center for review no later than three months after 
receiving the Data Center report. After revision by the Data Center and other co-authors (according 
to the statutes of the EORTC-GCCG) the manuscript will be sent to a major scientific journal. 
Authors of the manuscript will include the Study Coordinators, the investigators who have included 
more than 5% of the eligible patients in the trial (by order of inclusion), the Group chairman, and 
the Data Center data manager and statistician in charge of the trial. All participants and insitutes 
will be listed in the manuscript.  
Interim publications or presentations of the study may include demographic data, overall results and 
prognostic factor analyses, but no comparisons between randomized treatment arms may be made 
publicly available before the recruitment is discontinued. 
All publications, abstracts or presentations including data from the present trial will be submitted 
for review to the EORTC Data Center, the co-authors and the Group Chairman and Secretary at 
least two weeks prior to submission for abstracts, and four weeks prior to submission of 
manuscripts and slides for presentation. All data from this study are property of the EORTC-GCCG 
and the data can not be used without written agreement of the EORTC-GCCG chairman.  
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20. ADMINISTRATIVE SIGNATURES 
21. LIST OF PARTICIPANTS WITH EXPECTED YEARLY ACCRUAL 
Center Responsible Physician Accrual/year 
Leuven Vergote 30 
Coimbra De Oliveira 10-12 
Milano (EIO) Colombo 20-30 
Brescia Pecorelli 30 
Antwerp Vermorken 5-10 
Madrid Mendiola 10-20 
Amsterdam (AMC)  K. van der Velden 10-15 
Utrecht Witteveen 10-15 
Bristol Murdoch 5-10 
Nottingham Chan 5-10 
Gdansk Emerich 5-10 
Padova Maggino 8-15 
Oslo Kristensen 10 
Oviedo Lacave 10-12 
Rotterdam van der burg 5-10 
Barcelona Madronal 5-7 
Glasgow Reed 10-15 
Torino Zola 10 
TOTAL  198 - 271/year 
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APPENDIX 1. TUMOR SAMPLES FOR BASIC RESEARCH. 
The Task Force for Basic Research of the EORTC-GCCG encourages all investigators participating 
to this study to collect tumor tissue as described below for analyses of different prognostic factors.  
This study will represent represents a uniform and large group of patients with advanced ovarian, 
fallopian tube or peritoneal carcinoma which is ideal for the analyses of the value of new prognostic 
or predictive variables. In addition, sequential analyses will be able to perform on patients 
undergoing 2 or 3 surgical procedures during the protocol (primary surgery, interval debulking 
surgery, and eventual second-look surgery.   
Immunohistochemistry on p53, bcl-2, c-erb2, and MIB-1) and DNA flow cytometry have been 
suggested to be of importance in advanced ovarian carcinoma 35. Currently several in vitro drug 
response assays have been developed to improve the success of drug(s) selection 36-38. In particular, 
the “extreme drug resistance” (EDR) assay has been shown to provide accurate results 39,40, and will 
also be tested.  
1. Site and time points of biopsy. 
1.1 Site: Preferentially the site of the primary tumor will be sampled. If not possible a 
biopsy from metastatic sites is allowed. 
2.2 Time points: - Primary debulking surgery. 
- Interval debulking surgery. 
- Second-look surgery.  
2. Tumor Tissue Procurement and Processing:  
2.1 Sample Collection: Non-necrotic, sterile tumor specimens of minimum of 0.5 
grams (preferably between 1.5 and 3 grams, no more than 5 
grams) are obtained by excisional biopsy or core biopsy. 
2.2 Sample Packaging: All specimen containers, labels and patient identification 
sheets are provided by Oncotech.  Following incisional 
biopsy, tumor tissue is placed immediately into the sterile 
culture media tube.  This tube is sealed and labeled in smudge-
proof ink with the institution number, patient last name, 
patient first name, patient hospital record number and date of 
tissue sample collection.  The labeled inner tube is then placed 
into an outer protective tube, which is in turn sealed, placed in 
the supplied absorbent material, then enclosed in the zip-lock 
bag provided.  The patient identification sheet denoting the 
study number for the patient is completed.  Both the tumor 
tissue specimen and attached patient identification sheet are 
enclosed in the cardboard box provided. 
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2.3 Sample Shipment: On the day of tumor tissue acquisition, immediately after the 
sample is obtained and packaged, Oncotech is called at 
+17145660420 to arrange for Federal Express pick-up.  The 
specimen is to be identified by the referring institution as a 
protocol sample.  Tumor tissue samples must be received and 
processed by Oncotech within 24 hours of shipment.  When it 
is anticipated that the delay between tumor tissue sample 
collection and receipt at Oncotech will be more than 24 hours 
(for samples collected on Saturday or Sunday), the packaged 
sample must be stored refrigerated (not frozen) until courier 
pick-up.  The phone call for pick-up must then be made on the 
next business day. 
3.Tumor Tissue Processing and Assays. 
The majority of tumor tissue is disaggregated into single-cell suspension by the Oncotech 
laboratory.  Viability is determined by trypan blue exclusion.  Viable cells from the resultant 
suspension are then exposed to chemotherapeutic agents for the EDR assay. A fraction of untreated 
tumor tissue is then formalin-fixed/paraffin-embedded for histologic confirmation and 
immunohistochemical determination of p53, bcl2, MIB1 and c-erb2.  
4. Final Patient Registration. 
Once received at Oncotech, the tumor tissue sample will be assigned a protocol tracking number. 
Approximately 7 days will be required for sample processing. After successful completion of the 
EDR, p53, bcl2, MIB1 and c-erb2 assays, the site sending the tumor and one of the Study 
Coordinators (I. Vergote or S. Pecorelli) will be notified by Oncotech of the results of the assays.  
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PATIENT SPECIMEN ONCOTECH REQUISITION FORM 
 
PRINCIPAL MONITOR 
 
RITA S. MEHTA, M.D. 
PRINCIPAL INVESTIGATOR 
 
 
 EORTC Randomization  
NO. (if available) 
__ __ __ 
PROTOCOL NO. 
EORTC No. 55971  
STUDY PERIOD 
     SCREEN 
DATE OF SHIPMENT               
Day/Month/Year 
          /           / 
 
Hospital ______________________________     City___________________________________ 
Country ______________________________     Referring Physician______________________ 
Date of Biopsy _________________________ Birth Day: ___________________(dd/mm/yy)      
Patient’s  Initials________________________  Hospital I.D. #  __________________________ 
Type of surgery (Primary, Interval or Second-look Surgery): ____________________________ 
Anatomic Site: (Primary tumor or metastatic) ________________________________________ 
Instructions for Specimen Handling 
1. Obtain 1-3 grams of fresh viable tumor tissue. 
2. Specimens from contaminated sites should be washed with copious amounts of sterile saline. 
3. Place tissue immediately in Oncotech Transport Medium. 
4. Seal inner and outer vials tightly. 
5. Place vials and this form into the shipping package. 
6. Close transport package securely and keep refrigerated until courier arrives for pickup. 
7. To arrange for specimen pickup, call Federal Express. 
8. Notify Oncotech that this specimen for Protocol N° 55971 is on its way 
Oncotech contact person: 
Ricardo Parker, email: rparker@oncotech.com 
 Oncotech Incorporated 15501 Red Hill Avenue 
 Tustin, California 92780 
 Tel: +17145660420 or +17145660422 if after 4 pm CET 
  Fax: +17145660421 or  +17145660423 
NOTES: Do not expose tissue to formalin or other fixatives 
 Do not freeze specimen. 
 Do not mince specimen. 
Oncotech Transport Medium contains growth-supporting factors and antibiotics.  Please refrigerate until 
use.  Call Oncotech for additional vials of Transport Medium, or to replace out-of-date Transport Medium. 
COMMENTS (record item number from above for each comment): 
 
SIGNATURE: S-1 
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APPENDIX 2.  RECOMMENDED CHEMOTHERAPY REGIMENS.  
1. Paclitaxel -Cisplatinum.  
Paclitaxel 135 mg/m2 over 24 hours, followed by  
Cisplatinum 75 mg/m2   
Q 3 WEEKS. 
Neutrophils (109/l) Platelets (109/l) Cisplatinum* Paclitaxel* 
Day 1: > 1.5  
Day 1: < 1.5  
Nadir: < 0.5 during 7 d 
          < 0.5 and >38.5°C 
Day 1: > 100 
or, Day 1: < 100 
or, < 25.000 
100% 
delay 1 week 
100% 
100% 
100% 
delay 1 week 
75% 
75% 
* Percentage of dose of the previous course. 
Non-haematological toxicity: 
 
 Cisplatinum* Paclitaxel* 
Neurological  NCIC grade >2 
Renal creatinine > 1.25 N 
Ototoxicity NCIC grade > 2 
stop protocol 
stop protocol 
stop protocol 
stop protocol 
stop protocol 
stop protocol 
* Percentage of dose of the previous course. N: upper normal range 
 
or  
Paclitaxel 175 mg/m2 over 3 hours, followed by 
Cisplatinum 75 mg/m2 
Q 3 WEEKS. 
Neutrophils (109/l) Platelets (109/l) Cisplatinum* Paclitaxel* 
Day 1: > 1.5  
Day 1: < 1.5  
Nadir: < 0.5 during 7 d 
          < 0.5 and >38.5°C 
Day 1: > 100 
or, Day 1: < 100 
or, < 25.000 
100% 
delay 1 week 
100% 
100% 
100% 
delay 1 week 
75% 
75% 
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Non-haematological toxicity: 
 Cisplatinum* Paclitaxel* 
Neurological  NCIC grade >2 
Renal creatinine > 1.25 N 
Ototoxicity NCIC grade > 2 
stop protocol 
stop protocol 
stop protocol 
stop protocol 
stop protocol 
stop protocol 
* Percentage of dose of the previous course. N: upper normal range 
 
2. Paclitaxel - Carboplatinum.  
Paclitaxel 175 mg/m2 over 3 hours, followed by 
Carboplatinum AUC 5 
Q 3 WEEKS. 
Neutrophils (109/l) Platelets (109/l) Carboplatinum* Paclitaxel* 
Day 1: > 1.5  
Day 1: < 1.5  
Nadir: < 0.5 during 7 d 
          < 0.5 and >38.5°C 
Day 1: > 100 
or, Day 1: < 100 
or, < 25.000 
100% 
delay 1 week 
100% 
100% 
100% 
delay 1 week 
75% 
75% 
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APPENDIX 3. FIGO STAGING. OVARIAN CANCER 41.  
 
The staging is surgical.  
STAGE 1 TUMOR LIMITED TO THE OVARIES. 
STAGE 2 TUMOR INVOLVING ONE OR BOTH OVARIES WITH PELVIC EXTENSION. 
STAGE 3 TUMOR INVOLVING ONE OR BOTH OVARIES WITH INTRAPERITONEAL 
METASTASES OUTSIDE THE PELVIS AND/OR POSITIVE 
RETROPERITONEAL LYMPH NODES.  
3a. Microscopic disease in the upper abdomen. 
3b. Metastases smaller than 2 cm in the upper abdomen. 
3c. Metastases larger than 2  cm in the upper abdomen. 
Stage 4. Tumor involving one or both ovaries with distant metastases outside the upper abdomen or 
intrahepatic metastases.  
 
For cancer of the fallopian tube or peritoneal carcinoam stage 3c or 4 the same rules are 
followed as for  ovarian cancer.  
EORTC 55971  Upfront surgery vs. neoadjuvant chemotherapy in OC. 
Version 9.1 38/59 06 October 2003 
APPENDIX 4. SURGICAL GUIDELINES.  
Only senior surgeons will be allowed to have the responsibility for the primary, interval or second-
look surgery. Each institution will have to appoint their senior surgeons prior to starting the study.   
Each senior surgeon will follow carefully the guidelines for surgery as mentioned here.  
GUIDELINES FOR PRIMARY AND INTERVAL DEBULKING SURGERY: 
♦ Both primary debulking and interval debulking surgery will be performed through a vertical  
midline incision.  
♦ After opening the abdomen the abdominal cavity will be evaluated for the presence of 
tumor and if present for the amount of nodules and largest size of the tumors: 
♦ The number of tumor nodules will be categorized per region (see below) as 0, 1, 2-10, 11-
50, or uncountable.  
♦ The size of the tumor nodules will be categorized per region as :  0, ≤ 10 mm,  11-20 mm, 
21-50 mm, 51 - 100 mm or > 100 mm.  
♦ An evaluation of size and number of metastases will be done for the whole abdominal 
region and for in addition if possible for the following regions: 
1. Diaphragm  
2. Liver surface 
3. Paracolic gutters 
4. Omentum 
5. Intestines 
6. Peritoneal surface (abdominal) 
7.  Pelvis (including pouch of Douglas, uterus, bladder, rectum and sigmoid)  
8. Adnexa 
9. Pelvic and para-aortic lymph nodes 
10. Other metastases in the spleen, liver, … will be recorded separately.  
♦ Every surgical effort will be made to perform an optimal cytoreduction. Optimal 
cytoreduction is defined as a largest residual tumor mass of ≤ 1 cm, but whenever possible 
the goal of the cytoreduction should be to leave no residual tumor at all. The percentage of 
patients with “optimal cytoreduction” should be about 50% of the patients randomized to 
Primary Debulking Surgery.  
♦ Bowel resection or splenectomy is not recommended except when these procedures are 
necessary to obtain “no residual tumor” at the end of the operation.  
♦ Specimens preferentially of the primary tumor will be sampled for basic research on 
prognostic factors as stipulated in appendix 2.  
♦ The surgical management at the time of Debulking Surgery can not be standardized, but the 
surgeon will be asked to provide a very precise report of the procedures performed.  
♦ At the end of the operation the number and size of the residual tumor masses will have to 
be reported for the whole abdominal cavity and preferentially also for the regions mentioned 
under  “opening the abdomen”.  
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♦ All early and late complications (first 4 weeks) of the surgical report will be collected and 
classified according to the NCIC criteria (see Appendix 7).  
♦ An anonimized copy of the surgical report and the pathological report will be asked for.  
 
SECOND-LOOK SURGERY. 
♦ Second-look surgery is optional and may be performed with laparoscopy or laparotomy.  
♦ The same principals apply for second-look surgery as for Primary or Interval Debulking 
Surgery regarding reporting the number and size of tumor at the start and the end of 
operation, the need for a precise anonimized surgical report describing the procedures 
performed, and a the need for pathological report, the sampling of fluid for cytological 
examination and of tumor tissue for basic research, and the reporting of early and late 
complications.   
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APPENDIX 5. WORLD MEDICAL ASSOCIATION DECLARATION 
OF HELSINKI 
 
Ethical Principles for 
Medical Research Involving Human Subjects 
Adopted by the 18th World Medical Assembly 
Helsinki, Finland, June 1964 
and amended by the  
29th World Medical Assembly, Tokyo, Japan, October 1975  
35th World Medical Assembly, Venice, Italy, October 1983 
41st World Medical Assembly, Hong Kong, September 1989 
48th General Assembly, Somerset West, Republic of South Africa, October 1996 
and the  
52nd WMA General Assembly, Edinburgh, Scotland, October 2000 
A. INTRODUCTION 
1. The World Medical Association has developed the Declaration of Helsinki as a statement 
of ethical principles to provide guidance to physicians and other participants in medical 
research involving human subjects. Medical research involving human subjects includes 
research on identifiable human material or identifiable data. 
2. It is the duty of the physician to promote and safeguard the health of the people. The 
physician’s knowledge and conscience are dedicated to the fulfillment of this duty. 
3. The Declaration of Geneva of the World Medical Association binds the physician with the 
words, "The health of my patient will be my first consideration," and the International 
Code of Medical Ethics declares that, "A physician shall act only in the patient's interest 
when providing medical care which might have the effect of weakening the physical and 
mental condition of the patient." 
4. Medical progress is based on research which ultimately must rest in part on 
experimentation involving human subjects. 
5. In medical research on human subjects, considerations related to the well-being of the 
human subject should take precedence over the interests of science and society. 
6. The primary purpose of medical research involving human subjects is to improve 
prophylactic, diagnostic and therapeutic procedures and the understanding of the aetiology 
and pathogenesis of disease. Even the best proven prophylactic, diagnostic, and therapeutic 
methods must continuously be challenged through research for their effectiveness, 
efficiency, accessibility and quality.  
7. In current medical practice and in medical research, most prophylactic, diagnostic and 
therapeutic procedures involve risks and burdens.  
8. Medical research is subject to ethical standards that promote respect for all human beings 
and protect their health and rights. Some research populations are vulnerable and need 
special protection. The particular needs of the economically and medically disadvantaged 
must be recognized. Special attention is also required for those who cannot give or refuse 
consent for themselves, for those who may be subject to giving consent under duress, for 
those who will not benefit personally from the research and for those for whom the 
research is combined with care.  
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9. Research Investigators should be aware of the ethical, legal and regulatory requirements 
for research on human subjects in their own countries as well as applicable international 
requirements. No national ethical, legal or regulatory requirement should be allowed to 
reduce or eliminate any of the protections for human subjects set forth in this Declaration. 
B. BASIC PRINCIPLES FOR ALL MEDICAL RESEARCH 
10. It is the duty of the physician in medical research to protect the life, health, privacy, and 
dignity of the human subject.  
11. Medical research involving human subjects must conform to generally accepted scientific 
principles, be based on a thorough knowledge of the scientific literature, other relevant 
sources of information, and on adequate laboratory and, where appropriate, animal 
experimentation. 
12. Appropriate caution must be exercised in the conduct of research which may affect the 
environment, and the welfare of animals used for research must be respected. 
13. The design and performance of each experimental procedure involving human subjects 
should be clearly formulated in an experimental protocol. This protocol should be 
submitted for consideration, comment, guidance, and where appropriate, approval to a 
specially appointed ethical review committee, which must be independent of the 
investigator, the sponsor or any other kind of undue influence. This independent committee 
should be in conformity with the laws and regulations of the country in which the research 
experiment is performed. The committee has the right to monitor ongoing trials. The 
researcher has the obligation to provide monitoring information to the committee, 
especially any serious adverse events. The researcher should also submit to the committee, 
for review, information regarding funding, sponsors, institutional affiliations, other 
potential conflicts of interest and incentives for subjects.  
14. The research protocol should always contain a statement of the ethical considerations 
involved and should indicate that there is compliance with the principles enunciated in this 
Declaration.  
15. Medical research involving human subjects should be conducted only by scientifically 
qualified persons and under the supervision of a clinically competent medical person. The 
responsibility for the human subject must always rest with a medically qualified person 
and never rest on the subject of the research, even though the subject has given consent. 
16. Every medical research project involving human subjects should be preceded by careful 
assessment of predictable risks and burdens in comparison with foreseeable benefits to the 
subject or to others. This does not preclude the participation of healthy volunteers in 
medical research. The design of all studies should be publicly available. 
17 Physicians should abstain from engaging in research projects involving human subjects   
unless they are confident that the risks involved have been adequately assessed and can be 
satisfactorily managed. Physicians should cease any investigation if the risks are found to 
outweigh the potential benefits or if there is conclusive proof of positive and beneficial 
results. 
18. Medical research involving human subjects should only be conducted if the importance of 
the objective outweighs the inherent risks and burdens to the subject. This is especially 
important when the human subjects are healthy volunteers.  
19. Medical research is only justified if there is a reasonable likelihood that the populations in 
which the research is carried out stand to benefit from the results of the research.  
20. The subjects must be volunteers and informed participants in the research project. 
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21. The right of research subjects to safeguard their integrity must always be respected. Every 
precaution should be taken to respect the privacy of the subject, the confidentiality of the 
patient’s information and to minimize the impact of the study on the subject's physical and 
mental integrity and on the personality of the subject. 
22. In any research on human beings, each potential subject must be adequately informed of 
the aims, methods, sources of funding, any possible conflicts of interest, institutional 
affiliations of the researcher, the anticipated benefits and potential risks of the study and 
the discomfort it may entail. The subject should be informed of the right to abstain from 
participation in the study or to withdraw consent to participate at any time without reprisal. 
After ensuring that the subject has understood the information, the physician should then 
obtain the subject's freely-given informed consent, preferably in writing. If the consent 
cannot be obtained in writing, the non-written consent must be formally documented and 
witnessed.  
23. When obtaining informed consent for the research project the physician should be 
particularly cautious if the subject is in a dependent relationship with the physician or may 
consent under duress. In that case the informed consent should be obtained by a well-
informed physician who is not engaged in the investigation and who is completely 
independent of this relationship.  
24. For a research subject who is legally incompetent, physically or mentally incapable of 
giving consent or is a legally incompetent minor, the investigator must obtain informed 
consent from the legally authorized representative in accordance with applicable law. 
These groups should not be included in research unless the research is necessary to 
promote the health of the population represented and this research cannot instead be 
performed on legally competent persons.  
25. When a subject deemed legally incompetent, such as a minor child, is able to give assent to 
decisions about participation in research, the investigator must obtain that assent in 
addition to the consent of the legally authorized representative. 
26. Research on individuals from whom it is not possible to obtain consent, including proxy or 
advance consent, should be done only if the physical/mental condition that prevents 
obtaining informed consent is a necessary characteristic of the research population.  The 
specific reasons for involving research subjects with a condition that renders them unable 
to give informed consent should be stated in the experimental protocol for consideration 
and approval of the review committee.  The protocol should state that consent to remain in 
the research should be obtained as soon as possible from the individual or a legally 
authorized surrogate. 
27. Both authors and publishers have ethical obligations. In publication of the results of 
research, the investigators are obliged to preserve the accuracy of the results. Negative as 
well as positive results should be published or otherwise publicly available. Sources of 
funding, institutional affiliations and any possible conflicts of interest should be declared 
in the publication. Reports of experimentation not in accordance with the principles laid 
down in this Declaration should not be accepted for publication. 
C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH 
MEDICAL CARE 
28. The physician may combine medical research with medical care, only to the extent that the 
research is justified by its potential prophylactic, diagnostic or therapeutic value. When 
medical research is combined with medical care, additional standards apply to protect the 
patients who are research subjects. 
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29. The benefits, risks, burdens and effectiveness of a new method should be tested against 
those of the best current prophylactic, diagnostic, and therapeutic methods. This does not 
exclude the use of placebo, or no treatment, in studies where no proven prophylactic, 
diagnostic or therapeutic method exists. 
30. At the conclusion of the study, every patient entered into the study should be assured of 
access to the best proven prophylactic, diagnostic and therapeutic methods identified by 
the study. 
31. The physician should fully inform the patient which aspects of the care are related to the 
research. The refusal of a patient to participate in a study must never interfere with the 
patient-physician relationship. 
32. In the treatment of a patient, where proven prophylactic, diagnostic and therapeutic 
methods do not exist or have been ineffective, the physician, with informed consent from 
the patient, must be free to use unproven or new prophylactic, diagnostic and therapeutic 
measures, if in the physician’s judgement it offers hope of saving life, re-establishing 
health or alleviating suffering. Where possible, these measures should be made the object 
of research, designed to evaluate their safety and efficacy. In all cases, new information 
should be recorded and, where appropriate, published. The other relevant guidelines of this 
Declaration should be followed. 
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APPENDIX 6. PATIENT INFORMATION - EORTC PROTOCOL 
55971. 
 
 You have been asked by your doctor to take part in a clinical trial organized by the European 
Organization for Research and Treatment of Cancer (EORTC). The following information is meant 
to help you decide whether or not you wish to take part.  
Purpose of the study  
You have a malignant disease of the ovary, to be treated by a combination of surgery and 
chemotherapy. Both treatments have a well established value in the treatment of ovarian cancer. 
However, the main purpose of this study is to find out what is the best sequence of these 2 treatment 
modalities. The first possibility (A) is to give first 3 courses of chemotherapy followed by the 
surgical removal of the tumors in the abdomen, and then again followed by at least 3 courses of 
chemotherapy. The second possibility (B) is to try to remove the tumors in the abdomen first, then 
followed by at least 6 courses of chemotherapy, with or without interval debulking surgery.  It is the 
purpose of this study to find out if your chances for definitive cure, for complications of the 
treatment and for a good quality of life are improved by changing the sequence of the treatment. 
Side effects 
Surgical removal of the tumors in the abdomen can be complicated with bleeding during or after the 
operation, infections, bowel disorders,… Both in the treatment possibilities A and B these 
complications can occur. The side effects of the chemotherapy depend on the type of chemotherapy 
you will receive. You should ask your doctor about these side effects. The chemotherapy used in A 
and B is the same.  
Participation 
To definitively establish which treatment is the best, doctors all over Europe are treating half of the 
patients according to possibility A and half of the patients according to B. For this reason, chance 
will decide whether you will receive possibility A or B (randomization) if you decide to participate 
to this study.  
Participation to the trial is totally voluntary and you will be given sufficient time to decide whether 
or not you wish to take part. A decision not to take part will not affect your relation with your 
doctor or hospital staff in any way. At any time you are able to refuse further participation in the 
study. This will not prejudice your subsequent care. 
The information regarding your participation in this study will be treated as strictly confidential and 
will only be used anonymously for the purposes of this trial. 
Your doctors will be pleased to answer any further questions you may have.   
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Patient informed consent form. EORTC 55971 
 
Mrs. …….……………………………………….  
declares having been informed verbally and in writing on the trial. 
The aim of the trial has been explained to me and I hereby declare to be willing to participate 
voluntarily in the trial. 
 
Place: …………………………………   Date:   …………………………………… 
Signature patient: ………………………………………………………….. 
 
(An independent witness who records the patient’s assent may replace the patient) 
Name physician in charge: …………………………………………………. 
Place: ……………………………………    Date:   …………………………………… 
Signature Physician: ……………………………………………………………………       
For European Union member states, the informed consent procedure must conform to the EU 
guidelines on Good Clinical Practice. This implies that “consent must be documented either by the 
subject’s dated signature or by the signature of an patient’s legally acceptable representative”. 
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EORTC Data Center 
Av. E. Mounier 83/11 
1200 Brussels, Belgium 
Direct phone: +32 2 774 16 11 
Fax: +32 2 772 35 45 
Addendum to patient information sheet for trial 55971 
 
Clinical trials include only patients who choose to take part.  
Please take your time to make your decision. 
 
Title of the research protocol   
“Randomized phase III study comparing upfront debulking surgery versus neo-adjuvant 
chemotherapy in patients with Stage IIIc or IV epithelial ovarian carcinoma (EORTC 55971)” 
Invitation to participate in the study 
The EORTC Gynecological Cooperative Group is initiating a research study on patients that have a 
disease similar to yours. The study will be conducted at a European level under the supervision of 
physicians recognized as experts in this field of medicine. Today, you will be invited to take part in 
this research project after you are given full information about the study.  This is a phase III 
randomized study.  
Foreseeable risks and discomforts and methods of drugs administration 
With platinum derivatives, nausea, vomiting, diarrhea, hair loss, tickling in fingers, bone marrow 
depletion with a decrease in platelets and white blood cells, hearing problems, anaphylactic 
reactions and fatigue are frequent side effects.  With carboplatin, bone marrow depletion, kidney 
toxicity, hearing problems and tickling in fingers are less pronounced than with cisplatin.   
Paclitaxel can give different side effects: allergic reactions, change in blood cell count, tickling in 
fingers, heart problems, hair loss, unsettled stomach, vomiting, pain in joins and muscles, hearing 
problems, decreased kidney function. These side effects are common for all patients in the study. 
Before starting with paclitaxel all patients will receive medication to prevent the allergic reaction. If 
side effects occur the administration should be withheld until the patient recovers or the dose of the 
drug will be modified or even stopped. In case of low blood pressure requiring treatment, breathing 
problems requiring treatment, generalized skin itching, paclitaxel will be discontinued. For other 
allergic reactions, the paclitaxel infusion may be discontinued at the investigators discretion. 
Patients will receive adequate treatment and should not re-start in case of a severe allergic reaction. 
For the combination regimens with platinum derivatives and paclitaxel the main toxicity is bone 
marrow depletion, especially leading to decrease in white blood cells.  Peripheral neuropathy is 
rare.  Kidney toxicity can occur but is less pronounced when carboplatin is used in this 
combination. 
Nausea and vomiting will be prevented by giving you drugs against vomiting.  Hair loss is common, 
but the hair will grow again after completion of chemotherapy.  Bone marrow depression is 
temporary, is usually of short duration and is usually seen about two weeks after the chemotherapy.  
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The decrease in white blood cells may increase the risk of infections, a decrease in platelet count 
(thrombocytopenia) may increase the risk of bleeding.      
If neurological toxicity, kidney toxicity or hearing loss, is too high, your treatment will be 
reassessed. 
Cisplatin or carboplatin and Paclitaxel are given as an intraveinous infusion.  The chemotherapy 
regimen you will receive, will be chosen by your hospital and this may involve a different 
combination of drugs. 
During this study you are not allowed to breast feed.  
Description of the research 
Arm A:  
You will first have upfront maximal cytoreductive surgery performed within 3 weeks after the 
biopsy. This is followed by 3 courses of chemotherapy starting within 3 weeks after the surgery. In 
patients with non-optimal primary debulking surgery this treatment is followed by interval 
debulking surgery, which should be performed within 6 weeks after course 3 of chemotherapy in all 
patients with response or stable disease. This is than followed by at least 3 courses of chemotherapy 
starting again within 3 weeks after the surgery.  A second look surgery is allowed if clinically 
indicated. 
Arm B: 
You will first receive 3 courses of chemotherapy within 3 weeks after the biopsy.  Interval 
debulking surgery should be performed within 6 weeks after course 3 of chemotherapy in all 
patients with response or stable disease.  The surgery will be followed by at least 3 courses of 
chemotherapy, starting within 3 weeks after the surgery.  A second-look surgery is allowed if 
clinically indicated.  
Frequency of hospital visits, expected duration of your participation in the trial 
After treatment discontinuation, the frequency of your hospital visits for examination, blood 
samples, will be every 3 months for the first 2 years, every 6 months for year 3-5, and yearly 
afterwards.  The number of patients to be included in this study is 704 and the duration of 
recruitment into the study is 4 years. 
Possible benefits  
There might be less chance of your cancer coming back.  You might live longer.  The quality of 
your life might be better.  These things cannot be predicted for you.  Information from this study 
might help cancer patients in future. 
Participation 
Your participation in this research trial is entirely voluntary and you will be given sufficient time to 
decide whether or not you wish to participate. You are free to decide at all times without giving a 
reason that you no longer wish to participate in the trial. Withdrawal from the trial will not affect 
your subsequent treatment or relationship with your treating physician or the hospital staff in any 
way. 
Your doctors will be pleased to answer any further questions you may have. 
The trial involves the collection of information contained in your medical records and which relates 
to your disease. It is very important that the information collected is accurate and from time to time 
it may be checked against your medical records. Duly authorized persons (EORTC staff, national 
and/or foreign health authority) may have access to your medical records. All information will be 
EORTC 55971  Upfront surgery vs. neoadjuvant chemotherapy in OC. 
Version 9.1 48/59 06 October 2003 
strictly confidential and your identity will never be divulged, you have the right to access this 
information at any time. 
Insurance has been taken by the sponsor of the study according to the current legislation. 
Everything has been done and will continue to be done to prevent additional health problems 
occurring as a result of your taking part in this trial. 
Translational research  
The trial also wishes to involve translational research. 
Translational research is research which will be performed on biological samples (such as serum, 
plasma, tissue,…) that you provide.  In this trial biological samples will be tumor tissue removed at 
the time of your surgery.  Translational research will help us to understand prognostic factors, the 
factors which influence your disease. 
These biological samples and data will be treated as confidential as with the rest of data collected 
for the clinical trial. 
This research protocol has been submitted to an ethics committee whose mission is to verify all 
conditions for your safety and respect of your rights are respected. Approval to this research has 
been given by the Ethics Committee of ______________ on _______________ 
In case of any problem or question, your doctor will be pleased to answer any further questions and 
may be contacted as follows: 
Name of the doctor: 
Hospital: 
Telephone: 
If you consent to join this trial, you will be given a telephone number at the hospital that you can 
contact at any time if you feel unwell or have further questions. Your family doctor will also be told 
about your taking part in this trial and what is involved, if you agree.  
Please take your time to consider this information and do not hesitate to ask further questions of 
your doctor if anything is not clear. You are entitled to keep a copy of this document after you and 
your doctor have signed it. 
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Acceptance of participation 
  I have been properly informed of the clinical research that is being proposed to me 
  I have received a copy of the patient information sheet (original document + Addendum) 
  All my rights have been clearly explained 
  I have received a copy of the informed consent document 
  "I accept to participate in the research entitled “Randomized phase III study comparing 
upfront debulking surgery versus neo-adjuvant chemotherapy in patients with Stage IIIc 
or IV epithelial ovarian carcinoma” and registered under EORTC study number 55971. 
My participation is completely voluntary and I have the possibility to withdraw my consent 
at anytime without explanation This will not affect my relationship with my treating 
physician The data collected on my behalf will be strictly confidential and treated 
according to the "Directive on Human Protection " and the local applicable laws. 
My consent does not discharge the organizers of the research from their responsibilities 
and I keep all my rights guaranteed by the law". 
Investigator's signature: ___________________ Patient's signature: ______________ 
Date: ________________  Date: ________________ 
Person designated by the investigator to participate in the informed consent process 
Title/Position:  __________________________________________________________________ 
Signature:       Date:  _________________________ 
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Appendix 7. WHO Performance status.  
 
0 Able to carry out normal activity without restriction. 
1 Restricted in physically strenuous activity but ambulatory and able to do light work. 
2 Ambulatory and capable of all self-care but unable to carry out any work. Up and about 
more than 5O% of waking hours.  
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours.  
4 Completely disabled. Cannot carry out any self-care. Totally confined to bed and chair. 
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APPENDIX 8. NCIC TOXICITY CRITERIA.  
 
ALLERGY 
AL LER  Allergy none transient rash, fever 
< 38°C, 100.4°F 
urticaria, fever = 38°C, 
100.4°F, mild 
bronchospasm 
serum sickness, 
bronchospasm, req 
parenteral meds 
anaphylaxis 
 
Fever felt to be caused by drug allergy should be coded as ALLERGY (AL LER).  Non allergic drug fever (eg. as from 
biologics) should be coded under FLU-LIKE SYMPTOMS (FL FEV).  If fever is due to infection, code INFECTION only 
(IN FEC or IN NEU).  NB: Protocols requiring detailed reporting of hypersensitivity reactions, will include a 
Hypersensitivity Reaction module. 
AL OTH other * none mild moderate severe life threatening 
 
 
BLOOD/BONE MARROW (SI UNITS)  
 
BL WBC White 
Blood Count 
(WBC) 
≥ 4.0              109/l 3.0 - 3.9 2.0 - 2.9 1.0 - 1.9 < 1.0 
BL PLT Platelets WNL              109/l 75.0 - normal 50.0 - 7 4.9 25.0 - 49.9 < 25.0 
BL HGB 
Hemoglobin (Hgb) 
WNL              g/l 100 - normal 80 - 99 65 - 79 < 65 
BL GRA 
granulocytes (i.e 
neuts + bands) 
≥ 2.0              109/l 1.5 - 1.9 1.0 - 1.4 0.5 - 0.9 < 0.5 
BL LYM 
Lymphocytes 
≥ 2.0              109/l 1.5 - 1.9 1.0 - 1.4 0.5 - 0.9 < 0.5 
BL HEM 
Hemorrhage 
resulting from 
thrombocytopenia 
(clinical) 
none mild, no transfusion 
(includes 
bruise/hematoma, 
petechiae) 
gross, 1 - 2 units 
transfusion per episode 
gross, 3 - 4 units 
transfusion per episode 
massive, > 4 
units 
transfusion per 
episode 
BL OTH Other * none mild moderate severe life threatening 
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CANCER RELATED SYMPTOMS 
CA DEA Death 
from malignant 
disease within 30 
days of treatment * 
(grade = 5) 
- - - - - 
CA PAI Cancer 
pain * 
none pain, but no treatment 
req 
pain controlled with 
non-opioids  
pain controlled with 
opioids 
uncontrollable pain 
CA SEC Second 
malignancy * 
none 
- - 
present 
- 
CA OTH Other * none mild moderate severe  life threatening 
 
 
CARDIOVASCULAR 
CD ART Arterial * 
(non myocardial) 
none 
- - 
transient events (eg. 
transient ischemic 
attack) 
permanent event 
(eg. cerebral vascular 
accident) 
CD VEN Venous * none superficial (excludes IV 
site reaction  code 
SK LTO) 
deep vein thrombosis 
not req anticoagulant 
therapy 
deep vein thrombosis 
req anticoagulant 
therapy 
pulmonary embolism 
CD DYS 
Dysrhythmias 
none asymptomatic, 
transient, req no 
therapy 
recurrent or persistent, 
req no therapy 
req therapy req monitoring, or 
hypotension, or 
ventricular tachy-
cardia, or fibrillation 
CD EDE Edema * 
(eg. peripheral 
edema) 
none 1+ or dependent in 
evening only 
2+ or dependent 
throughout day 
3+ 4+, generalized 
anasarca 
 
CD FUN Function none asymptomatic, decline 
of resting ejection 
fraction of ≥ 10% but < 
20% of baseline value 
asymptomatic, decline 
of resting ejection 
fraction by > 20% of 
baseline value 
mild CHF, responsive 
to therapy 
severe or refractory 
CHF 
CD HBP 
Hypertension 
none or no change asymptomatic, transient 
increase by > 20mm Hg 
(D) or to > 150/100 if 
previously WNL.   
No therapy req 
recurrent or persistent 
increase by > 20mm Hg 
(D) or to > 150/100 if 
previously WNL. 
No therapy req 
req therapy hypertensive crisis 
CD LBP 
Hypotension 
none or no change changes req no therapy  
(incl. transient 
orthostatic 
hypotension) 
req fluid replacement or 
other therapy but no 
hospitalization 
req therapy + 
hospitalization; 
resolves within 48hrs of 
stopping agent 
req therapy + 
hospitalization for 
> 48hrs after stopping 
agent 
CD ISC Ischemia 
(myocardial) 
none non-specific T wave 
flattening 
asymptomatic, ST + T 
wave changes 
suggesting ischemia 
angina without 
evidence for infarction 
acute myocardial 
infarction 
CD PAI 
Pain (chest) * 
none pain, but no treatment 
req 
pain controlled with 
non-opioids 
pain controlled with 
opioids 
uncontrollable pain 
CD PER 
Pericardial 
none asymptomatic effusion  
no intervention req 
pericarditis (rub, chest 
pain, ECG changes) 
symptomatic effusion  
drainage req 
tamponade, drainage 
urgently req; or 
constrictive pericarditis 
req surgery 
CD TAC 
Sinus tachycardia * 
none mild moderate severe life threatening 
CD OTH Other * none mild moderate severe life threatening 
 
 
COAGULATION 
CG FIB Fibrinogen WNL 0.99 - 0.75  x N 0.74 - 0.50  x N 0.49 - 0.25  x N ≤ 0.24  x N 
CG PT 
Prothrombin time 
WNL 1.01 - 1.25  x N 1.26 - 1.50  x N 1.51 - 2.00  x N > 2.00  x N 
CG PTT Partial 
thromboplastin 
time 
WNL 1.01 - 1.66  x N 1.67 - 2.33  x N 2.34 - 3.00  x N > 3.00  x N 
CG OTH Other * none mild moderate severe life threatening 
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ENDOCRINE* 
EN AME 
Amenorrhea 
no irregular menses ≥ 3 months 
- - 
EN FLA 
Hot flashes 
none mild or < 1/day moderate & ≥ 1/day frequent & interferes 
with normal function  
- 
EN IMP 
Impotence/Libido 
normal decrease in normal 
function  
- 
absence of function 
- 
EN OTH Other none mild moderate severe life threatening 
 
FLU-LIKE SYMPTOMS 
FL FEV fever in 
absence of infect. * 
(incl. drug fever) 
none  37.1 - 38.0°C 
98.7 - 100.4°F 
38.1 - 40.0°C 
100.5 - 104.0°F 
> 40.0°C 
> 104.0°F 
for < 24 hrs 
> 40.0°C (104.0°F) for 
> 24 hrs or fever 
accompanied by 
hypotension 
 
Fever felt to be caused by drug allergy should be coded as ALLERGY (AL LER). Non-allergic drug fever (eg. as from biologics) 
should be coded under FLU-LIKE SYMPTOMS (FL FEV). If fever is due to infection, code INFECTION only (IN FEC or IN 
NEU). 
FL HAY Hayfever* 
(includes sneezing, 
nasal stuffiness, 
post-nasal drip) 
none mild moderate severe 
- 
FL JOI Arthralgia* 
(joint pain) 
none mild moderate severe 
- 
FL LET Lethargy* 
(fatigue, malaise) 
none mild, fall of 1 level in 
perf. status 
moderate, fall of 2 
levels in perf. status 
severe, fall of 3 levels 
in perf. status 
- 
FL MYA Myalgia* 
(muscle ache) 
none mild moderate severe 
- 
FL RIG 
Rigors/Chills* 
(Gr 3 incl cyanosis) 
none mild or brief pronounced or /and 
prolonged 
cyanosis 
- 
FL SWE Sweating* 
(diaphoresis) 
none mild moderate severe 
- 
FL OTH Other* none mild moderate severe life threatening 
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GASTROINTESTINAL 
GI ANO Anorexia* none mild moderate severe dehydration 
GI APP 
Appetite increased* 
none mild moderate 
- - 
GI ASC Ascites 
(non malignant)* 
none mild moderate severe life threatening 
GI DIA Diarrhea none increase of 2 - 3 stools 
per day ; or mild 
increase of loose 
watery colostomy 
output compared to pre-
trt 
increase of 4 - 6 stools 
per day, or nocturnal 
stools; or moderate 
increase in loose watery 
colostomy output 
compared to pre-trt 
increase of 7 - 9 stools 
per day, or 
incontinence, 
malabsorption; or 
severe increase in loose 
watery colostomy 
output compared with 
pre-trt 
increase of ≥ 10 stools 
per day, or grossly 
bloody diarrhea, or 
grossly bloody 
clostomy output or 
loose watery colostomy 
output req parenteral 
support; dehydration 
GI DPH 
Esophagitis/ 
dysphagia/ 
odynophagia* (incl 
recall reaction) 
none dys.or odyn. not req trt, 
or painless ulcers on 
esophagoscopy 
dys.or odyn. req trt dys. or odyn. lasting 
> 14 days despire trt 
dys. or odyn. with 10% 
loss of body wt, 
dehydration, hosp. req 
GI DRY Mouth, 
nose dryness* 
none mild moderate severe 
- 
GI FIS Fistula* 
(intestinal, 
esophageal, rectal) 
none 
- - 
req intervention req operation 
GI GAS 
Flatulence* 
none  mild moderate severe 
- 
GI HEA 
Heartburn* 
(incl. dyspepsia) 
none mild moderate severe 
- 
GI HEM 
Gastrointestinal 
bleeding * 
none mild, no transfusion  gross, 1 - 2 units 
transfusion per 
espisode 
gross, 3 - 4 units 
transfusion per episode 
massive > 4 units 
transfusion per episode 
 
Bleeding resulting from thrombocytopenia should be coded under BL HEM, not GI 
 
GI NAU Nausea none able to eat reasonable 
intake 
intake significantly 
decreased but can eat 
no significant intake 
- 
GI OBS Small 
bowel obstruction* 
no 
- 
intermittent, no 
intervention 
req intervention req operation 
GI PAI 
Gastrointestinal 
pain/cramping* 
(incl. rectal pain) 
none pain, but no treatment 
req 
pain controlled with 
non-opioids 
pain controlled with 
opioids 
uncontrollable pain 
GI PRO Proctitis 
(rectal) 
none perianal itch, 
hemorrhoids 
tenesmus or ulcerations 
relieved with therapy, 
anal fissure 
tenesmus or ulcerations 
or other symptoms not 
relieved with therapy 
mucosal necrosis with 
hemorrhage or other 
life threatening proctitis 
GI STO Stomatitis/ 
oral 
none painless ulcers, 
erythema, or mild 
soreness 
painful erythema, 
edema, or ulcers,  
but can eat 
painful erythema, 
edema, or ulcers, and 
cannot eat 
mucosal necrosis 
and/or req parenteral or 
enteral support, 
dehydration 
GI TAS Taste, 
sense of smell 
altered* 
none mild moderate severe 
- 
GI ULC 
Gastritis/ulcer* 
none antacid  req vigourous medical 
management or non-
surgical trt 
uncontrolled by 
medical management; 
req surgery for GI 
ulceration 
perforation or bleeding 
GI VOM Vomiting none 1 episode in 24hrs 2 - 5 episodes in 24hrs 6 - 10 episodes in 24hrs > 10 episodes in 24hrs 
or req parenteral 
support, dehydration 
GI OTH Other* none mild moderate severe life threatening 
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GENITO-URINARY 
GU BLA 
Bladder changes* 
none light epithelial atrophy, 
or minor telangiectasia 
generalized 
telangiectasia 
severe generalized 
telangiectasia (often 
with petechiae) or 
reduction in bladder 
capacity (< 15 ml) 
necrosis, or contracted 
bladder (capacity < 100 
ml), or fibrosis 
GU CRE 
Creatinine 
WNL < 1.5  x N 1.5 - 3.0  x N 3.1 - 6.0  x N > 6.0  x N 
GU CYS Cystitis* 
(non bacterial) 
none mild symptoms, req no 
intervention 
symptoms relieved 
completely with ther. 
symptoms not relieved 
despite therapy 
severe (life threatening) 
cystitis 
 
Urinary tract infection should be coded under infection not GU 
GU FIS Fistula* 
(vaginal, 
vesicovaginal) 
none 
- - 
req intervention req operation 
GU FRE 
Frequency* 
none freq of urination or 
nocturia twice pre-trt 
habit 
freq of urination or 
nocturia < hourly 
freq with urgency and 
nocturia ≥ hourly 
- 
GU HEM 
Hematuria, 
bleeding per vagina 
negative micro only gross, no clots gross + clots req transfusion 
 
Bleeding resulting from thrombocytopenia should be coded under BL HEM not GU. 
GU INC 
Incontinence* 
none  mild moderate severe 
- 
GU OBS Ureteral 
obstruction* 
none unilateral, no surgery bilateral, no surgery req not complete bilateral, 
but stents, nephrostomy 
tubes or surgery req 
complete bilateral 
obstruction 
GU PAI Genito-
urinary pain * (eg : 
dysuria, 
dysmenorrhea, 
dyspareunia) 
none pain, but no treatment 
req  
pain controlled with 
non-opioids 
pain controlled with 
opioids 
uncontrollable pain 
 
GU PRT 
Proteinuria 
no change 1 + 
or < 0.3  g/% 
or < 3  g/l 
2 - 3 + 
or  0.3 - 1.0  g/% 
or  3 - 10  g/l 
4 + 
or > 1.0  g/% 
or > 10  g/l 
nephrotic syndrome 
GU VAG Vaginitis* 
(+/- vaginal 
discharge) 
(non-infectious)  
none mild, no trt req moderate, relieved with 
trt 
severe, not relieved 
with trt 
life threatening 
GU OTH Other* none mild moderate severe life-threatening 
 
 
HEPATIC 
HP ALK Alk. Phos 
or 5'nucleotidase 
within normal limits 
(WNL) 
≤ 2.5  x N  (Normal) 2.6 - 5.0  x N 5.1-20.0 x N > 20  x N 
HP ALT 
Transaminase 
SGPT (ALT) 
WNL ≤ 2.5  x N  (Normal) 2.6 - 5.0  x N 5.1-20.0 x N > 20  x N 
HP AST 
Transaminase 
SGOT (AST) 
WNL ≤ 2.5  x N  (Normal) 2.6 - 5.0  x N 5.1 - 20.0  x N > 20  x N 
HP BIL Bilirubin WNL - < 1.5  x N 1.5 - 3.0  x N > 3.0  x N 
HP CLI Liver 
(clinical) 
no change from 
baseline 
- - 
precoma hepatic coma 
HP LDH LDH* WNL ≤ 2.5  x N  (Normal) 2.6 - 5.0  x N 5.1 - 20.0  x N > 20  x N 
HP OTH Other* none mild moderate severe life-threatening 
 Viral  Hepatitis should be coded as infection rather than liver toxicity. 
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INFECTION 
IN FEC Infection none mild, no active therapy moderate, localized 
infection, active 
therapy req 
severe systemic 
infection, req parenteral 
trt, specify site 
life threatening sepsis, 
specify site 
IN NEU Febrile 
Neutropenia* 
none 
- - 
present 
- 
Absolute granulocyt 
count < 1.0 x 109/l, 
fever ≥ 38.5 °C 
treated with 
(or ought to have 
been treated with ) 
IV antibiotics 
Fever felt to be caused by drug allergy should be coded as ALLERGY (AL LER). Non-allergy drug fever (eg. as from biologics) 
should be coded under FLU-LIKE SYMPTOMS (FL FEV). If fever is due to infection, code INFECTION only (IN FEC or IN 
NEU). 
 
 
METABOLIC (SI UNITS) 
MT AMY Amylase WNL < 1.5  x N 1.5 - 2.0  x N 2.1 - 5.0  x N > 5.1  x N 
MT HCA 
Hypercalcemia 
< 2.64           mmol/l 2.64 - 2.88 2.89 - 3.12 3.13 - 3.37 > 3.37 
MT LCA 
Hypocalcemia 
> 2.10           mmol/l 2.10 - 1.93 1.92 - 1.74 1.73 - 1.51 ≤ 1.50 
MT  HGL 
Hyperglycemia 
< 6.44           mmol/l 6.44 - 8.90 8.91 - 13.8 13.9 - 27.8 > 27.8 or ketoacidosis 
MT LGL 
hypoglycemia 
> 3.55           mmol/l 3.03 - 3.55 2.19 - 3.02 1.66 - 2.18 < 1.66 
MT LKA 
Hypokalemia* 
no change or > 3.5 
mmol/l 
3.1 - 3.5 2.6 - 3.0 2.1 - 2.5 ≤ 2.0 
MT LMA 
Hypomagnesemia 
> 0.70           mmol/l 0.70 - 0.58 0.57 - 0.38 0.37 - 0.30 ≤ 0.29 
MT LNA 
Hyponatremia* 
no change or >135 
mmol/l 
131 - 135 126 - 130 121 - 125 ≤ 120 
MT OTH Other* none mild moderate severe life threatening 
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NEUROLOGIC 
NE CER Cerebellar none slight incoordination, 
dysdiadochokinesis 
intention tremor, 
dysmetria, slurred 
speech, nystagmus 
locomotor ataxia cerebellar necrosis 
NE CON 
Constipation 
none or no change mild moderate severe, obstipation ileus > 96 hrs 
NE COR Cortical  
(includes 
drowsiness) 
none mild somnolence moderate somnolence severe somnolence, 
confusion, 
disorientation, 
hallucinations 
coma, seizures,  
toxic psychosis 
NE DIZ Dizziness* 
(includes 
lightheadedness) 
none mild moderate severe  
(includes fainting) 
- 
NE EXT 
Extrapyramidal/ 
Involuntary 
movement* 
none mild agitation  
(includes restlessness) 
moderate agitation torticollis, oculogyric 
crisis, severe agitation 
- 
NE HED Headache none mild moderate or severe but 
transient 
unrelenting and severe 
- 
NE HER 
Altered hearing 
none or no change asymptomatic hearing 
loss on audiometry only 
tinnitus, symptomatic 
hearing changes not req 
hearing aid or trt 
hearing loss interfering 
with function but 
correctable with 
hearing aid or trt 
hearing changes or 
deafness not 
correctable 
NE INS Insomnia* none mild moderate severe - 
NE MOO Mood no change mild anxiety or 
depression 
moderate anxiety or 
depression 
severe anxiety or 
depression 
suicidal ideation 
NE MOT Motor none or no change subjective weakness, no 
objective findings 
mild objective 
weakness without 
significant impairment 
of function 
objective weakness 
with impairment of 
function 
paralysis 
NE PAI 
Neurologic pain* 
(eg : jaw pain) 
none pain, but no treatment 
req 
pain controlled with 
non-opioids 
pain controlled with 
opioids 
uncontrollable pain 
NE PER 
Personality 
change* 
no change change, not disruptive 
to patient or family 
disruptive to patient or 
family 
harmful to others or 
self 
psychosis 
NE SEN Sensory none or no change mild paresthesias, loss 
of deep tendon reflexes 
(including tingling) 
mild or moderate 
objective sensory loss, 
moderate paresthesias 
sensory loss or 
paresthesias that 
interfere with function 
- 
NE VIS Vision none or no change blurred vision - symptomatic subtotal 
loss of vision 
blindness 
NE OTH Other * 
(includes pain) 
none mild moderate severe life-threatening 
 
Code chest pain CD PAI, muscle aches (myalgia) FL MYA, abdominal pain GI PAI, and local pain at IV site SK LTO. For all other 
types of pain (eg. bone pain), code NE OTH. 
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PULMONARY 
PU COU Cough* none  mild moderate severe - 
PU EDE 
Pulmonary edema* 
none 
- 
out-patient 
management 
in-patient management req intubation 
PU EFF 
Pleural effusion* 
(non-malignant) 
none mild moderate severe life threatening 
PU FIB Pulmonary 
fibrosis* 
normal radiographic changes,  
no symptoms 
- 
changes with symptoms 
- 
PU HEM 
Hemoptysis* 
none mild, no transfusion gross, 1 - 2 units 
transfusion per episode 
gross, 3 - 4 units 
transfusion per episode 
massive, > 4 units 
transfusion per episode 
 
Bleeding resulting from thrombocytopenia should be coded under BL HEM, not PU  
PU PAI 
Pulmonary pain* 
none pain , but not treatment 
req 
pain controlled with 
non-opioids 
pain controlles with 
opioids 
uncontrollable pain 
PU PNE 
Pneumonitis* 
(non-infectious) 
normal radiographic changes, 
symptoms do not req 
steroids 
steroids req oxygen req req assisted ventilation 
PU SOB Shortness 
of breath (dyspnea) 
(incl wheezing) 
none or no change asymptomatic, with 
abnormality in PFT's 
dyspnea on significant 
exertion 
dyspnea at normal level 
of activity, apnea 
without cyanosis 
dyspnea at rest, apnea 
with cyanosis  
PU VOI 
Voice changes* 
(incl. hoarseness, 
loss of voice) 
none mild moderate severe 
- 
PU OTH Other* none mild moderate severe life-threatening 
 
Pneumonia should be considered infection and not graded as pulmonary toxicity unless felt to be resultant from pulmonary changes 
directly induced by treatment 
 
 
SKIN 
SK ALO Alopecia no loss mild hair loss pronounced or total 
head hair loss 
total body hair loss 
- 
SK CHA 
Skin changes* (eg. 
photosensitivity) 
none localized pigmentation 
changes 
generalized 
pigmentation changes 
or atrophy 
subcut.fibrosis or 
localized shallow 
ulceration 
generalized ulcerations 
or necrosis 
SK DES 
Desquamation* 
none dry desquamation moist desquamation confluent moist 
desquamation 
- 
SK DRY Dry skin* none mild moderate  severe - 
SK FAC Flushing* 
(eg:-facial) 
none mild moderate severe 
- 
SK HEM 
Bruising/bleeding 
none mild, no transfusion  gross, 1 - 2 units 
transfusion per episode 
gross, 3 - 4 units 
transfusion per episode 
massive, > 4 units 
transfusion per episode  
 
Bleeding from thrombocytopenia should be coded under BL HEM, not SK 
SK LTO 
Local toxicity 
(reaction at IV site) 
none pain pain and swelling, with 
inflammation or 
phlebitis 
ulceration plastic surgery 
indicated 
 
SK NAI 
Nail changes* 
none mild moderate severe 
- 
SK PAI Skin pain* 
(include sclap pain) 
none pain, but no treatment 
req  
pain controlled with 
non-opioids 
pain controlled with 
opioids 
uncontrollable pain 
SK RAS Rash/Itch* 
(not due to allergy) 
(includes recall 
reaction) 
none or no change scattered macular or 
papular eruption or 
erythema that is 
asymptomatic 
scattered macular or 
papular eruption or 
erythema with pruritus 
or other associated 
symptoma 
generalized 
symptomatic macular, 
papular, or vesicular 
eruption 
exfoliative dermatitis or 
ulcerating dermatitis 
SK OTH Other* none mild moderate severe life threatening 
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WEIGHT 
WT GAI 
Weight Gain 
< 5.0% 5.0 - 9.9% 10.0 - 19.9% ≥ 20.0% 
- 
WT LOS 
Weight Loss 
< 5.0% 5.0 - 9.9% 10.0 - 19.9% ≥ 20.0% 
- 
 
 
OTHER 
OT OTH Other* none mild moderate severe life-threatening 
 
For toxicity which do not have an existing code, but do fit into an existing toxicity category, use "other" variable in the appropriate 
toxicity category (eg. code sinus tachycardia CARDIOVASCULAR OTHER (CD OTH). Only toxicities which do not fit into 
existing categories should be coded OTHER OTHER (OT OTH).  
 
 
 
